object
studi
want
examin
preval
caga
vaca
statu
helicobact
pylori
hp
isol
patient
gastriti
peptic
ulcer
compar
know
relationship
virul
factor
group
method
gastric
biopsi
specimen
hp
posit
patient
peptic
ulcer
case
gastriti
case
studi
dna
extract
pcr
perform
detect
caga
vaca
allel
gene
result
gastriti
strain
expect
caga
fragment
amplifi
pcr
carri
gene
detect
strain
peptic
ulcer
strain
caga
vaca
vaca
gene
detect
strain
signific
differ
preval
caga
vaca
found
group
neither
show
relationship
presenc
gene
caga
gene
vaca
conclus
although
risk
develop
seriou
gastric
lesion
increas
number
virul
factor
gene
accumul
given
hp
strain
find
signific
differ
relationship
caga
vaca
statu
hp
isol
patient
gastriti
peptic
ulcer
studi
low
percentag
gene
found
group
introduct
presenc
viabl
noncultiv
helicobact
pylori
cell
environment
sampl
may
underestim
import
way
transmiss
determin
resist
antibiot
strain
import
better
understand
epidemiolog
infect
object
evalu
use
fluoresc
situ
hybridis
fish
assay
directli
biopsi
wastewat
detect
h
pylori
simultan
macrolid
resist
genotyp
method
total
gastric
biopsi
sampl
ulcerpati
homogenis
ml
select
broth
aliquot
use
fish
detect
twentynin
wastewat
sampl
collect
differ
treatment
plant
centrifug
subsequ
fix
paraformaldehyd
solut
h
c
wash
pb
buffer
hpi
probe
rrna
target
fitclabel
oligonucleotid
sequenc
use
detect
h
pylori
strain
addit
set
three
probe
use
detect
rrna
mutat
associ
resist
clarithromycin
hybridis
perform
formamid
c
h
result
fish
allow
detect
h
pylori
clinic
sampl
sampl
posit
wastewat
posit
biopsi
show
presenc
clarithromycin
resist
strain
posit
wastewat
sampl
yield
resist
genotyp
macrolid
use
doubl
filter
set
could
observ
directli
clarithromicyn
resist
h
pylori
organ
sampl
morpholog
differ
type
environ
predomin
cell
morpholog
clinic
wastewat
sampl
helicoid
form
conclus
fish
specif
rapid
cultureindepend
method
determin
directli
presenc
clarithromycinresist
h
pylori
cell
clinic
environment
sampl
result
show
presenc
macrolid
resist
cell
water
therefor
water
must
consid
potenti
rout
h
pylori
transmiss
acknowledg
work
support
ministerio
ol
de
ciencia
project
effect
therapi
patient
helicobact
pylori
relat
gastriti
correl
organis
cag
pathogen
island
object
helicobact
pylori
lead
caus
variou
gastrointestin
diseas
atroph
gastriti
gastroduoden
ulcer
caga
gene
product
caga
directli
inject
bacteriaattach
host
cell
deregul
intracellular
signal
pathway
therebi
initi
pathogenesi
caga
gene
locat
pathoginicti
island
function
gene
island
unknown
goal
work
evalu
impact
cag
island
genotyp
outcom
therapi
materi
method
three
group
patient
total
number
patient
investig
first
group
take
typic
antibiot
therapi
amoxicillin
claritromycin
rabeprasol
patient
second
group
treat
antibiot
togeth
probiot
laminolact
e
faecium
strain
form
bonbon
togeth
pectin
soy
bean
amino
acid
sea
weed
third
group
take
laminolact
without
antibiot
genotyp
determin
pcr
dna
primer
three
h
pylori
gene
ureb
caga
cagh
cagh
use
marker
cag
island
integr
ureb
marker
h
pylori
presenc
five
differ
genotyp
determin
ureb
ure
ureb
cagacagh
ureb
ureb
treatment
antibiot
alon
lead
erad
best
erad
percentag
took
place
second
group
classic
antibiot
treatment
taken
togeth
probiot
interestingli
probiot
treatment
alon
give
erad
result
therapi
highli
consist
cag
genotyp
patient
found
statist
less
suscept
p
therapi
case
entir
cag
regulon
present
regardless
therapi
use
fact
suggest
immunosuppress
function
caga
protein
encod
gene
cag
pathogen
island
conclus
effect
h
pylori
erad
depend
cag
pathogen
island
genotyp
probiot
includ
e
faecium
might
significantli
improv
antih
pylori
treatment
object
arbitrarili
prime
polymeras
chain
reaction
appcr
use
epidemiolog
evolut
clinic
isol
p
aeruginosa
method
recommend
firstpass
clinic
microbiolog
infect
volum
supplement
screen
p
aeruginosa
isol
studi
done
determin
p
aeruginosa
strain
isol
cultur
patient
hospitalis
infecti
diseas
unit
individu
strain
techniqu
prefer
cheap
provid
rapid
detect
opportun
method
sampl
obtain
clinic
specimen
patient
hand
staff
infecti
diseas
unit
cultur
sampl
isol
blood
six
sputum
drainag
hand
medic
staff
p
aeruginosa
identif
made
api
system
dna
extract
cultur
materi
phenolchloroform
extract
method
appcr
perform
use
primer
gcg
subject
page
band
pattern
visualis
silver
stain
result
none
isol
hospit
staff
p
aeruginosa
cultur
clinic
sampl
patient
differ
genotyp
determin
conclus
p
aeruginosa
strain
patient
individu
strain
neither
relat
staff
depart
specif
patient
pseudomona
aeruginosa
microarray
rapid
determin
antibiot
suscept
virul
factor
j
weil
susa
bachmann
c
knabb
stuttgart
object
pseudomona
aeruginosa
lead
caus
nosocomi
infect
particularli
pneumonia
sepsi
intens
care
unit
high
intrins
antibiot
resist
abil
develop
multidrug
resist
pose
especi
critic
ill
patient
seriou
therapeut
problem
sinc
cultur
base
techniqu
pathogen
identif
resist
determin
requir
least
day
calcul
antibiot
therapi
may
harbour
risk
increas
antibiot
resist
therapi
failur
therefor
develop
fast
reliabl
identif
antimicrobi
suscept
test
essenti
improv
therapi
aim
present
studi
develop
oligonucleotidearray
quick
genotyp
test
antibiot
suscept
combin
determin
relev
virul
factor
method
dna
differ
clinic
specimen
isol
modifi
qiamp
dna
blood
mini
kit
templat
dna
amplifi
simultan
label
multiplex
pcr
oligonucleotid
captur
probe
contain
polyt
spacer
spot
epoxyslid
build
array
cover
regulatori
gene
multidrug
efflux
pump
mexr
mext
nfxb
algin
synthesi
muca
metallobetalactamas
blavim
blaimp
aminoglycosid
modifi
enzym
aac
aad
aph
virul
factor
exou
exo
exot
object
studi
want
examin
preval
caga
vaca
statu
helicobact
pylori
hp
isol
patient
gastriti
peptic
ulcer
compar
know
relationship
virul
factor
group
method
gastric
biopsi
specimen
hp
posit
patient
peptic
ulcer
case
gastriti
case
studi
dna
extract
pcr
perform
detect
caga
vaca
allel
gene
result
gastriti
strain
expect
caga
fragment
amplifi
pcr
carri
gene
detect
strain
peptic
ulcer
strain
caga
vaca
vaca
gene
detect
strain
signific
differ
preval
caga
vaca
found
group
neither
show
relationship
presenc
gene
caga
gene
vaca
conclus
although
risk
develop
seriou
gastric
lesion
increas
number
virul
factor
gene
accumul
given
hp
strain
find
signific
differ
relationship
caga
vaca
statu
hp
isol
patient
gastriti
peptic
ulcer
studi
low
percentag
gene
found
group
helicobact
pylori
cell
clinic
wastewat
sampl
p
piquer
moreno
jimenez
j
valencia
e
introduct
presenc
viabl
noncultiv
helicobact
pylori
cell
environment
sampl
may
underestim
import
way
transmiss
determin
resist
antibiot
strain
import
better
understand
epidemiolog
infect
object
evalu
use
fluoresc
situ
hybridis
fish
assay
directli
biopsi
wastewat
detect
h
pylori
simultan
macrolid
resist
genotyp
method
total
gastric
biopsi
sampl
ulcerpati
homogenis
ml
select
broth
aliquot
use
fish
detect
twentynin
wastewat
sampl
collect
differ
treatment
plant
centrifug
subsequ
fix
paraformaldehyd
solut
h
c
wash
pb
buffer
hpi
probe
rrna
target
fitclabel
oligonucleotid
sequenc
use
detect
h
pylori
strain
addit
set
three
probe
use
detect
rrna
mutat
associ
resist
clarithromycin
hybridis
perform
formamid
c
h
result
fish
allow
detect
h
pylori
clinic
sampl
sampl
posit
wastewat
posit
biopsi
show
presenc
clarithromycin
resist
strain
posit
wastewat
sampl
yield
resist
genotyp
macrolid
use
doubl
filter
set
could
observ
directli
clarithromicyn
resist
h
pylori
organ
sampl
morpholog
differ
type
environ
predomin
cell
morpholog
clinic
wastewat
sampl
helicoid
form
conclus
fish
specif
rapid
cultureindepend
method
determin
directli
presenc
clarithromycinresist
h
pylori
cell
clinic
environment
sampl
result
show
presenc
macrolid
resist
cell
water
therefor
water
must
consid
potenti
rout
h
pylori
transmiss
acknowledg
work
support
ministerio
ol
de
ciencia
project
object
helicobact
pylori
lead
caus
variou
gastrointestin
diseas
atroph
gastriti
gastroduoden
ulcer
caga
gene
product
caga
directli
inject
bacteriaattach
host
cell
deregul
intracellular
signal
pathway
therebi
initi
pathogenesi
caga
gene
locat
pathoginicti
island
function
gene
island
unknown
goal
work
evalu
impact
cag
island
genotyp
outcom
therapi
materi
method
three
group
patient
total
number
patient
investig
first
group
take
typic
antibiot
therapi
amoxicillin
claritromycin
rabeprasol
patient
second
group
treat
antibiot
togeth
probiot
laminolact
e
faecium
strain
form
bonbon
togeth
pectin
soy
bean
amino
acid
sea
weed
third
group
take
laminolact
without
antibiot
genotyp
determin
pcr
dna
primer
three
h
pylori
gene
ureb
caga
cagh
cagh
use
marker
cag
island
integr
ureb
marker
h
pylori
presenc
five
differ
genotyp
determin
ureb
ure
ureb
cagacagh
ureb
ureb
treatment
antibiot
alon
lead
erad
best
erad
percentag
took
place
second
group
classic
antibiot
treatment
taken
togeth
probiot
interestingli
probiot
treatment
alon
give
erad
result
therapi
highli
consist
cag
genotyp
patient
found
statist
less
suscept
p
therapi
case
entir
cag
regulon
present
regardless
therapi
use
fact
suggest
immunosuppress
function
caga
protein
encod
gene
cag
pathogen
island
conclus
effect
h
pylori
erad
depend
cag
pathogen
island
genotyp
probiot
includ
e
faecium
might
significantli
improv
antih
pylori
treatment
screen
p
aeruginosa
isol
studi
done
determin
p
aeruginosa
strain
isol
cultur
patient
hospitalis
infecti
diseas
unit
individu
strain
techniqu
prefer
cheap
provid
rapid
detect
opportun
method
sampl
obtain
clinic
specimen
patient
hand
staff
infecti
diseas
unit
cultur
sampl
isol
blood
six
sputum
drainag
hand
medic
staff
p
aeruginosa
identif
made
api
system
dna
extract
cultur
materi
phenolchloroform
extract
method
appcr
perform
use
primer
gcg
subject
page
band
pattern
visualis
silver
stain
result
none
isol
hospit
staff
p
aeruginosa
cultur
clinic
sampl
patient
differ
genotyp
determin
conclus
p
aeruginosa
strain
patient
individu
strain
neither
relat
staff
depart
specif
patient
object
pseudomona
aeruginosa
lead
caus
nosocomi
infect
particularli
pneumonia
sepsi
intens
care
unit
high
intrins
antibiot
resist
abil
develop
multidrug
resist
pose
especi
critic
ill
patient
seriou
therapeut
problem
sinc
cultur
base
techniqu
pathogen
identif
resist
determin
requir
least
day
calcul
antibiot
therapi
may
harbour
risk
increas
antibiot
resist
therapi
failur
therefor
develop
fast
reliabl
identif
antimicrobi
suscept
test
essenti
improv
therapi
aim
present
studi
develop
oligonucleotidearray
quick
genotyp
test
antibiot
suscept
combin
determin
relev
virul
factor
method
dna
differ
clinic
specimen
isol
modifi
qiamp
dna
blood
mini
kit
templat
dna
amplifi
simultan
label
multiplex
pcr
oligonucleotid
captur
probe
contain
polyt
spacer
spot
epoxyslid
build
array
cover
regulatori
gene
multidrug
efflux
pump
mexr
mext
nfxb
algin
synthesi
muca
metallobetalactamas
blavim
blaimp
aminoglycosid
modifi
enzym
aac
aad
aph
virul
factor
exou
exo
exot
result
clinic
p
aeruginosa
isol
could
correctli
genotyp
three
isol
display
hybridis
pattern
could
assign
neither
wildtyp
known
mutat
sequenc
analysi
isol
reveal
unknown
mutat
mexr
nfxb
hybridis
dna
nonferment
enterobacteriacea
show
crossreact
genotyp
resist
profil
p
aeruginosa
deduc
array
data
correl
fulli
suscept
pattern
obtain
standard
test
sensit
array
genom
equival
even
excess
nonpseudomona
dna
whole
analysi
includ
dna
process
array
hybridis
data
evalu
could
perform
less
h
conclus
due
good
correl
standard
procedur
pseudomonasarray
may
use
rapid
suscept
test
even
directli
clinic
sampl
combin
analysi
antibiot
resist
virul
factor
may
improv
outcom
antimicrobi
therapi
object
high
preval
pseudomona
aeruginosa
infect
cystic
fibrosi
cf
patient
conduct
studi
assess
p
aeruginosa
isol
collect
year
sputa
cf
adult
patient
attend
italian
cf
centr
phenotyp
charact
bacteria
oserotyp
motil
product
enzym
resist
antibiot
pfge
genotyp
pattern
evalu
analys
presenc
epidem
strain
moreov
sequenti
isol
collect
cf
patient
investig
look
chronicis
infect
strain
identifi
biochem
oserotyp
determin
slide
agglutin
product
enzym
proteas
elastas
gelatinas
haemolysin
betalactamas
motil
detect
use
specif
techniqu
antibiot
suscept
analys
vitek
am
system
disc
diffus
method
pfge
use
discrimin
genotyp
p
aeruginosa
result
hand
serotyp
fail
identifi
isol
consid
bacteria
collect
onset
colonis
frequent
serotyp
moreov
percentag
proteas
haemolysin
gelatinas
elastas
product
respect
wherea
microorgan
nonmotil
pfge
allow
type
strain
except
one
heterogen
isol
indic
crossinfect
unusu
also
observ
sever
strain
isol
last
year
predomin
pattern
cf
patient
harbour
p
aeruginosa
genotyp
sequenti
isol
suscept
bacteria
antibiot
test
vari
greatli
also
strain
belong
pfge
profil
conclus
result
indic
relationship
genotyp
phenotyp
suggest
phenotyp
variabl
due
adapt
microorgan
host
moreov
presenc
sever
strain
genotyp
profil
suggest
possibl
crosscolonis
cf
patient
due
circul
transmiss
strain
serthr
protein
kinas
phosphoprotein
phosphatas
pseudomona
aeruginosa
analysi
properti
j
nedvedova
p
lnenicka
k
hercik
p
branni
pragu
cz
object
pseudomona
aeruginosa
opportunist
pathogen
caus
infect
eye
urinari
tract
burn
immunocompromis
patient
three
genet
loci
p
aeruginosa
encod
serthr
protein
kinas
identifi
two
ppka
also
characteris
littl
known
function
cell
signal
gene
localis
upstream
encod
cognat
phosphoprotein
phosphatas
possibl
relationship
quorum
sens
protein
phosphoryl
gramneg
bacteria
alreadi
describ
aim
work
prepar
unmark
delet
mutant
ppka
gene
find
linkag
quorum
sens
protein
phosphoryl
p
aeruginosa
exist
prepar
unmark
delet
mutant
improv
method
gene
replac
p
aeruginosa
employ
broadhostrang
flpfrt
recombin
system
sitespecif
excis
chromosom
locat
dna
sequenc
use
phosphorprotein
pattern
biochem
properti
mutant
examin
doubl
mutant
homoserin
lacton
synthas
gene
lasi
rhli
also
subject
phosphoprotein
pattern
analysi
result
conclus
doubl
mutant
prepar
differ
found
either
biochem
properti
phosphoprotein
pattern
delet
ppka
gene
fail
due
integr
vector
unknown
specif
site
p
aeruginosa
genom
comparison
phosphoprotein
pattern
lasi
rhli
doubl
mutant
wild
type
strain
show
import
differ
result
suggest
phosphoryl
circuit
oper
p
aeruginosa
relat
quorum
sens
system
object
botul
rare
potenti
fatal
diseas
gener
caus
neurotoxin
produc
clostridium
botulinum
symptom
diseas
includ
paralysi
due
bont
inhibit
neurotransmitt
releas
laboratori
diagnosi
botul
reli
detect
bont
clinic
food
specimen
use
vivo
test
diagnosi
also
includ
isol
identif
bacterium
reli
vivo
test
detect
toxin
product
bacterium
grow
vitro
previous
describ
develop
realtim
pcr
assay
bonta
b
e
gene
fragment
present
evalu
data
method
dna
extract
faec
enrich
cultur
natur
contamin
food
clinic
sampl
coloni
grow
agar
plate
taqmanbas
assay
bonta
b
e
gene
fragment
perform
use
sequenc
detector
appli
biosystem
assay
perform
duplex
reaction
bonta
b
use
fam
vic
label
probe
respect
monoplex
bont
use
singl
fam
label
probe
sampl
test
use
convent
bioassay
result
compar
realtim
pcr
assay
result
result
pcr
bioassay
found
consist
sampl
except
contain
silent
b
neurotoxin
gene
addit
bonta
gene
sampl
test
compris
direct
examin
six
faecal
sampl
enrich
cultur
six
clinic
food
pure
cultur
grow
vitro
conclus
studi
first
report
success
identif
differ
c
botulinum
toxin
type
wild
type
bonta
b
e
use
taqman
realtim
pcr
assay
assay
alreadi
provid
use
adjunct
vivo
test
rapid
identif
bacteria
contain
bont
gene
wild
type
c
botulinum
vntr
polymorph
genotyp
rickettsia
conorii
complex
strain
l
vitorino
r
de
sousa
l
f
bacellar
r
tenreiro
lisbon
p
introduct
mediterranean
spot
fever
msf
acut
febril
tick
transmit
rickettsiosi
caus
strain
rickettsia
conorii
complex
msf
endem
portug
obligatori
notifi
diseas
annual
incid
rate
diseas
inhabit
portug
msf
caus
two
strain
r
conorii
malish
isra
tick
typhu
itt
strain
isol
first
time
patient
moreov
data
nation
institut
health
point
half
msf
case
occur
portug
caus
itt
show
similar
preval
infect
r
conorii
malish
object
work
present
pcrbase
method
detect
vntr
sequenc
enabl
amplicon
size
differenti
r
conorii
malish
itt
human
isol
vntr
high
discriminatori
capac
contain
greater
divers
also
often
vari
copi
therefor
use
molecular
type
mani
bacteria
speci
method
human
strain
isol
shellvial
techniqu
patient
total
blood
dna
tick
isol
refer
strain
also
use
compar
purpos
vntr
loci
identifi
tandem
repeat
finder
softwar
within
r
conorii
genom
locu
select
base
follow
criteria
repeat
unit
nucleotid
length
nucleotid
sequenc
ident
individu
repeat
unit
two
copi
repeat
unit
primer
flank
sequenc
design
enabl
vntrpcr
amplif
clinic
isol
identif
also
confirm
ompa
gene
sequenc
result
vntr
sequenc
chosen
highli
inform
sinc
possess
differ
repeat
consensu
pattern
among
strain
test
name
r
conorii
malish
itt
former
contain
five
tandem
repeat
later
three
repeat
bp
motif
unit
easili
detect
agaros
gel
electrophoresi
therefor
polymorph
observ
enabl
discrimin
two
strain
result
agreement
ompa
gene
sequenc
conclus
pcrbase
method
provid
use
rapid
way
genotyp
r
conorii
malish
itt
isol
r
conorii
complex
respons
msf
portug
ompa
glta
gene
amplif
current
wide
rickettsia
detect
method
use
howev
strain
identif
accomplish
sequenc
monitor
abil
human
intestin
microflora
becom
reestablish
antibiot
treatment
use
trflp
c
jernberg
sullivan
c
edlund
j
jansson
hudding
stockholm
object
studi
composit
human
normal
faecal
microflora
administr
clindamycin
probiot
placebo
product
sinc
small
portion
faecal
flora
cultiv
sampl
primarili
analys
use
cultur
independ
molecular
fingerprint
techniqu
terminalrestrict
fragment
length
polymorph
trflp
method
studi
includ
eight
healthi
volunt
subject
receiv
clindamycin
oral
day
four
subject
receiv
probiot
yoghurt
concomitantli
contain
exp
cfuml
strain
lactobacillu
lactobacillu
acidophilu
ncfb
bifidobacterium
lacti
placebo
group
receiv
ordinari
yoghurt
faecal
sampl
taken
administr
day
last
day
administr
day
day
administr
day
sampl
analys
convent
cultiv
trflp
univers
bacteri
primer
lactobacillu
specif
primer
use
analys
sampl
use
trflp
area
differ
termin
restrict
fragment
trf
theoret
correspond
one
group
close
relat
speci
use
calcul
rel
abund
valu
trf
valu
use
princip
compon
analys
pca
upgma
analys
compar
microbi
flora
three
differ
time
point
result
conclus
group
ingest
probiot
microflora
three
four
subject
becam
reestablish
close
origin
composit
week
antibiot
treatment
ceas
contrast
one
subject
four
placebo
group
intestin
microflora
show
tendenc
toward
normalis
time
period
find
accord
result
culturebas
analysi
trflp
also
use
monitor
specif
bacteri
popul
either
posit
neg
impact
clindamycin
exampl
one
domin
popul
belong
clostridium
coccoid
subgroup
highli
neg
impact
clindamycin
administr
subject
use
lactobacilli
specif
primer
l
acidophilu
lactobacillu
two
domin
popul
group
receiv
probiot
trflp
shown
reproduc
techniqu
analys
antibiot
probiot
induc
alter
normal
intestin
microflora
campylobact
speci
use
malditof
mass
spectrometri
dare
h
sutton
c
key
h
shah
lunt
g
well
manchest
london
uk
laser
interrog
bacteria
matrix
assist
laser
desorpt
ionis
time
flight
malditof
mass
spectrometri
ms
reveal
uniqu
fingerprint
pattern
biomark
pattern
reproduc
given
set
condit
use
basi
bacteri
identif
databas
known
bacteri
spectra
manchest
metropolitan
univers
collabor
health
protect
agenc
uk
water
corpor
creat
malditof
mass
spectral
databas
clinic
environment
food
born
pathogen
pathogen
suppli
uk
nation
collect
type
cultur
nctc
databas
spectra
therefor
repres
organ
worldrenown
collect
databas
continu
grow
last
year
initi
current
spectral
entri
cover
differ
genera
bacteri
identif
use
databas
often
conclus
top
five
match
suggest
generaspeci
howev
identif
robust
strain
within
databas
must
well
characteris
ident
well
establish
campylobact
number
repres
strain
databas
increas
significantli
around
year
speci
cover
within
taxa
c
coli
c
consicu
c
curvu
c
fetu
c
gracili
c
helveticu
c
hyolei
c
hyointestinali
c
jejuni
c
lari
c
rectu
c
sputorum
c
upsaliensi
studi
present
result
analys
dataset
campylobact
strain
expand
databas
contain
mass
spectral
entri
respect
result
demonstr
signific
improv
ie
number
campylobact
sp
correctli
identifi
number
repres
strain
increas
therefor
malditof
ms
provid
potenti
rapid
identif
system
campylobact
sp
applic
intergen
spacer
sequenc
detect
molecular
differenti
legionella
speci
f
grattard
c
ginevra
riffard
ro
j
etienn
b
pozzetto
saintetienn
f
object
among
speci
legionella
identifi
far
report
pathogen
human
precis
identif
clinic
isol
refer
laboratori
need
use
monoclon
antibodi
molecular
marker
rrna
mip
rpobor
dotagen
sequenc
develop
rapid
conveni
techniqu
base
sequenc
intergen
spacer
use
nondegener
primer
specif
legionella
spp
method
test
legionella
speci
refer
clinic
isol
includ
serogroup
l
pneumophila
subsp
pneumophila
amplif
step
perform
use
realtim
pcr
lightcycl
roch
diagnost
sequenc
perform
sequenc
beckman
compar
analysi
sequenc
done
comput
program
mega
dendrogram
obtain
neighbourjoin
method
result
phylogen
tree
intergen
spacer
sequenc
found
abl
clearli
differenti
legionella
speci
subspeci
level
actual
three
subspeci
l
pneumophila
subsp
pneumophila
subsp
fraseri
subsp
pascullei
clearli
distinguish
speci
share
autofluoresc
properti
ubiquinon
fatti
acid
composit
shown
phylogenet
relat
addit
rpob
sequenc
shown
previous
exhibit
similar
result
techniqu
found
abl
detect
identifi
strain
present
clinic
environment
specimen
could
cultur
agar
medium
although
tool
discriminatori
enough
differenti
strain
l
pneumophila
subsp
pneumophila
serogroup
level
use
two
differ
outbreak
demonstr
rapidli
ident
sequenc
strain
respons
sever
human
infect
isol
hot
water
reservoir
suggest
common
origin
conclus
intergen
spacer
sequenc
found
suitabl
rapid
detect
power
identif
legionella
speci
clinic
set
whippl
diseas
wd
rare
multisystem
bacteri
infect
variabl
clinic
manifest
occasion
involv
central
nervou
system
cultiv
aetiolog
agent
tropheryma
whippelii
difficult
laboratori
diagnosi
usual
base
histolog
method
last
year
molecular
detect
bacteri
gene
polymeras
chain
reaction
pcr
two
primer
set
greatli
contribut
diagnosi
present
cerebr
case
wd
male
success
diagnos
pcr
whippelii
blood
faec
far
know
first
case
report
greec
diagnosi
wd
histolog
examin
duodenum
biopsi
diastas
resist
nonacid
fast
period
acid
schiff
pa
posit
inclus
macrophag
molecular
detect
gene
pcr
csf
blood
faec
perform
histolog
detect
neg
pcr
posit
blood
faec
patient
neg
csf
seven
month
onset
antimicrobi
therapi
pcr
neg
three
clinic
specimen
conclus
applic
pcr
prove
invalu
tool
recognit
differenti
diagnosi
earli
start
antimicrobi
therapi
wd
gener
fatal
diseas
remain
untreat
result
one
clinic
isol
api
code
profil
refer
strain
fifteen
per
cent
clinic
strain
test
ureas
posit
refer
strain
fatti
acid
analysi
clinic
isol
could
separ
four
differ
group
iiv
contain
isol
respect
atcc
group
group
ii
sequenc
obtain
three
strain
group
ii
respect
one
strain
group
iii
iv
respect
comparison
determin
eight
sequenc
public
databas
show
greatest
similar
score
c
asperum
valu
c
asperum
c
amycolatum
consid
synonym
exhibit
level
dnadna
related
greater
ruimi
r
et
al
int
j
syst
bacteriol
homolog
c
amycolatum
atcc
sequenc
c
amycolatum
refer
strain
yield
homolog
publish
sequenc
conclus
data
confirm
hypothesi
atcc
atyp
clinic
c
amycolatum
strain
furthermor
data
concord
observ
pyrolysisgasliquid
chromatographi
c
amycolatum
isol
separ
two
differ
group
voisin
et
al
re
microbiol
detect
mutat
associ
resist
tetracyclin
clarithromycin
helicobact
pylori
use
pyrosequenc
lawson
c
arnold
r
owen
london
uk
object
clarithromycin
tetracyclin
key
compon
h
pylori
erad
therapi
resist
clarithromycin
occur
due
singl
nucleotid
mutat
rdna
assay
detect
amongst
first
develop
pyrosequenc
recent
shown
resist
reduc
suscept
tetracyclin
occur
due
singl
doubl
tripl
mutat
rdna
aim
studi
develop
singl
multiplex
assay
use
pyrosequenc
determin
suscept
clarithromycin
tetracyclin
h
pylori
isol
direct
gastric
biopsi
sampl
method
pyrosequenc
assay
detect
mutat
confer
tetracyclin
clarithromycin
resist
design
work
singli
multiplex
assay
evalu
use
isol
fulli
characteris
rdna
sequenc
subsequ
dna
extract
clinic
isol
h
pyloriposit
human
gastric
biopsi
unknown
antibiot
suscept
examin
result
compar
achiev
convent
culturebas
techniqu
name
antibiot
disc
diffus
etest
result
pyrosquenc
multiplex
assay
correctli
determin
rdna
sequenc
characteris
control
isol
appli
dna
extract
clinic
isol
gastric
biopsi
sampl
pyrosequenc
assay
agreement
clarithromycin
tetracyclin
suscept
determin
culturebas
analysi
conclus
pyrosequenc
assay
allow
rapid
determin
clarithromycin
tetracyclin
suscept
h
pylori
isol
gastric
biopsi
sampl
sequenc
data
obtain
mutat
occur
strain
may
provid
use
epidemiolog
inform
guid
patient
manag
diseas
aim
prospect
pilot
studi
detect
iga
igg
anticaga
antibodi
statu
evalu
correl
antih
pylori
iga
igg
western
blot
elisa
test
adult
dyspept
patient
method
upper
gastrointestin
endoscopi
two
gastric
antrum
two
corpu
perform
patient
mean
age
dyspept
symptom
h
pylori
assess
rapid
ureas
test
histopatholog
examin
biopsi
specimen
patient
sera
test
antih
pylori
iga
igg
western
blot
iga
igg
elisa
anticagaiga
igg
elisa
euroimmun
medizinisch
labordiagnostika
beck
test
result
total
patient
evalu
h
pylori
infect
diagnos
patient
rapid
ureas
test
andor
histopatholog
serolog
antih
pylori
test
result
shown
tabl
twentyeight
adult
dyspept
patient
sera
posit
anticagaigg
elisa
posit
anticagaiga
elisa
conclus
infect
h
pylori
result
product
local
system
antibodi
cag
import
patholog
marker
high
immunogen
power
set
serolog
test
may
give
accur
determin
h
pylori
infect
one
test
detect
specif
antibodi
bacteri
antigen
seem
good
correl
western
blot
elisa
test
result
gold
standard
acknowledg
work
support
euroimmun
medizinisch
labordiagnostika
beck
germani
suscept
helicobact
pylori
isol
antiadhes
activ
highmolecularweight
constitu
cranberri
h
shmueli
burger
neeman
j
yahav
z
samra
niv
n
sharon
e
weiss
tabak
athamna
ofek
petach
tiqva
haifa
rehovot
jerusalem
kfar
qaraa
tel
aviv
il
background
previou
studi
shown
high
molecular
mass
nondialys
constitu
deriv
cranberri
juic
inhibit
adhes
helicobact
pylori
human
gastric
mucu
human
erythrocyt
aim
present
studi
determin
sensit
larg
number
antibioticresist
suscept
clinic
isol
h
pylori
antiadhes
effect
cranberri
constitu
materi
method
confluent
monolay
gastric
cell
line
well
microtitr
plate
expos
bacteri
suspens
prepar
h
pylori
clinic
isol
includ
patient
treatment
failur
adhes
estim
ureas
assay
calcul
percent
inhibit
adhes
nondialys
materi
antibiot
suscept
h
pylori
isol
metronidazol
tetracyclin
amoxicillin
test
etest
result
twothird
isol
adhes
gastric
cell
inhibit
mgml
nondialys
materi
isol
suscept
amoxicillin
tetracyclin
isol
resist
metronidazol
relationship
antiadhes
effect
cranberri
materi
resist
metronidazol
isol
either
antibiotictr
untreat
patient
import
isol
resist
nondialys
materi
metronidazol
isol
resist
nondialys
materi
alon
crossresist
isol
cranberri
constitu
metronidazol
found
conclus
data
suggest
combin
antibiot
cranberri
prepar
may
improv
erad
h
pylori
method
seropreval
studi
total
peopl
differ
state
countri
evalu
symptomat
asymptomat
adult
symptomat
asymptomat
children
determin
specif
igg
antibodi
made
commerci
elisa
presenc
gene
caga
evalu
patient
metropolitan
area
center
gastric
cancer
control
san
bal
endem
zone
gastric
cancer
detect
vaca
determin
biopsi
patient
san
bal
biopsi
patient
metropolitan
area
biopsi
analys
differ
method
diagnosi
h
pylori
cultur
ureas
test
polymeras
chain
reaction
rapd
genotyp
h
pylori
isol
result
percentag
asymptomat
children
valu
specif
igg
antibodi
antih
pylori
u
vari
metropolitan
area
vs
san
bal
symptomat
adult
group
seropreval
accord
studi
geograph
area
decreas
titl
igg
antibodi
antih
pylori
observ
patient
diffus
antral
gastriti
associ
metaplasia
type
ii
group
endem
cancer
area
titl
igg
antihp
elev
patient
antral
diffus
gastriti
caga
gene
detect
patient
metropolitan
area
unlik
group
patient
san
bal
smaller
frequenc
observ
p
high
incid
genotyp
observ
h
pylori
isol
patient
endem
gastric
cancer
area
unlik
observ
metropolitan
h
pylori
isol
elev
preval
genotyp
found
sampl
gastric
antro
current
resid
area
patient
treat
previous
erad
therapi
exclud
sampl
homogenis
cultur
bloodagar
chocolateagar
pyloriagar
tioglicol
broth
incub
c
microaerofil
atmospher
day
studi
suscept
amoxicillin
claritromicin
ch
metronidazol
mz
tetracyclin
te
ciprofloxacin
cp
detect
imc
etest
follow
nccl
criteria
antibiogram
lectur
result
sampl
male
femal
found
follow
primari
resist
ch
mz
te
cp
sampl
mix
resist
ch
mz
ch
mz
resist
common
femal
differ
statist
signific
mz
p
conclus
progress
increas
antibiot
resist
h
pylori
area
may
relat
rais
use
antibiot
indic
ch
resist
data
agre
spanish
multicentr
european
studi
show
foremost
rate
mediterranean
area
mz
resist
higher
spanish
work
high
preval
resist
support
idea
avoid
imidazol
therapi
primari
choic
treatment
preval
consequ
antibiot
resist
danish
h
pylori
strain
isol
interv
year
object
background
treatment
h
pylori
hp
infect
complex
use
combin
therapi
imper
choic
antibiot
often
made
exclus
empir
basi
although
resist
mani
therapeut
relev
antibiot
describ
mainstay
hp
treatment
denmark
variou
combin
normal
two
follow
antibiot
metronidazol
amoxicillin
tetracyclin
clarithromycin
clarifi
whether
compound
remain
drug
choic
decid
determin
suscept
metronidazol
clarithromycin
tetracyclin
amoxicillin
hp
strain
recent
isol
patient
duoden
ulcer
result
compar
result
previous
obtain
us
use
similar
methodolog
period
year
develop
resist
metronidazol
appear
constitut
problem
otherwis
hp
remain
remark
suscept
therapeut
relev
antibiot
basi
result
recommend
surveil
especi
metronidazol
resist
denmark
markedli
intensifi
eg
increas
use
diagnost
method
hp
infect
allow
suscept
test
case
treatment
metronidazol
consid
suscept
test
cours
major
import
downright
necessari
object
helicobact
pylori
main
caus
agent
peptic
ulcer
diseas
clarithromycin
resist
h
pylori
common
reason
failur
erad
therapi
includ
amoxicillinclarithromycin
proton
pomp
inhibitor
aim
studi
determin
preval
clarithromycin
resist
among
h
pylori
strain
isol
gastric
biopsi
obtain
routin
endoscopi
baskent
univers
medic
faculti
ankara
turkey
method
h
pylori
strain
isol
antral
biopsi
specimen
taken
dyspept
patient
antibiot
suscept
isol
clarithromycin
perform
use
nccl
approv
agar
dilut
e
test
method
result
h
pylori
isol
includ
studi
clarithromycin
resist
found
isol
resist
rate
similar
e
test
agar
dilut
method
conclus
percentag
clarithromycin
resist
among
h
pylori
strain
popul
significantli
high
inform
import
monitor
erad
therapi
defin
region
treatment
polici
introduct
helicobact
pylori
subject
mani
studi
contribut
better
understand
epidemiolog
clinic
import
patholog
upper
gastrointestin
tract
import
caus
duoden
gastric
ulcer
definit
caus
gastric
adenocarcinoma
human
object
determin
seropreval
h
pylori
among
popul
live
rural
commun
relat
epidemiolog
aspect
studi
seropreval
anticaga
virul
factor
step
might
help
studi
magnitud
h
pylori
infect
also
determin
cutoff
valu
among
popul
commun
subject
method
commun
base
field
studi
perform
randomli
chosen
subject
repres
villag
eight
villag
giza
governor
egypt
serolog
test
antih
pylori
anticag
perform
elisa
result
overal
seropreval
antih
pylori
igg
differ
degre
posit
mild
moder
high
anticag
present
signific
agreement
presenc
two
antibodi
howev
studi
relat
antih
pylori
igg
level
anticaga
statist
signific
relat
found
denot
level
infect
even
mild
rule
possibl
associ
virul
strain
h
pylori
age
sex
differ
note
regard
antih
pylori
seroposit
subject
seroposit
anticag
statist
signific
higher
mean
age
relat
seropreval
antih
pylori
type
commun
found
semirur
commun
rural
one
investig
respect
condit
commun
found
preval
rather
relat
pattern
life
socioeconom
statu
possibl
vehicl
transmiss
anim
fli
faecali
contamin
water
consid
vehicl
h
pylori
transmiss
studi
conclus
h
pylori
holoendem
egypt
howev
infect
virul
strain
common
object
extendedspectrum
beta
lactamas
esbl
increas
caus
resist
enterobacteriacea
unfortun
laboratori
detect
esbl
complex
time
mislead
aim
studi
determin
whether
routin
method
perform
clinic
microbiolog
laboratori
tertiari
care
hospit
adequ
detect
emerg
esbl
produc
clinic
isol
method
evalu
esbl
confirm
protocol
collect
enterobacteriaca
strain
isol
laboratori
isol
met
nccl
screen
criteria
potenti
esbl
produc
ceftazidim
cefotaxim
mic
isol
test
kl
pneumonia
five
ent
cloaca
two
ent
aerogen
five
e
coli
four
pr
mirabili
strain
method
routin
use
laboratori
initi
isol
test
clavulan
acid
effect
disk
diffus
method
analys
autom
system
biomerieux
franc
perform
suscept
test
determin
mic
breakpoint
advanc
expert
system
ae
set
phenotyp
resist
knowledgebas
system
panel
use
parallel
isol
test
esbl
etest
ceftazidim
cefotaxim
plu
beta
lactamas
inhibitor
ab
biodisk
sweden
order
confirm
esbl
product
strain
test
isoelectr
focus
ief
follow
pcr
blatem
blashv
blaoxa
blaibc
blactx
gene
result
twentyon
isol
prove
produc
esbl
molecular
method
enterobact
strain
one
proteu
mirabili
esbl
produc
blaoxa
blaibc
gene
detect
pcr
detect
esbl
gene
result
compar
doubl
disk
diffus
esbl
etest
estim
sensit
specif
predict
valu
method
test
sensit
method
respect
specif
respect
predict
valu
respect
discuss
given
increas
incid
esbl
produc
clinic
isol
import
esbl
screen
incorpor
routin
diagnost
test
backup
simpl
disk
diffus
method
autom
system
increas
possibl
identifi
esbl
activ
clinic
strain
hospit
microbiolog
laboratori
set
object
extendedspectrum
betalactamas
esbl
plasmidmedi
betalactamas
mutant
tem
shv
betalactamas
esbl
associ
clinic
failur
due
seriou
interpret
problem
standard
laboratori
test
detect
esbl
remain
challeng
laboratori
sinc
routin
test
monitor
suscept
oxyiminocehalosporin
aztreonam
sensit
enough
detect
esbl
strain
requir
day
describ
oligonucleotid
array
rapid
identif
singl
nucleotid
polymorph
snp
esbl
tem
betalactamas
method
plasmid
dna
amplifi
label
pcr
consensu
primer
pair
flank
blatem
gene
oligonucleotid
array
construct
oligonucleotid
captur
probe
probe
design
snp
central
base
probe
sequenc
maximum
perfect
match
mismatch
discrimin
result
snp
posit
correctli
identifi
signal
intens
valu
rang
perfect
match
probe
discriminatori
power
array
express
rel
intens
mismatch
rimm
remain
mismatch
perfect
match
consid
correctli
identifi
rimm
exceed
analysi
array
reproduc
reveal
analys
sampl
snp
posit
could
identifi
mean
rimm
valu
vari
remain
dna
isol
clinic
sampl
mismatch
blatem
identifi
without
ambigu
remain
rimm
limit
sinc
reduct
arrayhybridis
time
min
influenc
rimm
rimm
limit
less
mismatch
posit
assay
may
perform
within
h
keep
discriminatori
power
conclus
blatem
gene
variant
could
amplifi
use
singl
consensu
primer
pair
use
dnaarray
abl
discrimin
snp
tem
variant
snp
mismatch
could
analys
array
within
h
enabl
identif
correspond
esbl
inhibitor
resist
tem
nccl
recommend
product
extendedspectrum
betalactamas
esbl
detect
doubl
diffus
test
presenc
blatem
gene
determin
pcr
method
transfer
resist
determin
studi
bacteri
conjug
result
clinic
isol
resist
ampicillin
ampi
cefoxitin
cfox
cefotaxim
ctax
ceftazidim
ctaz
ceftriaxon
ciax
cefepim
cepi
azthreonam
aztr
meropenem
merp
gentamicin
gen
tobramycin
tob
netilmicin
net
amikacin
ami
isepamicin
ise
ciprofloxacin
cip
total
clinic
isol
identifi
esbl
produc
presenc
blatem
gene
code
temtyp
betalactamas
detect
clinic
isol
test
resist
determin
antibiot
test
one
except
merp
transfer
bacteri
conjug
recipi
strain
escherichia
coli
frequenc
transfer
rang
conclus
occurr
resist
betalactam
antibiot
high
effici
betalactam
carbapenem
meropenem
fourthgener
cephalosporin
cefepim
aminoglycosid
antibiot
netilmicin
amikacin
isepamicin
high
effici
hand
one
half
clinic
isol
test
resist
fluoroquinolon
ciprofloxacin
betalactam
resist
due
product
esbl
presenc
blatem
gene
major
clinic
isol
transfer
betalactam
aminoglycosid
resist
determin
bacteri
conjug
import
epidemiolog
point
view
object
today
signific
data
effect
cephalosporin
antibiot
nosocomi
infect
caus
microorgan
produc
esbl
method
case
nosocomi
infect
caus
enterobacteriacea
prove
esbl
product
analys
esbl
produc
enterobacteriacea
strain
assay
suscept
differ
antimicrobi
mic
determin
broth
microdilut
method
determin
molecular
type
esbl
gene
polymeras
chain
reaction
sequenc
reaction
use
patient
receiv
initi
empir
intraven
antibacteri
therapi
thirdgener
cephalosporin
cefotaxim
case
failur
cefepim
g
day
prescrib
result
infect
treatment
thirdand
fourthgener
cephalosporin
assess
depend
mic
result
esbl
product
specif
shv
ctx
oligonucleotid
prove
six
strain
enterobacteriacea
four
patient
nosocomi
pneumonia
two
case
mix
infect
took
place
among
four
strain
klebsiella
spp
two
strain
e
coli
analysi
depend
mic
result
treatment
gave
follow
result
tabl
may
state
prove
enterobacteriacea
esbl
product
mic
valu
thirdgener
cephalosporin
major
strain
within
resist
rang
lgml
antibiot
effect
case
cefepim
mic
show
intermedi
sensit
lgml
drug
case
rest
strain
mic
lgml
sensit
therapi
cefepim
effect
three
four
patient
n
n
n
n
conclus
use
mic
breakpoint
mgl
reduc
suscept
thirdgener
cephalosporin
detect
esblproduc
e
coli
k
pneumonia
low
micvalu
mgl
ii
cefotaximehydrolysi
domin
profil
esblposit
e
coli
strain
wherea
ceftazidim
sensit
substrat
detect
esblproduct
k
pneumonia
iii
differ
method
show
almost
sensit
detect
esbl
product
assum
one
substrat
use
ie
cefotaxim
ceftazidim
iv
ctxm
domin
esbltyp
object
srmd
receiv
isol
escherichia
coli
confirm
esbl
product
phenotyp
impli
ctxmtype
betalactamas
ie
cefotaxim
ctx
mic
fourfold
greater
ceftazidim
ctz
mic
isol
hospit
patient
instanc
commun
patient
littl
recent
hospit
contact
temand
shvtype
esbl
larg
confin
nosocomi
isol
appar
spread
ctxm
enzym
commun
caus
concern
compar
isol
investig
genet
basi
ctxm
phenotyp
method
isol
compar
pfge
xbaidigest
genom
dna
data
analys
use
bionumer
softwar
mic
determin
etest
agar
dilut
interpret
use
bsac
breakpoint
isol
ctxm
phenotyp
test
blactxm
allel
pcr
initi
univers
primer
primer
specif
variou
blactxm
group
select
amplicon
sequenc
either
directli
clone
transfer
ctxm
e
coli
attempt
broth
agar
plate
result
ctxmproduc
e
coli
obtain
uk
centr
isol
repres
multipl
strain
although
cluster
relat
isol
similar
observ
includ
isol
one
centr
sequenc
confirm
e
coli
differ
centr
produc
isol
substanti
resist
ctx
mic
mgl
ctz
mic
mgl
consist
isol
n
associ
larg
commun
cluster
produc
atyp
larg
amplicon
group
ctxm
primer
two
relat
isol
anoth
centr
isol
less
resist
ctx
mic
mgl
ctz
mic
mgl
suscept
gentamicin
sequenc
repres
isol
identifi
within
termin
invert
repeat
isecpi
element
upstream
separ
allel
usual
promot
spacer
isecpi
tc
polymorph
seen
sequenc
isol
studi
also
antimicrobi
sensit
strain
coresist
nonbetalactam
antimicrobi
relationship
antibiot
use
method
data
monthli
nondupl
ebslec
antibiot
use
hospit
patday
commun
ddd
inhabitantsday
collect
januari
octob
time
seri
dynam
regress
model
adjust
evalu
relationship
use
antimicrobi
emerg
bacteria
sensit
test
determin
microdilut
gramneg
urin
panel
esbl
produc
strain
initi
select
screen
urin
panel
mic
lgml
cefotaxim
ceftazidim
aztreonam
andor
differ
three
dilut
ceftazidim
ceftazidim
lgml
clavulan
acid
univari
analysi
connect
tissu
diseas
p
genitourinari
patholog
p
infect
past
year
p
previou
exposur
secondgener
cephalosporin
p
factor
associ
ca
infect
due
esbl
ec
regress
model
previou
exposur
secondgener
cephalosporin
strongli
associ
conclus
last
year
mark
increas
infect
due
esbl
ec
especi
commun
previou
exposur
secondgener
cephalosporin
ciprofloxacin
thirdgener
cephalosporin
aminoglycosid
predict
esbl
ec
ca
infect
strikingli
neither
comorbid
previou
contact
healthcar
system
risk
factor
esbl
ec
enzym
ctxm
famili
current
classifi
extendedspectrum
betalactamas
esbl
last
decad
ctxmtype
enzym
increasingli
report
sever
countri
europ
aim
studi
search
ctxmtype
enzym
escherichia
coli
isol
obtain
institut
vares
northern
itali
method
studi
consecut
e
coli
isol
recov
period
stain
suspect
produc
esbl
accord
nccl
criteria
investig
doubledisk
synergi
test
etest
esbl
strip
ab
biodisk
solna
sweden
use
confirm
esbl
product
etest
method
also
use
evalu
mic
amikacin
gentamicin
ciprofloxacin
betalactam
includ
lastgener
cephalosporin
carbapenem
aztreonam
esblposit
isol
evalu
presenc
ctxmtype
gene
use
specif
dna
probe
patient
record
examin
assess
risk
factor
infect
underli
clinic
condit
result
total
consecut
e
coli
isol
studi
overal
esblposit
strain
found
carri
ctxmtype
gene
produc
ctxmtype
enzym
isol
show
high
mic
valu
cefotaxim
mgl
borderlin
valu
ceftazidim
mgl
remain
five
isol
also
high
mic
ceftazidim
ctxmposit
isol
obtain
inpati
n
outpati
n
epidemiolog
analysi
show
strain
isol
urinari
tract
infect
even
though
isol
recov
lower
respiratori
tract
wound
blood
patient
treat
immunosuppress
therapi
recurr
urinari
infect
occur
five
outpati
conclus
ctxmtype
enzym
appear
emerg
among
e
coli
isol
hospit
commun
environ
analysi
clinic
record
demonstr
microorgan
caus
sever
persist
infect
therefor
despit
current
low
preval
ctxm
phenotyp
suggest
monitor
resist
phenotyp
establish
avoid
spread
resist
trait
background
object
class
c
betalactamas
cbl
enzym
confer
broadspectrum
betalactam
resist
includ
penicillin
expandedspectrum
cephalosporin
cephamycin
poorli
suscept
commerci
avail
betalactamas
inhibitor
strain
reduc
outer
membran
permeabl
also
provid
resist
carbapenem
number
enzym
chromosom
encod
plasmidmedi
cbl
also
known
caus
acquir
resist
expandedspectrum
cephalosporin
cephamycin
clinic
isol
enterobacteriacea
itali
acquir
cbl
previous
report
klebsiella
spp
work
report
first
detect
acquir
cbl
cmylat
lineag
escherichia
coli
klebsiella
pneumonia
clinic
isol
italian
hospit
method
ten
consecut
nonrepl
clinic
isol
e
coli
eight
k
pneumonia
two
resist
expandedspectrum
cephalosporin
cephamycin
collect
laboratori
microbiolog
matteo
hospit
pavia
northern
itali
vitro
suscept
test
determin
microdilut
method
accord
nccl
betalactamas
product
investig
analyt
isoelectr
focus
ief
coupl
bioassay
molecular
characteris
betalactamas
gene
carri
multiplex
pcr
approach
design
detect
major
lineag
acquir
cbl
gene
sequenc
transfer
resist
gene
test
mate
assay
liquid
medium
result
two
isol
one
e
coli
one
k
pneumonia
found
resist
expandedspectrum
cephalosporin
except
cefepim
cephamycin
cefoxitin
mic
mgl
isol
produc
betalactamas
pi
show
hydrolyt
activ
cefoxitin
cefotaxim
ceftazidim
molecular
characteris
reveal
case
presenc
acquir
cbl
gene
cmylat
lineag
compat
leader
peptideencod
region
sequenc
cbl
determin
transfer
conjug
e
coli
isol
conjug
transfer
detect
k
pneumonia
isol
conclus
find
reveal
acquir
cbl
cmylat
lineag
common
acquir
cbl
also
encount
nosocomi
set
northern
itali
enteropathogen
dissemin
sulphonamid
resist
gene
first
found
salmonella
portug
p
antun
j
machado
jc
sousa
l
peix
porto
lisbon
p
object
purpos
studi
determin
distribut
sulphonamid
resist
gene
class
integron
portugues
salmonella
isol
collect
human
nonhuman
sourc
method
eight
hundr
seventyf
isol
test
resist
antimicrobi
agent
agar
dilut
method
sulphonamid
resist
isol
screen
resist
gene
class
integron
pcr
assay
result
resist
found
multiresist
isol
sulphonamideresist
isol
mic
mgl
gene
gene
nine
gene
detect
isol
one
gene
encod
sulphonamid
resist
present
three
four
class
integron
found
isol
among
isol
carri
class
integron
present
gene
found
alon
isol
simultan
two
strain
class
integron
lack
gene
carri
gene
isol
harbour
class
integron
conclus
class
integron
sulphonamid
resist
gene
widespread
among
salmonella
newli
describ
gene
identifi
nine
salmonella
isol
collect
human
nonhuman
sourc
portug
salmonella
portug
p
antun
j
machado
jc
sousa
l
peix
porto
lisbon
p
object
aim
studi
characteris
betalactamas
product
portugues
salmonella
isol
collect
human
nonhuman
sourc
method
eight
hundr
seventyf
isol
test
resist
antimicrobi
agent
agar
dilut
method
doubledisk
synergi
test
detect
extendedspectrum
betalactamas
product
perform
disk
diffus
method
identif
betalactamas
done
ampicillin
resist
isol
ief
pcr
assay
primer
detect
gene
encod
tem
oxa
group
iii
enzym
evalu
associ
betalactamas
gene
class
integron
primer
use
pcr
assay
pcr
product
purifi
strand
sequenc
result
total
isol
exhibit
resist
ampicillin
mic
mgl
resist
ampicillin
confer
betalactamas
isol
nine
isol
note
detect
extendedspectrum
betalactamas
esbl
one
isol
temtyp
betalactamas
associ
class
integron
contrast
gene
insert
bp
class
integron
respect
conclus
consider
percentag
portugues
salmonella
resist
betalactam
mostli
due
product
like
betalactamas
insert
integron
detect
isol
produc
esbl
nine
isol
carri
class
integron
caus
concern
due
possibl
therapeut
failur
broadspectrum
betalactam
increas
incid
salmonella
typhii
reduc
suscept
ciprofloxacin
kuwait
aa
dashti
pwj
west
panigrahi
suleibikhat
kwt
object
determin
current
incid
reduc
ciprofloxacin
suscept
salmonella
typhi
compar
previou
data
investig
mechan
respons
method
isol
typhi
collect
test
suscept
ciprofloxacin
antibiot
use
vitek
etest
isol
show
reduc
ciprofloxacin
suscept
subject
pcr
determin
mutat
gyra
gene
respons
pcr
carri
use
two
primer
atgagcgaccttgcgagagaaattacaccg
ttccatcagcccttcaatgctgatgtcttc
result
compar
isol
collect
result
isol
resist
multipl
antibiot
includ
ampicillin
chloramphenicol
tetracyclin
trimethoprim
show
resist
nalidix
acid
reduc
suscept
ciprofloxacin
mic
mgl
suscept
isol
seven
show
reduc
ciprofloxacin
suscept
isol
show
multiresist
strain
none
suscept
isol
reduc
ciprofloxacin
suscept
pcr
result
show
mutat
gyra
gene
conclus
reduc
suscept
ciprofloxacin
multiresist
typhi
increas
suscept
strain
mutat
gyra
mechan
respons
comparison
antimicrobi
resist
diarrhoeagen
escherichia
coli
isol
caus
travel
diarrhoea
two
period
e
mendez
arancibia
j
ruiz
r
cabrera
j
gascon
j
vila
barcelona
e
object
compar
antimicrobi
resist
level
escherichia
coli
clinic
isol
caus
travel
diarrhoea
two
period
materi
method
presenc
enteroaggreg
eaec
enterotoxigen
e
coli
etec
establish
pcr
among
isol
travel
diarrhoea
period
suscept
ampicillin
amp
amoxicillin
plu
clavulan
acid
amc
tetracyclin
tet
chloramphenicol
chl
cotrimoxazol
sxt
nalidix
acid
nal
ciprofloxacin
cip
determin
disk
diffus
result
one
hundr
thirtytwo
eaec
etec
eaec
etec
diarrhoeagen
e
coli
recov
two
period
respect
level
resist
eaec
test
antibacteri
agent
increas
second
period
amp
amc
tet
sxt
nal
cip
p
wherea
leav
resist
chl
show
slight
decreas
statist
signific
etec
strain
resist
amp
nal
cip
amc
increas
respect
resist
chl
decreas
level
resist
tet
sxt
present
greater
differ
suggest
slight
increas
resist
respect
conclus
trend
increas
resist
eaec
etec
amp
amc
nal
cip
detect
decreas
resist
cip
worthi
note
due
fact
antimocrobi
agent
consid
first
choic
treatment
travel
diarrhoea
aj
hakanen
siitonen
p
kotilainen
j
jalava
p
huovinen
turku
helsinki
fin
object
quinoloneresist
salmonella
isol
emerg
finland
main
origin
strain
travel
return
southeast
asia
studi
perform
evalu
incid
chang
fluoroquinolon
resist
salmonella
isol
finland
method
collect
total
salmonella
enterica
isol
consid
epidemiolog
unrel
isol
divid
two
group
finnish
foreign
isol
basi
travel
histori
collect
perform
four
phase
year
start
januari
consecut
collect
finnish
foreign
isol
mic
nalidix
acid
ciprofloxacin
addit
fluoroquinolon
determin
standard
agar
dilut
method
nccl
result
studi
period
number
isol
decreas
ciprofloxacin
suscept
mic
ciprofloxacin
lgml
increas
isol
p
similar
trend
could
seen
among
isol
foreign
finnish
origin
addit
within
nonsuscept
popul
mic
valu
increas
ciprofloxacin
increas
lgml
among
isol
decreas
ciprofloxacin
suscept
respect
figur
lgml
isol
decreas
ciprofloxacin
suscept
also
increas
mic
addit
fluoroquinolon
conclus
number
salmonella
isol
decreas
ciprofloxacin
suscept
continu
grow
finland
moreov
mic
level
isol
increas
phenomenon
might
seriou
clinic
implic
bacteraemia
caus
esblproduc
salmonella
enterica
serovar
virchow
caus
concern
guleri
gd
corcoran
sr
alcock
dj
brown
glasgow
uk
background
antibiot
resist
salmonella
common
develop
countri
strain
larg
zoonot
acquir
resist
anim
host
transmiss
human
food
present
first
case
bacteraem
ill
multiresist
extend
spectrum
beta
lactamas
esbl
produc
nontyphoid
salmonella
case
summari
male
histori
recent
foreign
travel
admit
hospit
day
histori
gastrointestin
symptomsfev
admiss
febril
splenomegali
detect
physic
examin
otherwis
normal
biochemistri
reveal
mildli
derang
liver
function
salmonella
enterica
serovar
virchow
isol
blood
cultur
sensit
vitro
nccl
disk
test
ciprofloxacin
gentamicin
resist
ampicillin
cefuroxim
cefotaxim
ceftriaxon
ceftazidim
cotrimoxazol
nalidix
acid
streptomycin
mic
ciprofloxacin
mgl
antibiot
treatment
ciprofloxacin
respond
well
esbl
detect
isol
identifi
salmonella
enterica
serovar
virchow
api
identif
system
serogroup
serotyp
phagetyp
isol
resist
vitro
nccl
cefotaxim
ceftazidim
test
extendedspectrum
beta
lactamaseampc
product
phenotyp
method
ab
biodisk
esbl
etest
cefepim
ceftazidim
cefotaxim
ae
clavulan
acid
oxoid
esbl
combin
disk
cefpodoxim
ceftazidim
cefotaxim
cefpirom
ae
clavulan
acid
cefoxitin
alon
use
base
modifi
ncclsmanufactur
guidelin
isol
test
posit
esbl
product
esbl
etest
combin
disk
molecular
type
esbl
await
conclus
invas
infect
salmonella
virchow
uncommon
sourc
infect
case
appear
undercook
chicken
emerg
resist
antimicrobi
agent
within
salmonella
worldwid
problem
associ
use
antibiot
livestock
invas
infect
virchow
resist
broadspectrum
betalactam
caus
concern
antimicrobi
therapi
indic
travel
histori
recent
foreign
travel
physician
awar
possibl
treatment
failur
case
mic
thirdgener
cephalosporin
ciprofloxacin
determin
aim
present
studi
assess
distribut
antibiot
resist
rate
arr
variou
nontyphoid
salmonella
serotyp
origin
nonhuman
sourc
greec
period
materi
method
total
isol
belong
differ
serotyp
select
collect
nation
refer
center
salmonella
shigella
nrcss
order
reflect
preval
serotyp
mention
period
sampl
consist
isol
anim
isol
food
environment
isol
suscept
antibiot
variou
class
determin
use
mic
broth
microdilut
method
result
conclus
highest
arr
also
higher
incid
multiresist
observ
virhow
follow
hadar
typhimurium
vast
part
typhimurium
isol
resist
least
ampicillin
tetracyclin
chloramphenicol
main
resist
phenotyp
enteritidi
isol
monoresist
ampicillin
tabl
arr
phenotyp
resist
isol
four
serotyp
similar
correspond
one
human
isol
result
recent
greek
studi
deriv
also
nrcss
eur
j
epidemiol
fact
consist
possibl
transfer
antibiot
resist
strain
anim
human
food
chain
incid
resist
rest
serotyp
low
examin
isol
suscept
ceftriaxon
ciprofloxacin
interestingli
almost
examin
isol
belong
anim
bred
nonindustri
scale
eg
pigeon
environment
isol
sensit
test
antimicrobi
possibl
reduc
antibiot
pressur
isol
isol
rate
enteritidi
typhimurium
other
respect
first
period
second
period
isol
rate
found
respect
antimicrobi
resist
amp
tmpsxt
enteritidi
typhimurium
other
found
laboratori
data
analys
shigella
spp
isol
stool
materi
adult
patient
period
retrospect
shigella
isol
identifi
standard
biochem
reaction
use
specif
antisera
antimicrobi
suscept
ampicillin
amp
trimethoprimsulfamethoxazol
tmpsxt
ciprofloxacin
cip
determin
disk
diffus
method
accord
nation
committe
clinic
laboratori
standard
result
order
show
differ
epidemiolog
antimicrobi
resist
studi
divid
two
period
first
period
second
period
total
shigella
spp
isol
obtain
first
period
isol
second
period
isol
rate
strain
first
second
period
respect
shigella
flexneri
shigella
sonnei
shigella
dysenteria
shigella
boydii
rate
resist
amp
first
second
period
respect
flexneri
sonnei
dysenteria
boydii
rate
resist
tmpsxt
flexneri
sonnei
dysenteria
boydii
strain
suscept
ciprofloksasin
conclus
flexneri
common
speci
isol
first
period
sonnei
common
speci
second
period
ankara
data
show
increas
resist
commonli
use
antimicrobi
agent
ampicillin
trimethoprimsulfamethoxazol
ciprofloxacin
seem
best
choic
treatment
shigelliosi
determin
antimicrobi
resist
salmonella
shigella
strain
isol
stool
specimen
period
patient
admit
clinic
diagnosi
diarrhoea
method
identif
suscept
test
done
vitec
biomerieux
fr
autom
system
antibiot
test
studi
ampicillin
ampicillinsulbactam
cefotaxim
cefepim
ciprofloxacin
ofloxacin
trimethoprimsulfametaxazol
result
nineteen
salmonella
seven
shigella
isol
obtain
januari
novemb
test
suscept
seven
antimicrobi
agent
total
number
isol
includ
year
big
marmara
earthquak
five
six
shigella
isol
sonnei
one
flexneri
thirteen
salmonella
isol
typhimurium
three
enteritidi
two
identifi
salmonella
spp
one
arizona
although
isol
found
suscept
therapeut
agent
ampicillin
suscept
decreas
trimethoprimsulfametaxazol
suscept
decreas
salmonella
strain
period
one
strain
resist
cefotaxim
resist
found
ofloxacin
ciprofloxacin
shigella
isol
suscept
test
antibiot
conclus
incid
salmonella
shigella
infect
seem
decreas
significantli
period
typhimurium
shigella
sonnei
commonli
identifi
serotyp
signific
chang
resist
old
new
antibiot
isol
show
good
sensit
antimicrobi
test
care
rotat
use
antibiot
might
best
polici
make
old
drug
activ
abus
new
agent
object
sinc
incid
human
campylobacteriosi
shown
signific
increas
austria
consumpt
contamin
poultri
product
well
known
risk
factor
human
infect
slaughter
process
meat
product
becom
contamin
intestin
organ
furthermor
antibiot
resist
increas
human
anim
aim
studi
determin
resist
pattern
transmiss
rout
campylobact
sp
chickencarcass
along
slaughter
line
compar
frequenc
isol
occurr
antimicrobi
resist
among
c
jejuni
c
coli
isol
human
retail
poultri
meat
farm
broiler
method
fiftythre
human
retail
poultri
meat
campylobact
spp
isol
broiler
cloacal
swab
investig
antibiot
suscept
antimicrobi
diskdiffus
method
mic
determin
erythromycinand
ciprofloxacinresist
isol
etest
confirm
ciprofloxacinresist
use
mismatch
amplif
mutat
assay
mama
pcr
detect
gyra
mutat
speci
determin
multiplex
pcr
genet
divers
pfge
type
result
c
coli
isol
signific
proport
three
sourc
respect
resist
one
antibiot
test
multiresist
human
retail
poultri
farm
isol
respect
signific
differ
found
overal
resist
rate
antibiot
test
c
jejuni
c
coli
isol
three
sourc
unusu
find
moreov
higher
c
jejuni
given
war
popul
region
mostli
muslim
c
coli
human
origin
sourc
pig
thu
may
suggest
c
coli
resist
originrel
erythromycinand
ciprofloxacinresist
high
almost
equal
three
sourc
respect
import
retail
poultri
meat
five
countri
higher
resist
rate
erythromycin
domest
one
vs
ciprofloxacin
resist
higher
domest
one
vs
conclus
distribut
c
jejuni
c
coli
speci
drug
resist
isol
chicken
farm
anim
similar
seen
human
even
absenc
antibiot
pressur
patient
year
age
growth
promot
ban
bosnia
herzegovina
suggest
poultri
may
play
role
human
infect
pfge
pattern
consid
remark
divers
suggest
consider
genet
heterogen
may
support
hypothesi
campylobact
spp
food
anim
human
may
repres
discret
popul
rather
form
part
common
popul
share
food
anim
human
suggest
relat
sourc
infect
object
investig
design
studi
potenti
use
econom
benefit
oral
linezolid
altern
outpati
parenter
antibiot
therapi
opat
treatment
primari
cellul
method
patient
moder
sever
cellul
refer
infus
centr
antibiot
treatment
enrol
open
nonrandomis
pilot
studi
inform
written
consent
patient
treat
oral
linezolid
mg
h
place
prescrib
parenter
antibiot
patient
follow
clinic
visit
lab
monitor
result
total
patient
five
male
five
femal
mean
age
year
enrol
seven
obes
mean
weight
kg
rang
kg
six
lower
extrem
cellul
one
lymphedema
two
smoker
averag
length
linezolid
therapi
day
rang
day
compliant
treatment
regimen
clinic
cure
infect
mild
sideeffect
nausea
loos
stool
headach
metal
tast
report
four
patient
none
develop
thrombocytopenia
prematur
discontinu
therapi
cours
linezolid
therapi
drug
cost
clinic
visit
lab
monitor
found
less
expens
day
vancomycin
treatment
g
h
infus
centr
conclus
studi
found
oral
linezolid
safe
effect
treatment
moder
sever
cellul
could
suitabl
replac
opat
furthermor
oral
linezolid
potenti
improv
patient
satisfact
well
lower
overal
treatment
cost
compar
opat
object
vancomycin
v
combin
rifampin
r
gentamicin
g
recommend
regimen
treatment
pve
caus
mrsa
intoler
agent
emerg
mrsa
strain
reduc
suscept
glycopeptid
creat
need
altern
agent
describ
case
patient
mrsa
tricuspid
pve
success
treat
linezolid
l
failur
glycopeptid
case
man
admit
persist
mrsa
bacteraemia
treat
v
g
r
trimethoprim
sulfamethoxazol
ts
mrsa
pve
tricuspid
valv
recur
cours
v
cours
ts
due
acut
renal
failur
g
discontinu
v
chang
teicoplanin
transfer
depart
persist
bacteraemia
day
durat
despit
adequ
blood
level
blood
cultur
reveal
mrsa
strain
mic
v
l
mgl
respect
start
l
mg
bid
r
mg
tid
bacteraemia
clear
seventh
day
treatment
complet
cours
l
cours
r
treatment
develop
anaemia
manag
blood
transfus
erythropoetin
mild
leucopenia
mild
thrombocytopenia
discharg
afebril
steril
blood
cultur
tee
show
reduct
size
veget
patient
remain
well
blood
cultur
steril
one
month
later
pancytopenia
fulli
recov
mrsa
isol
investig
heteroresist
glycopeptid
simplifi
detail
popul
analysi
profil
method
ml
cfuml
bacteri
suspens
plate
bhi
agar
v
mgl
subclon
grew
h
submit
mic
determin
tenfold
serial
diluent
inoculum
cfuml
plate
bhi
agar
plate
increas
concentr
v
alon
nacl
viabl
coloni
count
h
plot
antibiot
concentr
subclon
v
mic
mgl
identifi
suggest
isol
heterogen
reduc
suscept
v
probabl
explain
failur
v
treatment
popul
curv
show
origin
inoculum
surviv
concentr
mgl
suggest
heteroresist
three
studi
patient
treat
lnz
shorter
intraven
antibiot
treatment
ivat
durat
patient
compar
group
result
increas
rate
earli
patient
discharg
reduc
use
resourc
two
studi
patient
significantli
shorter
mean
lo
greater
odd
earli
discharg
hospit
inde
compar
tei
treatment
lnz
greater
odd
earli
discharg
p
similar
earli
discharg
potenti
also
seen
lnz
compar
van
p
select
patient
popul
cssti
due
suspectedconfirm
mrsa
reduct
lo
may
even
pronounc
lnzv
vantreat
patient
cost
comparison
third
studi
total
mean
adjust
cost
also
reduc
us
p
lnz
group
compar
tei
group
patient
south
america
mexico
conclus
across
multipl
studi
consist
evid
signific
reduct
lo
ivat
associ
lnz
treatment
signific
differ
rate
earli
patient
discharg
therapi
lnz
show
pharmacoeconom
advantag
potenti
reduc
total
cost
treatment
vitro
activ
mrsa
oral
administr
repres
excel
altern
iv
vancomycin
current
recommend
cf
patient
colonis
mrsa
materi
method
oral
lnz
bid
administr
two
male
cf
patient
year
day
respect
aureu
isol
cultur
differ
sputum
sampl
recov
lnz
treatment
antibiot
suscept
perform
nccl
microdilut
method
use
wider
system
fco
soria
melguizo
sa
madrid
spain
pfgesmai
appli
analys
genet
related
aureu
isol
result
first
patient
total
isol
analys
studi
period
six
recov
previou
year
lnz
administr
two
isol
lnz
administr
period
two
isol
month
end
treatment
except
one
isol
methicillinsuscept
recov
lnz
treatment
period
isol
mrsa
present
homogen
antibiot
suscept
pattern
singl
clone
subtyp
variant
includ
two
isol
identifi
isol
except
meticillinsuscept
one
second
patient
two
mrsa
one
meticillinsuscept
isol
recov
month
lnz
therapi
anoth
methicillinsuscept
isol
recov
lnz
therapi
aureu
identifi
follow
cf
control
month
mrsa
isol
share
pfge
antibiot
suscept
pattern
wherea
meticillinsuscept
isol
correspond
two
differ
clone
unrel
mrsa
clone
independ
microbiolog
result
patient
pulmonari
function
remain
unchang
lnz
administr
conclus
oral
lnz
treatment
cf
may
affect
popul
dynam
aureu
colonis
effect
mrsa
erad
despit
fact
assum
brief
followup
period
mainten
erad
mrsa
colonis
lnz
treatment
seem
affect
pulmonari
function
may
relat
uncertain
role
pathogen
cf
patient
vitro
spectrum
linezolid
agent
clinic
isol
anaerob
k
aldridg
c
mander
broyl
new
orlean
usa
object
linezolid
oxazolidinon
antimicrobi
establish
vitro
vivo
activ
aerob
gramposit
cocci
infect
wound
gramposit
pathogen
may
mix
pathogen
includ
anaerob
role
linezolid
antianaerob
agent
yet
determin
studi
perform
establish
vitro
activ
linezolid
compar
agent
recent
isol
anaerob
method
approxim
anaerob
test
suscept
linezolid
lzd
ceftriaxon
axo
cefoxitin
fox
clindamycin
cl
metronidazol
mrd
use
twofold
dilut
mgl
agent
use
ncclsrecommend
broth
microdilut
method
sourc
test
isol
includ
wound
abscess
bodi
fluid
tissu
result
test
isol
lzd
mic
rang
mgl
mode
mic
mgl
valu
mgl
respect
lzd
activ
judg
percentag
isol
inhibit
mgl
overal
lzd
inhibit
isol
mgl
respect
mgl
respect
lzd
inhibit
bacteroid
fragili
group
clostridium
isol
prevotella
isol
fusobacterium
isol
peptostreptococcu
isol
comparison
valu
lzd
activ
axo
activ
fox
activ
cl
group
isol
lzd
mrd
virtual
equal
vitro
activ
interestingli
isol
mic
mgl
higher
lzd
mic
mgl
less
mrd
isol
mic
mgl
higher
mrd
mic
mgl
less
lzd
conclus
base
result
arbitrari
use
nccl
breakpoint
gramposit
isol
conclud
lzd
highli
activ
anaerob
pathogen
need
verifi
pharmacokinet
clinic
studi
result
compar
mic
current
studi
result
year
ago
unmistak
alarm
declin
suscept
note
antimicrobi
agent
test
greatest
differ
suscept
note
cefoxitin
metronidazol
piperacillin
amoxicillin
antimicrobi
agent
decreas
suscept
found
includ
meropenem
clindamycin
ciprofloxacin
great
concern
howev
decreas
found
suscept
imipenem
conclus
decad
ago
anaerob
bacteria
suscept
antimicrobi
agent
usual
use
infect
caus
bacteria
result
studi
howev
indic
situat
undergon
dramat
chang
rel
short
period
concern
agent
frequent
use
empir
treatment
anaerob
infect
metronidazol
blactam
cefoxitin
piperacillin
shown
alarm
decreas
suscept
ever
definit
need
continu
suscept
test
anaerob
seriou
restructur
treatment
regim
anaerob
infect
camarda
pennelli
p
battista
corrent
alloggio
valenzano
object
escherichia
coli
isol
fatteningrabbit
dead
enter
biotypis
test
pcr
presenc
virul
gene
eae
code
intimin
fimbrial
adhesin
investig
antimicrobi
resist
method
fiftysix
strain
e
coli
isol
farm
biotypis
use
ferment
sorbos
dulcitol
raffinos
sucros
l
lrhamnos
detect
drug
resist
determin
use
method
kirbybau
muellerhinton
agar
antibiot
disk
contain
gentamicin
amikacin
tetracyclin
erythromicin
spiramicin
enrofloxacin
flumequin
trimethoprim
sulphametoxazol
sxt
amoxicillin
amx
apramycin
difloxacin
marbofloxacin
nalidix
acid
neomycin
colistin
streptomycin
result
biotyp
detect
biotyp
predomin
rabbitri
eae
gene
almost
observ
e
coli
strain
belong
result
antibiogram
shown
isol
resist
high
rate
resist
also
found
toward
sxt
e
coli
test
show
suscept
rate
suscept
exhibit
strain
respect
sensit
quit
high
multipl
antibiot
resist
express
e
coli
test
preval
resistotyp
resist
detect
strain
account
detect
isol
conclus
signific
correl
observ
enteropathogen
e
coli
eae
pattern
antibiot
resist
quinolon
shown
good
activ
particular
recent
adopt
veterinari
medicin
seem
possess
high
efficaci
hand
e
coli
strain
exhibit
highlevel
resist
antimicrobi
like
human
e
coli
rabbit
strain
reveal
differ
pattern
multiresist
could
make
diseas
control
difficult
rabbit
also
promot
dissemin
increas
antimicrobi
resist
human
strain
object
determin
frequenc
suscept
pattern
bacteri
pathogen
isol
bloodstream
bsi
haematologyoncolog
patient
hospitalis
latin
american
medic
centr
materi
method
part
sentri
antimicrobi
surveil
program
total
bsi
isol
recov
haematologyoncolog
patient
isol
suscept
test
antimicrobi
agent
central
laboratori
use
nccl
broth
microdilut
method
result
frequent
isol
pathogen
coagulaseneg
staphylococci
con
follow
escherichia
coli
staphylococcu
aureu
klebsiella
pneumonia
pseudomona
aeruginosa
enterobact
spp
acinetobact
spp
enterococcu
spp
oxacillinresist
rate
among
aureu
con
respect
isol
preval
esblproduc
strain
rang
e
coli
k
pneumonia
enterobact
spp
suscept
rate
ceftazidim
cefepim
respect
enterobacteriacea
isol
test
suscept
carbapenem
suscept
p
aeruginosa
imipenem
meropenem
respect
gramneg
bacilli
suscept
cefepim
meropenem
respect
enterococcu
spp
isol
resist
vancomycin
conclus
contrast
american
european
report
gramneg
bacilli
repres
major
caus
bsi
among
haematologyoncolog
patient
latin
american
hospit
evalu
antimicrobi
agent
best
cover
pathogen
carbapenem
cefepim
howev
none
evalu
antimicrobi
agent
inhibit
growth
gramneg
bacilli
thu
continu
monitor
surveil
program
necessari
determin
observ
trend
would
continu
record
object
attempt
verifi
frequenc
occurr
fo
antimicrobi
suscept
profil
asp
bacteri
isol
respons
caus
bloodstream
infect
bsi
paediatr
patient
vari
along
year
age
categori
method
total
bloodstream
isol
collect
paediatr
patient
hospitalis
latin
american
hospit
sentri
program
asp
variou
antimicrobi
determin
nccl
broth
microdilut
method
fo
asp
studi
accord
age
categori
ac
year
year
year
result
overal
aureu
sa
frequent
isol
pathogen
among
children
year
year
follow
coagulas
neg
staphylococci
con
among
children
year
year
pneumonia
spn
rank
among
top
five
pathogen
contrast
caus
less
bsi
among
children
year
curious
age
group
acinetobact
spp
p
aeruginosa
assum
fifth
posit
rank
order
frequenc
gener
among
sa
oxacillin
resist
rate
lower
ac
p
children
year
year
contrast
among
con
elev
rate
notic
ac
year
year
year
p
esblproduc
k
pneumonia
frequent
detect
ac
year
k
pneumonia
isol
year
year
contrari
esblproduc
e
coli
isol
less
frequent
encount
among
children
year
children
year
howev
differ
reach
statist
signific
p
spn
isol
show
reduc
suscept
penicillin
detect
frequent
ac
year
year
year
p
conclus
although
slight
differ
fo
bsi
pathogen
notic
along
year
ac
import
differ
observ
asp
bsi
pathogen
accord
age
categori
especi
spn
sa
isol
object
aim
prospect
multicentr
studi
assess
incid
gramposit
bacteria
bloodstream
infect
bsi
characterist
resist
antibiot
czech
republ
method
studi
done
site
czech
republ
januari
april
consecut
gramposit
strain
isol
blood
assess
clinic
signific
evalu
result
strain
staphylococcu
aureu
coagulaseneg
staphylococci
streptococcu
pneumonia
enterococcu
spp
identifi
etiolog
agent
gramposit
bsi
frequenc
oxacillinresist
strain
staphylococcu
aureu
coagulaseneg
staphylococci
respect
streptococcu
pneumonia
strain
suscept
penicillin
chloramphenicol
strain
resist
glycopeptid
found
enterococci
clinic
signific
isol
gramposit
bacteria
significantli
condit
bacteri
speci
p
reach
streptococcu
pneumonia
staphylococcu
aureu
enterococcu
spp
strain
coagulaseneg
staphylococci
product
bacteri
biofilm
shown
staphylococcu
aureu
strain
coagulaseneg
staphylococci
bsi
immedi
caus
death
patient
conclus
could
confirm
presenc
artifici
materi
mean
signific
risk
factor
bsi
catheterrel
infect
present
case
fortysix
per
cent
bsi
characteris
secondari
pneumonia
git
infect
urinari
tract
infect
common
sourc
frequenc
staphylococcu
spp
posit
find
biofilm
studi
find
support
clinic
signific
method
total
aureu
posit
sampl
isol
januari
decemb
laboratori
analys
suscept
antibiot
assess
antibiogram
base
api
system
accord
french
guidelin
casfm
sa
strain
classifi
methicillin
suscept
gentamicin
suscept
gentasmssa
methicillin
resist
gentamicin
suscept
gentasmrsa
methicillin
suscept
gentamicin
resist
gentarmssa
methicillin
resist
gentamicin
resist
gentarmrsa
number
isol
calcul
admiss
mean
per
year
compar
use
kruskal
walli
test
spearman
coeffici
r
use
calcul
correl
proport
isol
antibiot
resist
profil
month
result
overal
proport
sa
posit
sampl
admiss
studi
period
respect
r
p
percentag
mssa
genta
gentar
percentag
mssa
genta
gentar
total
period
patient
mrsa
older
year
compar
patient
mssa
mean
age
p
patient
gentarmrsa
younger
year
compar
patient
gentasmrsa
mean
age
p
proport
gentasmssa
admiss
similar
time
p
r
p
howev
proport
gentasmrsa
strain
increas
significantli
p
r
p
proport
gentarmrsa
strain
decreas
significantli
period
conclus
although
proport
sa
posit
sampl
admiss
remain
constant
last
year
continu
increas
trend
isol
gentasmrsa
decreas
trend
isol
gentarmrsa
age
differ
two
subgroup
explor
greek
region
corfu
island
e
gatsouli
ovrenovit
pasxali
tzanavari
corfu
gr
background
order
assess
region
trend
microbiolog
resist
pattern
cultur
bacteria
isol
laboratori
review
specimen
sourc
suscept
profil
materi
method
sampl
cultur
hospitalis
patient
ambulatori
patient
sampl
urin
blood
cultur
lesion
sampl
secret
classic
cultur
method
vitek
system
nccl
breakpoint
use
result
cultiv
posit
adult
children
sampl
distribut
bacteria
differ
accord
type
specimen
distribut
gram
enterobacteriacea
nonfer
bacilli
gram
cocci
yeast
e
coli
predomin
enterobacteriacea
follow
klebsiella
sp
p
aeruginosa
nonfer
bacilli
baumanii
among
gram
aureu
frequent
follow
cn
ampicillin
inhibit
growth
e
coli
ttimesulfa
combin
could
inhibit
less
secondgener
cephalosporin
less
fluoroquinolon
effect
enterobacteriacea
strain
piperacillin
inhibit
growth
p
aeruginosa
quinolon
less
enterococcu
strain
highli
sensit
teicoplanin
nitrofurantoin
mrsa
gisa
baumanii
gisa
icu
conclus
perman
surveil
frequenc
sensit
level
common
pathogen
respons
infecti
enabl
identifi
local
antimicrobi
activ
play
key
role
start
empir
therapi
pend
bacteri
identif
vitro
assay
object
biochemistri
genet
antibiot
resist
well
document
howev
inform
regard
medic
social
factor
influenc
occurr
remain
lack
aim
studi
elucid
latter
relationship
examin
dynam
effect
method
antibiot
resist
data
bacteri
isol
obtain
commun
collect
microbiolog
laboratori
wale
antibiot
prescrib
data
practic
demograph
depriv
indic
gener
practition
demograph
detail
sampl
behaviour
also
obtain
period
gener
practic
wale
initi
analys
explor
natur
data
relationship
variou
compon
undertaken
use
excel
spss
result
preliminari
analys
indic
antibiot
resist
prescrib
vari
practic
coliform
uti
clear
associ
high
prescrib
higher
level
resist
prescrib
account
variat
resist
correl
prescrib
resist
confin
urinari
coliform
seen
throughout
rang
pathogen
includ
respons
respiratori
skin
infect
associ
resist
social
depriv
exceed
expect
high
prescrib
depriv
area
appar
associ
resist
number
practition
practic
practic
list
size
resist
common
infect
young
year
age
year
pathogen
resist
significantli
greater
male
multilevel
model
regress
analysi
time
seri
analysi
complex
data
set
progress
conclus
antibiot
usag
appear
affect
resist
practic
level
dynam
select
process
current
investig
hope
studi
assist
design
intervent
limit
futur
impact
resist
contribut
abil
predict
outcom
object
data
preval
antimicrobi
resist
indonesia
limit
amrin
studi
measur
preval
antimicrobi
resist
indonesian
popul
insid
outsid
hospit
method
individu
target
screen
constitut
four
differ
popul
two
citi
patient
admit
hospit
patient
discharg
hospit
patient
visit
primari
health
centr
rel
patient
admit
hospit
nasal
swab
rectal
swab
taken
cultur
use
phenol
red
mannitol
agar
isol
staphylococcu
aureu
chrom
agar
orient
medium
escherichia
coli
suscept
test
perform
disk
diffus
method
recommend
nccl
result
individu
includ
studi
juli
octob
surabaya
januari
may
semarang
equal
distribut
four
group
two
citi
aureu
isol
n
frequent
resist
tetracyclin
oxacillin
without
obviou
differ
four
popul
none
oxacillin
resist
strain
aureu
harbour
mec
gene
e
coli
isol
n
show
consider
level
resist
number
commonli
use
antibiot
highest
level
resist
ampicillin
chloramphenicol
gentamicin
cefotaxim
ciprofloxacin
cotrimoxazol
among
e
coli
isol
patient
day
discharg
hospit
resist
rate
consist
lowest
among
e
coli
rel
patient
admiss
hospit
among
patient
visit
primari
health
care
centr
conclus
result
show
antimicrobi
resist
among
common
bacteri
pathogen
emerg
indonesia
among
e
coli
preval
resist
ciprofloxacin
antibiot
remark
high
especi
individu
hospitalis
although
preval
mrsa
low
tetracyclin
resist
common
among
aureu
associ
hospit
stay
method
isol
patient
invas
diseas
caus
haemophilu
influenza
hi
neisseria
meningitidi
nm
group
streptococcu
ga
group
b
streptococcu
gb
forward
refer
laboratori
alaska
alaska
canada
canada
greenland
greenland
confirm
serotyp
chart
review
conduct
confirm
case
verifi
ill
episod
inform
data
report
preliminari
result
total
number
report
case
hi
nm
ga
gb
crude
annual
rate
invas
diseas
per
popul
vari
countri
organ
hi
conclus
nativ
peopl
ak
n
high
rate
invas
bacteri
diseas
caus
hi
nm
ga
gb
overal
rate
nm
diseas
higher
gn
ak
n
case
invas
hib
diseas
continu
occur
children
year
age
rate
hia
appear
elev
n
increas
ak
howev
caution
need
use
interpret
rate
due
small
number
case
trend
merit
surveil
elev
case
fatal
rate
ak
hi
nm
also
warrant
investig
object
tertiari
care
hospit
know
local
pattern
spectrum
suscept
refer
institut
add
significantli
select
appropri
antimicrobi
therapi
object
get
inform
regard
region
specif
frequenc
occurr
pattern
antimicrobi
suscept
common
bacteri
infect
central
illinoi
method
use
hospit
antibiogram
data
assess
predomin
pathogen
pattern
vitro
antimicrobi
suscept
bacteri
infect
four
region
west
southwest
central
south
central
illinoi
januari
june
result
gramneg
bacteria
predomin
four
region
respect
region
e
coli
common
organ
follow
aureu
e
faecali
p
aeruginosa
k
pneumonia
also
among
five
frequent
report
speci
hand
frequenc
occurr
pneumonia
four
region
pattern
methicillinresist
aureu
differ
four
region
total
number
aureu
show
intermedi
resist
vancomycin
e
faecali
respect
suscept
vancomycin
suscept
pneumonia
penicillin
almost
four
region
surpris
p
aeruginosa
least
suscept
speci
among
gramneg
bacteria
speci
show
decreas
suscept
gentamicin
ciprofloxacin
conclus
data
show
differ
commun
central
illinoi
variabl
occurr
pattern
antimicrobi
suscept
common
bacteri
infect
plan
formul
region
antibiogram
distribut
hospit
area
follow
pattern
prospect
renew
antibiogram
year
antimicrobi
resist
surveil
gramneg
anaerob
bacteria
isol
six
greek
hospit
j
papaparaskeva
nj
legaki
katsandri
avlami
hellen
studi
group
gramneg
anaerob
bacteria
object
antimicrobi
resist
surveil
gramneg
anaerob
bacteria
isol
six
greek
hospit
method
total
gramneg
anaerob
clinic
strain
bacteroid
fragili
group
bacteroid
spp
nonfragili
prevotella
spp
fusobacterium
spp
miscellan
isol
period
novemb
novemb
test
use
etest
method
brucella
blood
agar
plate
incub
chellab
anaerob
chamber
perform
h
interpret
accord
nccl
guidelin
result
overal
gramneg
nonsuscept
intermedi
fulli
resist
rate
penicillin
ticarcillin
clavulan
acid
cefoxitin
tetracyclin
clindamycin
metronidazol
imipenem
ertapenem
respect
bacteroid
fragili
group
rate
respect
prevotella
spp
rate
respect
overal
gramneg
mgl
respect
bacteroid
fragili
group
respect
prevotella
spp
respect
metronidazol
resist
detect
among
four
prevotella
spp
one
bacteroid
spp
one
porphyromona
spp
one
fusobacterium
spp
isol
addit
b
fragili
strain
found
highli
resist
mic
mgl
imipenem
ertapenem
resist
antimicrobi
test
except
metronidazol
conclus
carbapenem
betalactam
inhibitor
combin
metronidazol
remain
antimicrobi
agent
choic
gramneg
anaerob
howev
metronidazol
resist
seem
emerg
problem
greec
especi
among
prevotella
spp
isol
respect
speci
identif
period
suscept
surveil
mandatori
imipenem
ertapenem
activ
compar
though
ertapenem
mic
slightli
higher
acknowledg
member
hellen
studi
group
gram
neg
anaerob
bacteria
dr
avlami
c
koutsiakarouz
c
kontoukastelan
pangali
e
papafranga
e
trikagrafako
valu
qualiti
control
strain
suscept
test
k
huppertz
noll
b
wiedemann
genar
group
object
goal
qualiti
control
programm
assist
monitor
precis
accuraci
suscept
test
procedur
perform
reagent
use
test
perform
person
carri
test
read
result
best
accomplish
test
qualiti
control
qc
strain
known
suscept
antimicrobi
agent
test
nccl
therefor
qc
strain
measur
done
laboratori
take
part
genarsproject
german
network
antimicrobi
resist
surveil
use
comparison
perform
three
differ
method
mic
determin
method
genarsproject
two
commerci
mic
test
system
one
manual
microdilut
system
accord
nccl
use
determin
antimicrobi
suscept
commerci
system
vitek
micronaut
system
merlin
diagnost
microtitrepl
qc
strain
measur
test
system
evalu
antibiot
rang
dilut
step
modal
valu
respect
qc
strain
includ
rang
concentr
test
reliabl
assess
test
qualiti
distanc
modal
valu
lowest
highest
concentr
test
two
dilut
step
result
multitud
antibiot
test
drug
test
rang
concentr
meet
mention
requir
tabl
indic
number
test
combin
avail
evalu
vitek
system
offer
shortest
rang
concentr
howev
rang
concentr
test
other
calcul
eg
gentamicin
rang
includ
six
concentr
three
measur
conclus
evalu
qc
strain
measur
possibl
antibiot
test
howev
due
concentr
chosen
short
rang
concentr
avail
differ
testsystem
antimicrobi
agent
use
comparison
perform
test
method
therefor
either
rang
concentr
extend
suitabl
qc
strain
implement
way
mic
fall
rang
concentr
suffici
clinic
term
lack
evid
dna
antibiot
prepar
sourc
antibiot
resist
gene
skp
lau
pci
woo
apc
atk
lau
ky
yuen
hong
kong
hk
object
investig
signific
dna
encod
antibiot
resist
gene
present
antibiot
prepar
rapid
develop
antibioticinduc
antimicrobi
resist
method
comprehens
studi
use
sequenc
align
phylogenet
analysi
gene
encod
antibiot
resist
antibioticproduc
bacteria
correspond
one
nonantibioticproduc
human
anim
bacteri
isol
erythromycin
resist
methylas
erm
aminoglycosid
phosphotransferas
aminoglycosid
phosphotransferas
aminoglycosid
acetyltransferas
aac
class
betalactamas
tetracyclin
resist
efflux
protein
tetracyclin
resist
ribosom
protect
protein
vancomycin
resist
protein
vana
vanh
vanx
bacitracin
transport
protein
bcra
bcrb
bcrc
carri
dna
encod
antibiot
resist
gene
present
antibiot
prepar
import
develop
antibiot
resist
gene
almost
ident
amino
acid
sequenc
would
expect
present
antibioticproduc
organ
human
anim
bacteria
infer
horizont
transfer
antibioticresist
gene
occur
former
latter
result
maximum
amino
acid
ident
gene
among
differ
nonantibioticproduc
bacteri
isol
close
gene
antibioticproduc
human
anim
bacteria
rang
therefor
recent
horizont
transfer
antibiot
resist
gene
occur
antibioticproduc
organ
human
anim
bacteria
hand
frequent
horizont
transfer
antibiot
resist
gene
observ
among
human
anim
bacteria
even
phylogenet
distantli
relat
moreov
transfer
particularli
common
among
gastrointestin
tract
flora
pathogen
conclus
dna
encod
antibiot
resist
gene
antibiot
prepar
import
sourc
antibiot
resist
gene
dna
decontamin
process
antibiot
synthesi
probabl
necessari
human
gastrointestin
tract
import
place
bacteri
gene
exchang
role
human
gut
dissemin
antibiot
resist
investig
enterococci
gramposit
bacteria
glycopeptideresist
enterococci
gre
emerg
import
pathogen
sinc
late
import
factor
associ
appear
gre
commun
europ
avoparcin
glycopeptid
antimicrobi
drug
use
year
mani
european
countri
growth
promot
foodproduc
anim
europ
evid
suggest
foodborn
gre
may
caus
human
colonis
infect
object
object
studi
investig
preval
determin
genotyp
gre
differ
human
anim
sourc
styria
austria
method
stool
specimen
patient
preced
antibiot
therapi
nonhospitalis
human
without
preced
antibiot
therapi
faecal
cattl
specimen
faecal
pig
specimen
faecal
poultri
specimen
collect
one
millilitr
dilut
faec
ad
ml
enterococcosel
bouillon
bd
enrich
incub
ml
subcultur
vre
screen
agar
bd
speci
identif
perform
api
strep
system
resist
vancomycin
teicoplanin
determin
etest
method
ab
biodisk
determin
glycopeptid
resist
genotyp
vana
vanb
perform
pcr
result
patient
preced
antibiot
therapi
harbour
vre
among
two
identifi
e
faecium
vana
two
e
gallinarum
e
casseliflavu
respect
eight
per
cent
nonhospitalis
human
specimen
contain
vre
six
e
gallinarum
two
e
casseliflavu
total
vre
strain
isol
anim
sampl
e
faecium
e
gallinarum
e
casseliflavu
strain
resist
e
faecali
strain
detect
pcr
confirm
e
gallinarum
e
casseliflavu
e
faecium
strain
vana
genotyp
e
faecium
vana
strain
isol
poultri
sampl
one
strain
isol
cattl
sampl
specimen
pig
yield
glycopeptideresist
e
faecium
conclus
present
studi
indic
preval
gre
human
pig
cattl
husbandri
appear
low
reveal
high
preval
gre
e
faecium
styrian
poultri
year
use
avoparcin
ban
glycopeptid
resist
enterococci
gre
becom
increas
problem
us
europ
enterococci
intrins
resist
cephalosporin
aminoglycosid
lowlevel
polymixin
lincomycin
clindamycin
furthermor
enterococci
abl
acquir
resist
wide
rang
antibiot
remain
concern
antibiot
use
growth
promot
prophylaxi
therapi
anim
husbandri
may
lead
increas
resist
antibiot
use
human
medicin
object
aim
studi
evalu
speci
distribut
antibiot
resist
gre
isol
styrian
foodproduc
anim
method
total
gre
strain
isol
cattl
pig
poultri
faecal
specimen
collect
strain
identifi
use
autom
method
gpc
api
strep
system
antimicrobi
suscept
determin
vitek
card
disk
diffus
linezolid
strain
studi
suscept
antibiot
ampicillin
amoxicillinsulbactam
amc
ciprofloxacin
cip
erythromycin
eri
gentamicin
high
level
ge
linezolid
li
norfloxacin
penicillin
p
quinupristin
dalfopristin
syn
streptomycin
high
level
str
teicoplanin
tp
tetracyclin
te
vancomycin
va
result
e
casseliflavu
common
gre
speci
isol
follow
e
gallinarum
e
faecium
e
gallinarum
e
casseliflavu
vanc
e
faecium
vana
phenotyp
investig
strain
sensit
linezolid
gentamicin
high
level
p
resist
reduc
suscept
cip
seen
e
faecium
eri
resist
e
faecium
reveal
e
casseliflavu
e
gallinarum
resist
te
e
faecium
e
casseliflavu
e
gallinarum
e
faecium
strain
suscept
quinupristindalfopristin
conclus
resist
phenotyp
p
cip
eri
te
differ
among
enterococcu
speci
resist
found
tetracyclin
quinupristindalfopristin
erythromycin
caus
concern
high
level
antibiot
multidrug
resist
observ
among
e
faecium
strain
identif
carri
vitek
system
biomerieux
suscept
test
perform
either
breakpoint
system
mini
api
vitek
system
biomerieux
result
streptococci
strain
isol
outpati
inpati
urin
cultur
respect
distribut
sex
men
outpati
men
inpati
total
streptococci
strain
enterococcu
faecali
enterococcu
faecium
enterococcu
gallinarum
streptococci
group
b
vitro
antibiot
resist
enterococci
spp
penicillin
ampicillin
gentamicin
nitrofurantoin
ciprofloxacin
tetracyclin
vancomycin
linezolid
eight
vre
strain
enterococcu
faecium
three
enterococcu
gallinarum
two
enterococcu
faecali
vitro
antibiot
resist
group
b
streptococci
vancomycin
nitrofurantoin
ampicillin
penicillin
erythromycin
tetracyclin
conclus
streptococci
respons
urinari
tract
infect
enterococcu
faecali
frequent
pathogen
enterococci
spp
show
high
resist
ciprofloxacin
tetracyclin
gentamicin
penicillin
ampicillin
object
enterococc
infect
becom
increas
concern
particularli
due
emerg
spread
resist
animicrobi
agent
investig
phenotyp
genotyp
properti
enterococcu
faecium
clinic
isol
express
resist
combin
quinupristin
dalfopristin
recov
period
univers
hospit
patra
method
isol
characteris
speci
level
gram
stain
catalas
product
crystal
id
gram
posit
system
bbl
minim
inhibitori
concentr
mic
ampicillin
amp
erythromycin
em
chloramphenicol
chl
gentamicin
gm
ciprofloxacin
cip
vancomycin
va
teicoplanin
tp
quinupristindalfopristin
rp
linezolid
lin
perform
etest
ab
biodisk
accord
nccl
recommend
presenc
vana
vanb
gene
investig
evigen
commerci
kit
staten
serum
institut
presenc
vga
vgb
gene
pcr
specif
primer
clonal
type
characteris
pfge
smai
dna
digest
result
collect
e
faecium
express
mic
rp
mgl
among
isol
show
mic
mgl
highlevel
resist
gm
detect
isol
cip
chl
amp
em
fortythre
isol
vancomycinresist
carri
vana
gene
isol
found
carri
vga
vgb
gene
pfge
classifi
isol
clonal
type
type
b
type
c
remain
isol
belong
type
conclus
high
preval
lowlevel
resist
quinupristindalfopristin
mic
mgl
detect
collect
e
faecium
strain
express
higher
mic
level
mainli
due
dissemin
certain
clone
hospit
previou
work
describ
dissemin
e
faecali
multiresist
clone
colonis
patient
four
differ
icu
clone
frequent
found
bacteraemia
suggest
blood
invas
intestin
origin
aim
studi
analys
dynam
popul
evolut
enterococc
intestin
isol
acquisit
epidem
hospit
clone
may
occur
icu
admitt
materi
method
close
followup
four
patient
neurosurgeri
icu
admit
acut
traumat
perform
rectal
swab
collect
admitt
daili
discharg
icu
stool
sampl
seed
menterococcu
agar
eventu
supplement
select
antibiot
multipl
coloni
analys
sampl
pfgesmai
phoretrix
softwar
appli
analys
genet
related
among
isol
previous
describ
hospit
endem
clone
result
patient
stay
icu
day
patient
day
patient
carri
along
day
origin
e
faecali
e
faecium
clone
moreov
five
e
faecali
clone
one
ident
epidem
clone
one
e
faecium
clone
acquir
icu
stay
persist
rest
studi
period
patient
present
admiss
three
e
faecali
two
e
faecium
clone
two
e
faecali
lost
day
e
faecium
lost
second
day
four
new
e
faecali
one
e
faecium
clone
found
stay
wherea
five
clone
occasion
isol
without
persist
patient
e
faecium
clone
identifi
along
studi
period
two
new
e
faecium
clone
later
acquir
patient
two
e
faecium
clone
admiss
one
lost
first
day
second
persist
day
new
e
faecium
clone
acquir
icu
stay
patient
method
patient
woman
hysterectomis
year
ago
report
four
surgic
intervent
due
cystocel
last
oper
took
place
year
ago
report
admitt
hospit
last
year
patient
also
suffer
repeat
urinari
tract
infect
present
episod
consult
typic
uti
symptom
dysuria
bladder
tenesmu
urin
sampl
collect
h
incub
gram
posit
coccu
isol
ufcml
identif
suscept
preliminarili
achiev
commerci
avail
method
follow
manufactur
recommend
microscan
dade
identif
confirm
api
rapid
strep
system
biomerieux
discard
enterococcu
speci
intrins
resist
vancomycin
absenc
motil
observ
direct
microscop
detect
absenc
pigment
determin
cultur
tsa
agar
suscept
vancomycin
teicoplanin
ampicillin
assess
disk
diffus
etest
broth
mcrodilut
result
isol
microorgan
identifi
enterococcu
faecali
show
high
mic
vancomycin
mgl
broth
microdilut
mm
disk
diffus
teicoplanin
mgl
broth
microdilut
mm
disk
diffus
suscept
ampicillin
mgl
broth
microdilut
characteris
resist
mechan
involv
seri
vancomycin
resist
enterococcu
faecium
vref
strain
recov
two
spanish
hospit
citi
determin
clonal
relationship
method
surveil
programm
carri
period
mshospit
order
detect
vref
intestin
colonis
seven
vref
strain
recov
seven
faecal
sampl
repres
vref
intestin
colonis
period
four
clinic
vref
strain
implic
infecti
process
recov
mshospit
n
rvhospit
n
vref
strain
n
recov
unrel
patient
previous
treat
glycopeptid
broad
spectrum
antibiot
diagnos
sever
diseas
antibiot
suscept
test
perform
agar
dilut
method
vancomycin
resist
gene
vana
vanb
vand
studi
pcr
vanb
amplicon
sequenc
determin
subtyp
vanb
cluster
gene
also
characteris
resist
gene
studi
pcr
aph
iiia
ant
ia
erm
b
pfge
assay
perform
smai
digest
result
nine
vref
strain
eight
mshospit
one
rvhospit
show
vanb
phenotyp
mic
mgl
vancomycin
teicoplanin
gene
detect
nine
strain
addit
intergen
vansbyb
region
show
characterist
mutat
subtyp
gene
cluster
integr
element
demonstr
specif
pcr
sequenc
strain
resist
streptomycin
kanamycin
erythromycin
ant
ia
aph
iiia
erm
b
gene
detect
pcr
includ
pfge
clonal
type
two
close
relat
subtyp
distinguish
seven
strain
hospit
two
strain
mshospit
subtyp
found
clinic
strain
well
strain
recov
faecal
sampl
three
seriou
infect
rest
isol
carrier
one
present
vana
phenotyp
harbour
vana
gene
vanb
harbour
strain
resist
teicoplanin
outbreak
haematolog
begin
polyclon
pfge
clone
eventu
three
becam
predomin
ward
outbreak
cracov
centr
spread
two
ward
hospit
surgeri
geriatri
vrem
isol
respect
five
seriou
infect
wound
surgeri
rest
repres
carrier
detect
infectioncontrol
measur
two
vana
phenotypegenotyp
vanb
phenotypegenotyp
isol
one
predomin
pfge
clone
observ
differenti
pfge
subtyp
hospit
clone
five
pfge
clone
detect
seem
uniqu
one
five
isol
outbreak
two
basic
mechan
vre
spread
detect
clonal
spread
vre
strain
vanael
horizont
transfer
conclus
time
vrem
present
vanb
phenotyp
caus
sporad
outbreak
two
haematolog
centr
poland
becom
stage
multidrugresist
vana
vrem
outbreak
eventu
turn
endem
colonis
rate
time
higher
infect
case
danger
transmiss
centr
nonhaematolog
hospit
countri
appear
high
circumst
materi
method
thirtythre
select
vrefl
differ
patient
three
hospit
huc
hsa
hst
north
centr
portug
portug
studi
suscept
antibiot
perform
agar
dilut
method
nccl
isol
search
gene
code
resist
glycopeptid
macrolid
aminoglycosid
characteris
done
overlap
pcr
strategi
sequenc
necessari
clonal
related
perform
smaipfg
virul
trait
cyl
agg
gele
esp
investig
multiplex
pcr
assay
result
vrefl
show
vana
phenotyp
mostli
resist
eri
cipro
hlrgm
hlrkm
respect
resist
gene
found
vana
erm
b
nine
pfge
type
isol
eight
eight
patient
one
clone
b
patient
clone
b
dissemin
among
three
hospit
year
give
eight
pfge
subtyp
one
characterist
specif
hospit
vsefl
show
pfge
pattern
ident
two
clone
b
subtyp
found
hst
six
variant
found
five
among
isol
clone
b
found
hospit
year
predomin
huc
hst
contain
insert
intergen
vanxvani
region
found
hsa
lack
gene
involv
transposit
variant
recov
huc
variant
found
hsa
vre
one
isol
clone
b
agg
gel
cyl
esp
present
vre
conclus
find
indic
dissemin
establish
success
e
faecali
clone
hospit
set
amplifi
particular
genet
determin
local
metagenom
resist
vancomycin
therefor
influenc
futur
evolutionari
event
also
report
first
contain
insert
staphylococcu
spp
wide
distribut
medic
veterinari
patholog
repres
one
import
caus
infect
mani
strain
antibioticresist
even
presenc
esopolysaccharid
matrix
aim
work
individu
among
differ
staphylococci
human
anim
origin
slime
produc
strain
correl
presenc
biofilm
resist
eight
antibiot
total
coagulas
neg
staphylococci
cn
aureu
isol
differ
sourc
identifi
sceptor
system
test
antibiot
suscept
kirbi
bauer
method
slime
product
polystyren
plate
stain
alcian
blue
spectrophotometr
read
nm
strain
classifi
weak
strong
slimeproduc
basi
od
result
result
submit
statist
analysi
use
student
ttest
chisquar
test
evalu
differ
slime
product
among
medic
veterinari
strain
found
differ
statist
frequenc
p
statist
differ
obtain
aureu
cn
instead
statist
analysi
epidermidi
vs
staphylococci
shown
statist
differ
among
averag
valu
use
student
ttest
p
signific
frequenc
differ
use
chi
squar
test
p
final
cn
epidermidi
strain
statist
differ
found
relat
slime
product
origin
strain
evalu
correl
found
correl
antibioticresist
slime
product
resist
increment
obtain
strongli
slime
produc
strain
staphylococcu
spp
often
involv
nosocomi
infect
complic
postsurgeri
wound
cathet
orthopaed
devic
presenc
antibioticresist
strain
interfer
therapi
success
seem
strictli
relat
biofilm
product
beyond
genet
acquir
human
veterinari
strain
shown
similar
behaviour
toward
biofilm
product
antibioticresist
result
confirm
epidermidi
one
slimeproduc
introduc
aureu
new
high
slimeproduc
recommend
macrolid
resist
phenotyp
determin
use
erythromycinclindamycin
doubl
disk
test
result
agalactia
isol
test
found
suscept
penicillin
g
vancomycin
resist
rate
erythromycin
seven
strain
express
macrolid
resist
phenotyp
among
resist
strain
evalu
doubl
disk
test
constitut
cmlsb
phenotyp
four
isol
induc
imlsb
phenotyp
three
isol
agalactia
strain
assign
resist
phenotyp
overal
resist
rate
clindamycin
conclus
find
demonstr
agalactia
remain
fulli
suscept
penicillin
vancomycin
rel
low
resist
valu
macrolid
lincosamid
mlsb
phenotyp
predomin
among
macrolideresist
strain
find
rais
concern
use
clindamycin
instead
erythromycin
prophylaxi
treatment
agalactia
infect
patient
allerg
beta
lactam
howev
continu
surveil
need
detect
chang
suscept
pattern
effect
enteroviru
infect
risk
type
diabet
mellitu
studi
mainli
use
indirect
serolog
evid
past
infect
use
rtpcr
detect
viru
plasma
respect
enteroviru
biolog
decid
assess
exposur
enteroviru
use
realtim
rtpcr
detect
quantif
stool
sampl
exposur
studi
relat
sign
autoimmun
process
ultim
lead
type
diabet
method
studi
popul
come
norwegian
midia
studi
screen
newborn
gener
popul
highest
hlaencod
risk
type
diabet
mellitu
highrisk
babi
followedup
questionnair
serum
sampl
marker
betacel
autoimmun
stool
sampl
collect
monthli
interv
month
month
stool
sampl
collect
parent
mail
laboratori
rna
dna
copurifi
qiagen
column
togeth
low
quantiti
exogen
control
rna
enteroviru
quantifi
realtim
rtpcr
use
armor
rna
standard
control
rna
detect
late
cycl
reaction
use
differ
colour
probe
report
adenoviru
quantiti
simultan
investig
viral
exposur
implic
trigger
type
diabet
present
result
pilot
studi
object
conflict
report
regard
cmvdna
posit
among
healthi
cmvseroposit
individu
aim
determin
frequenc
cmvdna
posit
among
healthi
subject
evalu
associ
physic
mental
stress
longitudin
studi
subject
method
weekli
peripher
blood
sampl
drawn
healthi
cmv
seroposit
subject
age
year
studi
period
subject
rate
physic
mental
stress
also
record
alcohol
consumpt
chang
health
statu
cmv
dna
screen
plasma
peripher
blood
leukocyt
sampl
nest
pcr
use
primer
target
mie
gene
cmv
result
total
sampl
plasma
peripher
blood
leukocyt
screen
one
peripher
blood
sampl
obtain
second
week
studi
gave
posit
result
sampl
belong
oldest
subject
studi
accord
result
cmvdna
posit
among
healthi
cmv
seroposit
individu
seem
rare
event
result
centr
report
qualit
result
four
centr
also
report
quantit
result
sampl
correctli
identifi
centr
variou
extract
amplif
method
use
fourteen
centr
report
result
intern
control
centr
control
amplif
step
adjust
detect
sensit
intern
control
detect
limit
target
three
centr
fail
detect
one
intern
control
two
posit
sampl
one
neg
sampl
quantif
hcmv
dna
centr
use
realtim
quantit
pcr
cv
hcmv
dna
load
centr
low
except
one
sampl
could
attribut
heterogen
prepar
sampl
organis
use
student
ttest
statist
signific
differ
observ
hcmv
load
whatev
medium
number
ad
cell
conclus
result
extern
qualiti
assess
molecular
detect
quantif
hcmv
dna
excel
almost
centr
use
intern
control
pcr
inhibit
howev
control
whole
pcr
process
includ
extract
better
adjust
detect
sensit
intern
control
sensit
limit
pcr
target
desir
accur
way
identifi
fals
neg
result
eg
caus
pcr
inhibitor
realtim
pcr
assay
spike
sampl
intern
control
coamplifi
target
pathogen
dna
howev
current
intern
control
procedur
usual
involv
introduct
dna
fragment
complex
time
consum
expens
present
novel
techniqu
simpl
intern
control
realtim
amplif
assay
method
singlestrand
oligonucleotid
contain
littl
primer
probe
bind
site
use
intern
control
realtim
pcr
assay
mismatch
includ
probebind
region
intern
control
oligonucleotid
ico
prevent
probecontrol
hybridis
fluoresc
acquisit
step
pcr
ico
could
ad
directli
sampl
materi
prior
dna
extract
result
demonstr
feasibl
new
approach
design
ico
follow
lightcycl
hybridis
probe
assay
mycobacterium
tuberculosi
complex
hepat
b
viru
herp
simplex
viru
varicella
zoster
viru
case
control
interfer
detect
pathogen
clearli
detect
subsequ
melt
point
analysi
pcr
product
conclus
singlestrand
oligonucleotid
mimic
target
region
pathogen
yet
clearli
distinguish
target
analysi
serv
simpl
costeffect
intern
control
realtim
amplif
assay
control
oligonucleotid
easi
design
cheap
costli
second
probe
system
necessari
moreov
intern
control
assay
use
one
fluoresc
detect
channel
instrument
leav
second
channel
free
multiplex
applic
object
develop
new
nucleic
acid
isol
method
nuclisen
magnet
extract
reagent
use
boom
chemistri
combin
magnet
silica
particl
nuclisen
mini
mag
instrument
facilit
wash
collect
silica
particl
user
friendli
effici
way
principl
extract
method
gener
appli
broad
rang
differ
sampl
type
object
studi
measur
perform
new
extract
platform
term
rna
dna
recoveri
puriti
integr
addit
user
aspect
also
address
studi
method
rna
recoveri
measur
spike
e
coli
rna
human
normal
edta
plasma
extract
rna
quantifi
use
fluoresc
dye
rna
detect
sybr
green
ii
dna
recoveri
measur
spike
plasmid
dna
extract
dna
determin
measur
indic
rna
dna
puriti
obtain
measur
ratio
integrityintact
extract
nucleic
acid
determin
gel
analysi
use
bioanalyz
agil
technolog
rna
dna
respect
extract
method
test
three
extern
test
site
order
score
relev
user
aspect
result
averag
recoveri
rate
rna
dna
respect
rna
extract
averag
ratio
measur
wherea
dna
valu
valu
indic
puriti
prepar
high
sinc
pure
prepar
expect
valu
rna
dna
respect
addit
found
rna
dna
intact
recov
sinc
degrad
product
detect
addit
user
score
method
labour
friendli
total
amount
time
need
process
sampl
min
throughput
time
improv
use
two
instrument
parallel
way
sampl
complet
within
min
addit
method
also
verifi
broad
rang
differ
sampl
type
includ
plasma
serum
csf
sputum
stool
dna
sequenc
gold
standard
method
accur
genotyp
human
papillomavirus
hpv
provid
nucleic
acid
sequenc
inform
core
everi
organ
pyrosequenc
method
success
use
hpv
genotyp
sequenc
base
multipl
hpv
infect
common
phenomenon
clinic
sampl
vari
rate
depend
group
investig
dna
sequenc
techniqu
differenti
differ
genotyp
uninterrupt
sequenc
result
obtain
multipl
infect
unspecif
amplif
product
present
amplicon
address
problem
typespecif
multiplesequenc
primer
dna
sequenc
strategi
suitabl
genotyp
detect
develop
new
method
seven
typespecif
sequenc
primer
combin
pool
ad
dna
sampl
oligonucleotid
hybridis
dna
sampl
function
primer
subsequ
dna
sequenc
procedur
new
method
especi
suit
detect
type
sampl
harbour
differ
hpv
genotyp
multipl
infect
unspecif
amplif
elimin
need
nest
pcr
stringent
pcr
condit
clone
furthermor
method
prove
use
sampl
contain
subdomin
typesspeci
sampl
low
pcr
yield
avoid
reperform
fail
pcr
also
introduc
sequenc
pattern
recognit
plural
genotyp
sampl
facilit
type
one
target
dna
sampl
moreov
target
specif
sequenc
primer
could
easili
tailor
adapt
accord
desir
applic
clinic
set
base
region
preval
hpv
well
microorgan
virus
cost
dna
sequenc
drop
sampl
could
sequenc
parallel
two
three
differ
target
specif
primer
pool
cover
broader
rang
genotyp
pyrosequenc
hpv
detect
assay
fulli
autom
could
use
detect
identif
differ
microorgan
virus
reagent
refer
extract
method
isol
rna
dna
variou
sampl
type
result
perform
sever
extract
dilut
seri
strain
coxacksi
csf
shown
analyt
sensit
enteroviru
rtpcr
found
independ
extract
method
use
wherea
low
frequenc
higher
sensit
obtain
combin
magnet
extract
expect
higher
input
sampl
gave
better
reproduc
result
lower
input
sampl
evalu
enteroviru
pcr
use
csf
stool
sampl
correl
two
extract
method
found
addit
use
broad
panel
clinic
specimen
tuberculosi
pcr
sampl
identifi
posit
use
boom
extract
method
magnet
extract
howev
latter
method
result
less
sampl
inhibit
pcr
need
confirm
larger
studi
group
method
conjunctiv
scrape
sent
laboratori
ml
viral
transport
medium
inocul
monolay
cell
tube
incub
c
stationari
phase
score
daili
cytophath
effect
cpe
day
cpe
develop
characterist
adenoviru
cpe
observ
usual
day
cultur
passag
done
two
homolog
monolay
shell
vial
incub
h
c
stain
specif
fluoresc
reagent
adenoviru
dna
ml
remain
transport
medium
purifi
commerci
procedur
resuspend
final
volum
five
microlitr
purifi
dna
use
realtim
amplif
final
reaction
volum
use
fast
start
sybr
green
master
mix
roch
mgcl
mm
lm
primer
region
amplifi
belong
hexon
gene
total
process
time
less
h
result
adenoviru
isol
sampl
process
convent
cell
cultur
these
cultureposit
sampl
posit
realtim
pcr
sampl
test
neg
convent
cell
cultur
realtim
pcr
detect
eight
neg
five
posit
gel
electrophoresi
analysi
show
amplif
band
expect
molecular
weight
realtim
pcr
posit
cell
cultur
neg
sampl
control
group
sampl
patient
bacteri
conjunct
test
neg
pcr
plasmid
contain
sequenc
spike
neg
synovi
tissu
blood
specimen
use
posit
control
extract
dna
neg
synovi
tissu
blood
specimen
includ
everi
two
specimen
neg
control
suitabl
dna
pcr
verifi
use
pcr
assay
betaglobin
posit
specimen
subject
bidirect
sequenc
fisher
exact
test
twotail
use
statist
analysi
result
specimen
posit
betaglobin
extract
control
clone
provir
dna
spike
tissu
mononuclear
cell
granulocyt
follow
extract
yield
amplifi
product
case
limit
detect
assay
copiesml
blood
copiesmg
tissu
two
hundr
tissu
specimen
mononuclear
cell
granulocyt
specimen
test
neg
provir
dna
two
ra
two
oa
granulocyt
specimen
howev
yield
posit
signal
provir
dna
detect
low
copi
number
quantit
comparison
known
quantiti
clone
provir
dna
spike
blood
rang
copi
provir
dnaml
blood
four
show
ident
genbank
sequenc
ncbi
blast
search
conclus
find
associ
ra
oa
p
use
real
time
pcr
assay
recent
shown
actual
rabbit
endogen
retroviru
h
j
virol
hypothesis
experiment
rabbit
studi
ongo
laboratori
granulocyt
specimen
prepar
account
low
level
provir
dna
detect
specimen
test
result
csf
viru
load
rang
copi
per
millilitr
comparison
viru
load
vesicular
fluid
copi
per
millilitr
highest
viru
load
detect
patient
paresi
facial
nerv
young
patient
rel
mild
diseas
lowest
viru
load
copi
per
millilitr
child
varicella
mening
old
patient
sever
herp
zoster
trunk
quantit
pcr
good
reproduc
use
assess
viral
load
csf
sampl
howev
correl
viru
load
sever
ill
remain
uncertain
purpos
studi
develop
enzym
immunoassay
eia
detect
igg
activ
use
two
new
recombin
protein
antigen
target
evalu
eia
aid
statist
method
method
fragment
glycoprotein
g
compris
residu
herp
simplex
viru
type
glycoprotein
express
e
coli
gst
fusion
protein
develop
assay
detect
typespecif
antibodi
result
new
enzym
immunoassay
detect
igg
iggeia
sera
develop
use
two
new
recombin
protein
iggeia
evalu
use
serum
specimen
obtain
patient
cultureproven
infect
cp
n
normal
blood
donor
bd
n
specimen
addit
test
igg
activ
two
commerci
avail
eia
new
iggeia
detect
activ
specimen
infect
patient
bd
test
overal
concord
three
assay
vari
concord
posit
sampl
rang
absenc
gold
standard
accuraci
eia
assess
comput
program
base
maximum
likelihood
approach
use
latent
class
model
analysi
estim
iggeia
sensit
specif
within
rang
respect
dna
detect
one
csf
specimen
patient
asept
mening
three
aqueou
humor
specimen
patient
uveiti
one
swab
patient
herpet
vesicular
skin
lesion
three
conjunctiv
swab
patient
conjunct
b
vzv
dna
detect
two
aqueou
humor
specimen
patient
iridocycl
two
swab
patient
vesicular
skin
lesion
vesicl
aspir
bronchoalveolar
lavag
patient
varicella
pneumon
precis
diagnosi
herpet
infect
avail
within
h
allow
earli
initi
adapt
antivir
therapi
conclus
detect
six
commonest
human
herpesvirus
clinic
specimen
herpesviru
consensu
pcr
methodolog
allow
rapid
sensit
specif
result
object
bovin
aetiolog
agent
mani
infect
may
predispos
infect
anim
possibl
immunosupress
secondari
bacteri
infect
immunosupress
may
directli
associ
induct
program
cell
death
pcd
viru
infect
cell
nitric
oxid
import
mediat
role
fungal
bacteri
protozo
viral
pathogen
tumour
studi
role
question
pcd
process
method
studi
plan
two
consecut
stage
first
stage
morpholog
without
staurosporin
biochem
chang
caus
virusinduc
pcd
mdbk
cell
investig
morpholog
assess
pcd
perform
use
hoechst
nuclear
stain
fluoresc
microscopi
techniqu
second
phase
studi
induct
pcd
staurosporin
ss
alon
addit
apoptot
rout
infect
withwithout
staurosporin
analys
appli
caspas
inhibitor
r
germani
result
interest
see
inhibit
pcd
follow
h
poi
instead
induc
staurosporin
induc
apoptosi
alon
h
poi
mdbk
cell
howev
h
poi
pcd
respons
found
decreas
result
show
similar
obtain
herp
simplex
infect
human
epitheli
cell
follow
caspas
inhibitor
applic
pcd
respons
decreas
h
wherea
respons
increas
follow
h
infect
caspas
inhibitori
peptid
conclus
conclus
inhibit
apoptot
respons
caspaseindepend
way
may
modul
respons
apoptot
pathway
object
aim
studi
question
program
cell
death
pcd
process
acut
phase
infect
cultur
epitheli
like
cell
microenviron
investig
relat
possibl
nitric
oxid
respons
cell
infect
without
staurosporin
induct
method
studi
plan
two
consecut
stage
first
stage
morpholog
without
staurosporin
biochem
chang
caus
virusinduc
pcd
cell
investig
morpholog
assess
pcd
perform
use
hoechst
nuclear
stain
fluoresc
microscopi
techniqu
second
phase
studi
induct
pcd
staurosporin
ss
alon
addit
apoptot
rout
infect
withwithout
staurosporin
analys
appli
total
caspas
inhibitor
r
germani
result
known
follow
infect
h
poi
antiapoptot
activ
trigger
human
cell
activ
caspas
interest
see
experi
follow
h
infect
number
apoptot
cell
reduc
wherea
respons
continu
increas
follow
poi
conclus
antiapoptot
activ
seem
activ
caspas
like
invers
proport
relat
pcd
respons
seem
relat
trigger
effect
pcd
respons
effect
explain
nonspecif
stimul
host
immun
system
howev
direct
antivir
effect
exclud
goal
present
studi
evalu
effect
probiot
strain
deriv
metabolit
reproduct
herp
simplex
viru
type
materi
method
probiot
strain
use
lactobacillu
plantarum
enterococcu
escherichia
coli
one
hundr
six
vero
cell
infect
id
incub
supernat
bacteria
bacteriocin
prepar
appli
serial
dilut
acyclovir
lek
slovenia
use
antivir
drug
control
cytopath
effect
viru
determin
light
immunoflouresc
microscopi
h
result
alon
presenc
e
coli
extract
caus
profound
cytopath
effect
addit
acyclovir
complet
inactiv
effect
viru
taken
supernat
obtain
l
plantarum
e
faecium
gener
dose
depend
effect
viral
inhibit
e
faecium
strain
extract
activ
l
plantarum
extract
strain
analys
presenc
bacteriocin
two
type
peptid
determin
enterocin
enterocin
b
kd
bacteriocin
prepar
demonstr
similar
antivir
effect
inhibit
allow
consid
enterococc
bacteriocin
major
antivir
agent
present
model
conclus
extract
sever
probiot
bacteri
strain
express
specif
activ
reproduct
vitro
antivir
effect
e
faecium
strain
strongest
due
presenc
enterocin
b
supernat
acknowledg
work
support
public
health
servic
grant
nih
grant
rffi
region
foundat
support
new
technolog
medicin
detect
ribotyp
among
toxin
b
produc
strain
one
ribotyp
detect
among
nontoxigen
strain
four
ribotyp
detect
seem
interest
observ
domin
ribotyp
toxigen
tcdatcdb
five
belong
ribotyp
four
strain
n
belong
one
ribotyp
summari
pcrribotyp
good
method
discrimin
c
difficil
strain
decid
continu
epidemiolog
studi
poland
object
aim
studi
identifi
risk
factor
c
difficileassoci
diarrhoea
due
adpribosyl
transferas
produc
strain
materi
method
retrospect
case
control
studi
perform
case
patient
diarrhoea
due
actinspecif
adpribosyl
transferas
produc
strain
compar
two
control
patient
diarrhoea
due
c
difficil
strain
produc
actinspecif
adpribosyl
transferas
match
ward
date
hospitalis
cdta
cdtb
gene
screen
pcr
stubb
et
al
fem
microbiol
letter
product
cdt
studi
western
blot
use
antiserum
anti
ia
ib
c
perfringen
activ
toxin
assess
use
adpribosyl
transferas
assay
result
twentysix
case
male
femal
identifi
hospitalis
six
differ
hospit
pari
surround
area
cdt
posit
strain
also
posit
toxin
b
case
compar
control
case
control
differ
significantli
sex
age
previou
administr
antibiot
chemotherapi
immunosuppress
treatment
endoscop
examin
perform
case
control
p
frequenc
mucos
abnorm
similar
diarrhoea
often
communityacquir
case
control
vs
p
repres
often
caus
hospitalis
vs
p
moreov
diarrhoea
case
frequent
associ
abdomin
pain
vs
p
liquid
stool
vs
p
conclus
result
suggest
could
correl
product
binari
toxin
sever
diarrhoea
binari
toxin
could
induc
intestin
lesion
independ
toxin
b
may
act
synergi
toxin
method
outbreak
detect
c
difficil
surveil
programm
survey
infect
control
unit
c
difficil
infect
diagnos
stool
cultur
detect
toxin
qualit
rapid
immunoassay
isol
c
difficil
genotyp
use
pulsedfield
gel
electrophoresi
result
incid
c
difficileassoci
diarrhoea
increas
case
per
patientday
case
per
patientday
outbreak
outbreak
involv
patient
four
geriatr
ward
locat
two
geograph
distinct
site
medic
team
mean
age
rang
year
sexratio
fm
case
receiv
one
antibiot
onset
diarrhoea
case
longterm
care
facilitiesacquir
diarrhoea
secondari
hospit
transmiss
result
three
cluster
involv
case
serotyp
genotyp
perform
isol
differ
stool
strain
belong
type
wherea
three
display
profil
differ
outbreak
strain
manag
outbreak
consist
reinforc
contact
isol
precaut
patient
diarrhoea
cohortag
infect
patient
ward
promot
hand
disinfect
alcohol
solut
environment
disinfect
hypochlorit
introduc
outbreak
ward
transmiss
occur
close
day
complet
disinfect
last
patient
discharg
resolut
outbreak
incid
acquisit
case
per
patientday
nineti
per
cent
patient
treat
metronidazol
vancomycin
relaps
occur
patient
two
patient
die
sever
coliti
mean
hospit
stay
rang
day
annual
mean
length
stay
depart
day
conclus
rapid
control
nosocomi
outbreak
c
difficil
among
geriatr
patient
obtain
earli
implement
cohortag
ward
closur
associ
reinforc
environment
disinfect
hand
hygien
enter
isol
introduct
toxigen
clostridium
difficil
main
caus
nosocomi
diarrhoea
recent
describ
involv
commun
acquir
infect
two
main
toxin
classic
describ
main
virul
factor
although
strain
lack
one
emerg
increas
frequenc
object
aim
characteris
toxigen
phenotyp
institut
high
preval
c
difficileassoci
diarrhoea
cdad
materi
method
c
difficil
isol
obtain
collect
period
diarrheic
stool
submit
laboratori
specimen
cultur
ccfa
plate
blood
presumpt
coloni
identifi
standard
procedur
toxin
b
detect
standard
cytotox
assay
human
fibroblast
cultur
use
dilut
sampl
pure
broth
cultur
microorgan
toxin
detect
commerci
enzymeimmunoassay
cdtox
oia
biostar
finland
use
coloni
suspens
order
increas
sensit
test
neg
result
toxin
check
pcr
use
previous
publish
primer
condit
result
total
c
difficil
isol
obtain
studi
period
one
hundr
ninetynin
isol
produc
toxin
ab
isol
classifi
nontoxigen
phenotyp
procedur
isol
toxin
b
detect
isol
classifi
produc
toxin
exclus
nontoxigen
strain
show
pcr
posit
result
gene
b
four
also
gene
six
isol
four
ab
isol
five
confirm
pcr
six
toxin
gene
also
detect
conclus
vast
major
c
difficil
isol
obtain
laboratori
toxigen
ab
tradit
approach
detect
use
classic
method
confirm
pcr
presenc
isol
collect
isol
consid
nontoxigen
phenotyp
method
pcrposit
one
toxin
disagr
result
phenotyp
genet
method
justifi
presenc
incomplet
unexpress
gene
lack
sensit
former
method
background
estim
extra
cost
nh
everi
patient
contract
c
difficil
hospit
light
seem
imper
possibl
compon
involv
mode
transmiss
nosocomi
infect
investig
view
control
spread
object
look
level
contamin
health
care
worker
hand
c
difficil
deal
known
posit
patient
method
hand
sampl
use
finger
streak
method
c
difficil
moxalactam
norfloxacin
cdmn
agar
plate
plate
incub
h
anaerob
condit
examin
possibl
coloni
c
difficil
identifi
use
gram
stain
rapid
ana
ii
system
hand
sampl
directli
patient
contact
type
contact
also
note
hand
also
sampl
remov
glove
hand
wash
duplic
sampl
taken
variou
contact
colonis
patient
result
sampl
taken
immedi
patient
contact
posit
nine
per
cent
sampl
taken
remov
glove
posit
sampl
taken
hand
wash
posit
conclus
studi
show
hand
readili
regularli
becom
contamin
contact
known
posit
patient
contamin
follow
fairli
minim
contact
patient
object
conduct
phase
clinic
trial
efficaci
tolevam
g
tid
day
compar
vancomycin
mg
qid
day
collect
serial
faecal
sampl
studi
entri
day
determin
nonantibiot
therapi
neutralis
c
difficil
toxin
b
faecal
filtrat
promot
restor
normal
microbiota
achiev
clinic
respons
method
patient
randomis
studi
calgari
studi
site
centr
faecal
filtrat
concentr
c
difficil
cytotoxin
b
quantit
count
c
difficil
veget
organ
c
difficil
spore
count
determin
quantit
aerobicanaerob
cultur
use
serial
dilut
faec
g
wet
weight
perform
use
criteria
outlin
wadsworth
anaerob
laboratori
manual
stool
healthi
donor
serv
normal
microflora
control
result
thirti
patient
provid
one
sampl
provid
serial
sampl
beyond
day
day
normal
flora
control
show
averag
four
differ
bacteroid
speci
count
g
faec
wet
weight
plu
anaerob
genera
inconsist
manner
use
bacteroid
speci
marker
genu
anaerob
microflora
patient
bacteroid
count
limit
detect
cfug
faec
respect
studi
entri
vancomycin
treatment
elimin
veget
c
difficil
variabl
spore
persist
bacteroid
genera
remain
suppress
major
patient
cours
therapi
hand
respons
tolemav
therapi
appear
account
interrelationship
toxin
neutralis
c
difficil
growthpersist
pattern
recoveri
microflora
gener
patient
respond
toxin
bind
therapi
exhibit
nonemerg
toxin
combin
increas
number
anaerob
organ
recoveri
anaerob
microflora
appear
complet
day
major
patient
object
treatment
choic
baumannii
bacteraemia
establish
data
guid
select
agent
treat
infect
carbapenem
gener
consid
drug
choic
increas
resist
strain
describ
sever
altern
guid
line
propos
ampicillinsulbactam
sam
alon
associ
aminoglycosid
piperacillintazobactam
tzp
tetracyclin
aim
studi
know
best
altern
empir
treatment
infect
accord
tempor
evolut
nosocomi
outbreak
endem
infect
hospit
method
june
decemb
collect
baumannii
strain
bacteraemia
infect
relat
focu
isol
characteris
molecular
method
order
obtain
differ
clone
use
pfge
reppcr
suscept
studi
perform
disk
diffus
antibiot
micetest
mainli
treatment
altern
imipenem
meropenem
sam
tzp
tobramicin
tm
amikacin
ceftazidim
interpret
accord
nccl
criteria
result
empir
antimicrobi
treatment
eat
choic
imipenem
isol
carbapenem
sensibl
two
mainli
molecular
clone
isol
resist
r
netilmicin
tm
accord
detect
outbreak
carbapenemr
isol
clone
multiresist
strain
sam
antnsens
eat
chang
sam
tm
clone
persist
replac
anoth
multiresist
outbreak
samr
aminoglycosidesr
eat
chosen
monotherapi
tn
one
sensibl
antimicrobi
test
last
period
emerg
new
clone
sam
aminoglycosid
doxycyclin
imipenem
return
like
actual
eat
hospit
control
bloodstream
baumannii
infect
conclus
empir
antimicrobi
treatment
patient
bloodstream
baumannii
infect
hospit
chang
tempor
evolut
clone
associ
outbreak
endem
infect
must
establish
accord
suscept
test
molecular
characteris
strain
differ
clone
gentamicinresist
enterococci
paediatr
bloodstream
infect
tertiari
hospit
tanzania
b
blomberg
sc
mohn
kp
manji
n
langeland
behalf
joint
studi
group
antimicrobi
resist
muhimbili
nation
hospit
dar
es
salaam
tanzania
univers
bergen
norway
object
enterococci
emerg
major
pathogen
caus
urinari
tract
wound
blood
stream
infect
bsi
nosocomi
spread
enterococci
resist
multipl
antimicrobi
great
therapeut
challeng
littl
known
role
pathogen
bsi
east
africa
object
studi
assess
preval
resist
pattern
enterococc
isol
caus
bsi
children
muhimbili
nation
hospit
dar
es
salaam
tanzania
method
blood
cultur
obtain
children
age
year
fever
sign
seriou
infect
admit
hospit
period
august
august
isol
identifi
standard
method
ident
enterococcu
fecali
e
faecium
isol
confirm
polymeras
chain
reaction
pcr
isol
suscept
test
etest
assess
genet
related
puls
field
gel
electrophoresi
pfge
twelv
e
faecium
isol
also
investig
mlst
result
thirtytwo
children
growth
enterococc
isol
blood
cultur
nine
e
faecium
isol
show
combin
resist
ampicillin
ciprofloxacin
highlevel
gentamicin
resist
hlgre
six
e
fecali
isol
hlgre
none
resist
ampicillin
ciprofloxacin
except
one
hlgre
also
resist
chloramphenicol
resist
strain
recov
sever
geograph
separ
ward
includ
neonat
ward
major
e
faecium
e
fecali
close
relat
investig
pfge
mlst
conduct
e
faecium
strain
also
confirm
result
conclus
first
studi
identifi
outbreak
bloodstream
infect
caus
combin
arehlgr
e
faecium
hlgre
e
fecali
tanzania
e
faecium
frequent
e
fecali
commonli
use
treatment
regimen
hospit
ampicillin
gentamicin
penicillin
chloramphenicol
insuffici
infect
caus
arehlgr
enterococci
nonrepetit
one
per
patient
resist
fox
k
pneumonia
strain
isol
clinic
specimen
blood
two
bronchial
secret
four
urin
two
wound
five
cathet
tip
patient
care
differ
ward
includ
intens
care
unit
icu
neonat
intens
care
unit
nicu
speci
identif
done
use
vitek
system
biomerieux
franc
mic
determin
vitek
autom
microdilut
system
disk
diffus
method
criteria
nccl
use
defin
suscept
resist
antimicrobi
agent
expand
spectrum
alactamas
esbl
product
assess
doubl
disk
synergi
test
isol
type
enterobacteri
repetit
intergen
consensu
eric
pcr
primer
isoelectr
focus
ief
blactamas
perform
repres
group
isol
result
antimicrobi
profil
demonstr
isol
resist
thirdgener
cephalosporin
aztreonam
cefoxitin
amoxicillinclavulan
ticarcillinclavulan
piperacillintazobactam
four
isol
also
resist
cefepim
cefpirom
isol
suscept
imipenem
ief
show
isol
express
two
blactamas
one
pi
correl
one
pi
correspond
ericpcr
analysi
demonstr
three
strain
type
type
consist
two
subtyp
common
strain
indic
clonal
spread
mainli
respons
outbreak
type
ii
compris
two
isol
type
iii
uniqu
five
isol
identifi
ericpcr
conclus
k
pneumonia
strain
harbour
plasmidcod
ampctyp
blactamas
establish
hospit
nosocomi
infect
surveil
restrict
particular
antibiot
adjust
infect
control
measur
recommend
acinetobact
baumannii
produc
extendedspectrum
blactamas
object
recent
extendedspectrum
blactamas
esbl
discov
peudomona
aeruginosa
strain
franc
subsequ
detect
acinetobact
spp
pseudomona
aeruginosa
countri
includ
turkey
purpos
studi
clarifi
molecular
epidemiolog
infect
caus
strain
cefepimeresist
baumannii
also
determin
mechan
drug
resist
method
cefepimeresist
baumannii
strain
isol
clinic
specimen
nine
patient
hospitalis
intens
care
unit
busan
korea
antimicrobi
suscept
determin
disk
diffus
agar
dilut
method
doubl
disk
synergi
dd
test
perform
screen
esbl
product
isoelectr
focus
conjug
experi
perform
allel
detect
pcr
sequenc
amplifi
product
determin
use
dideoxychain
termin
method
pulsedfield
gel
electrophoresi
pfge
perform
molecular
type
isol
result
isol
show
antimicrobi
suscept
pattern
posit
dd
result
pfge
pattern
isol
contain
three
blactamas
band
pi
pcrbase
experi
detect
gene
mic
ampicillin
piperacillin
cephalothin
cefoxitin
cefoperazon
ceftazidim
cefotaxim
cefepim
aztreonam
isol
mgl
respect
imipenem
mgl
despit
repeat
attempt
resist
cefepim
baumannii
isol
transfer
recipi
conclus
baumannii
isol
clinic
specimen
nine
patient
hospitalis
intens
care
unit
shown
clone
isol
contain
gene
caus
resist
cefepim
best
knowledg
outbreak
caus
esblproduc
baumannii
previous
describ
object
hospit
outbreak
salmonella
spp
infect
uncommon
europ
also
unit
state
neonat
unit
rarer
matern
unit
approxim
deliveri
year
describ
result
well
infect
control
stop
outbreak
method
octob
januari
six
neonat
infect
neonat
unit
hospit
index
case
correspond
newborn
deliv
hospit
born
normal
vagin
deliveri
patient
admit
neurolog
deficit
seven
day
hospit
develop
diarrhoea
group
includ
five
prematur
case
index
prematur
stool
specimen
famili
case
index
neg
stool
sampl
request
cultur
asymtomat
staff
babi
neonat
unit
n
isol
identifi
standard
method
serotyp
agglutin
monospecif
antisera
antibiot
ab
taken
studi
ampicillin
ticarcillin
amoxicillinclavulan
ac
cefalothin
ce
ciprofloxacin
cp
cotrimoxazol
co
nalidix
acid
na
gentamicin
g
thirdgener
cephalosporin
evalu
microdilut
method
confirm
etest
result
eight
strain
salmonella
enteritidi
serotyp
h
g
identifi
phage
type
pt
involv
case
pt
seven
isol
faec
one
blood
cultur
isol
demonstr
antibiot
suscept
pattern
resist
ampicillin
ticarcillin
fortun
babi
die
salmonella
stool
nurs
staff
personnel
mother
isol
conclus
hand
wash
suffici
frequent
infect
probabl
transmit
hand
contact
prepar
milk
infus
equip
index
case
hypothesi
subsequ
confirm
outbreak
termin
erad
presum
contamin
sourc
chang
mattress
disinfect
unit
ensur
strict
observ
hand
wash
everi
manipul
salmonella
enteritidi
third
commonest
phage
type
spain
object
investig
caus
outbreak
pseudomona
aeruginosa
isol
follow
bronchoscop
procedur
method
januari
detect
cluster
p
aeruginosa
isol
associ
bronchoscopi
nine
sampl
eight
patient
laboratori
cultur
bronchoscop
medic
record
case
review
relat
one
bronchoscop
environment
sampl
obtain
microbiolog
identif
suscept
test
perform
microscan
walkaway
system
dade
behr
random
amplifi
polymorph
dna
analysi
rapd
puls
field
gel
electrophoresi
pfge
perform
avail
isol
p
aeruginosa
eight
clinic
isol
seven
patient
six
bronchoscop
relat
isol
result
two
eight
patient
show
clinic
evid
infect
requir
specif
antimicrobi
therapi
index
case
patient
two
isol
separ
day
isol
ceftazidim
aminoglycosid
ciprofloxacin
suscept
imipenem
resist
rapd
pfge
pattern
reveal
clinic
bronchoscop
isol
eight
six
respect
indistinguish
bronchoscop
replac
case
appear
conclus
document
contamin
bronchoscop
p
aeruginosa
possibl
secondari
infect
least
one
patient
microbiologist
essenti
role
detect
medic
devic
contamin
especi
surveil
emerg
infrequ
bacteri
recoveri
three
case
klebsiella
pneumonia
isol
blood
cultur
aim
studi
investig
epidemiolog
relat
among
isol
tri
find
common
sourc
infect
method
environment
sampl
includ
differ
iv
fluid
drug
skin
sampl
obtain
order
detect
sourc
infect
microbi
identif
vitro
suscept
test
carri
automat
microscan
system
dade
clinic
isol
molecular
type
random
amplif
polymorph
dna
rapd
use
one
oligonucleotid
pcrribotyp
oligonucleotid
intergen
region
pfge
use
xbai
restrict
enzym
unrel
strain
also
includ
experi
control
order
check
discrimin
power
techniqu
result
three
clinic
isol
k
pneumonia
obtain
blood
cultur
share
biotyp
antibiotyp
resist
ampicillin
gentamycin
tobramycin
molecular
type
method
prove
clonal
ident
among
clinic
strain
pattern
gener
differ
control
strain
sourc
infect
could
demonstr
environment
newborn
skin
sampl
conclus
singl
k
pneumonia
strain
caus
fulmin
sepsi
three
newborn
three
molecular
type
method
rapd
pcrribotyp
pfge
accur
demonstr
clonal
ident
isol
common
sourc
infect
could
detect
due
probabl
logic
delay
cultur
growth
identif
object
present
describ
outbreak
infect
control
measur
implement
constitut
exampl
handl
possibl
futur
outbreak
limit
resourc
first
ekc
outbreak
report
turkey
method
eye
clinic
kou
hospit
equip
modern
devic
howev
limit
physic
condit
eg
insuffici
handwash
facil
temporari
settlement
hospit
earthquak
decemb
infect
control
team
ict
alert
ekc
case
investig
began
infect
control
measur
icm
implement
conjunctiv
swab
patient
ekc
environment
swab
obtain
studi
gata
hacettep
univers
microbiolog
laboratori
infect
control
protocol
icp
implement
recommend
apic
guidelin
modif
addit
termin
disinfect
td
appli
two
time
td
clinic
close
first
day
figur
result
total
ekc
case
diagnos
among
patient
visit
eye
clinic
outbreak
gener
attack
rate
seventyf
ekc
case
male
averag
age
ae
rang
month
year
primari
secondari
attack
rate
found
respect
adenoviru
type
isol
patient
sampl
biomicroscop
devic
solut
implement
icp
td
ekc
case
decreas
time
outbreak
disappear
day
second
td
close
clinic
four
day
figur
conclus
first
outbreak
report
turkey
isol
viru
biomicroscop
devic
solut
use
one
patient
evid
transmiss
environ
although
sever
report
describ
icm
termin
outbreak
nosocomi
ekc
studi
demonstr
implement
td
andor
close
clinic
four
day
addit
icm
may
control
nosocomi
ekc
outbreak
background
sever
underli
diseas
multipl
venou
access
parenter
nutrit
often
increas
length
stay
intens
care
unit
icu
patient
increas
risk
catheterrel
candidemia
crc
investig
health
econom
outcom
icu
patient
crc
method
retrospect
match
cohort
studi
attribut
mortal
excess
length
stay
crc
investig
match
ratio
base
sever
underli
diseas
acut
ill
apach
ii
score
admiss
diagnosi
length
icu
stay
prior
onset
candidemia
expect
mortal
deriv
apach
ii
match
procedur
result
equal
prognosi
case
control
subject
attribut
mortal
determin
subtract
hospit
mortal
rate
control
candidem
case
excess
length
icu
stay
hospitalis
determin
subtract
median
length
stay
control
case
result
studi
period
icu
patient
develop
microbiolog
document
crc
total
candidem
patient
nineteen
cathet
remov
within
h
case
n
control
n
equal
age
resp
ae
vs
ae
year
p
apach
ii
score
resp
ae
vs
ae
p
incid
respiratori
failur
vs
p
acut
renal
failur
vs
p
haemodynam
instabl
vs
p
excess
length
icu
stay
day
median
vs
day
p
although
patient
crc
longer
length
hospit
stay
differ
signific
vs
day
p
attribut
mortal
crc
ci
hospit
mortal
rate
case
control
respect
p
conclus
data
reveal
care
adjust
sever
underli
diseas
acut
ill
crc
associ
significantli
higher
mortal
icu
patient
howev
associ
signific
excess
length
icu
stay
therebi
repres
import
econom
burden
patient
hospitalis
two
intern
medicin
depart
two
surgic
depart
nephrolog
depart
intens
care
unit
period
juli
novemb
cathet
tip
cultur
use
follow
method
semiquantit
maki
co
b
quantit
cleri
co
sampl
cultur
taken
also
site
cathet
insert
skin
hub
blood
cultur
sampl
taken
peripher
vein
case
clinic
suspicion
bacteraemia
sepsi
incub
use
bactalert
organon
teknika
autom
system
day
result
case
ccbri
record
incid
ccbri
per
cathet
day
case
ccbri
origin
colonis
determin
case
posit
cathet
tip
hub
cultur
strain
gramneg
bacteria
prevail
analyt
e
aerogen
three
k
pneumonia
two
p
aeruginosa
one
four
case
candida
spp
three
case
coagulas
neg
staphylococcu
con
one
case
isol
contrast
case
ccbri
posit
cathet
tip
skin
point
entri
cultur
strain
gramposit
bacteria
prevail
analyt
aureu
eight
con
six
corynobacterium
spp
one
conclus
incid
ccbri
per
cathet
day
ccbri
caus
gramposit
bacteria
mainli
deriv
cathet
site
entri
whilst
colonis
hub
caus
mainli
gramneg
ccbri
prevent
measur
focus
better
asept
techniqu
hand
hygien
care
cathet
entri
site
better
train
medic
staff
studi
patient
suspect
catheterrel
infect
cri
icu
hdu
central
venou
cathet
use
parenter
nutrit
drug
administr
haemodialysi
prefer
vein
icu
vsubclavia
hdu
v
femorali
cathet
mean
durat
catheteris
day
icu
day
hdu
sign
colonis
cathet
found
case
icu
hdu
common
microorgan
icu
gramneg
rod
kesgroup
b
cepacia
pseudomona
spp
follow
coagulaseneg
staphylococci
cn
hdu
case
isol
cn
aureu
p
catheterrel
bacteraemia
crb
consid
case
icu
hdu
caus
microorgan
crb
icu
gramneg
rod
syaphylococcu
spp
hdu
p
conclus
frequenc
crb
icu
significantli
higher
hdu
p
develop
earlier
caus
gramneg
rod
probabl
way
develop
crb
icu
cathet
hub
hdu
skin
patient
catheterrel
infect
cri
consid
caus
increas
hospit
morbid
influenc
hospit
mortal
remain
matter
debat
critic
ill
patient
baselin
sever
underli
condit
variou
confound
factor
may
explain
observ
increas
mortal
rather
cri
order
determin
influenc
cri
hospit
mortal
icu
episod
nosocomi
septicaemia
review
materi
method
retrospect
analysi
nosocomi
septicaemia
occur
period
teach
hospit
septicaemia
episod
separ
secondari
primari
proven
catheterrel
bloodstream
infect
baselin
sever
sap
score
delay
admiss
infect
hospit
mortal
determin
result
period
patient
admit
hospit
episod
cri
record
catheterday
ktd
hospit
mortal
septicaemia
mortal
relat
secondari
septicaemia
p
period
patient
admit
icu
correspond
ktd
four
hundr
twentyfour
episod
septicaemia
occur
patient
ktd
primari
septicaemia
proven
cri
ktd
mean
sap
score
icu
patient
hospit
mortal
icu
patient
develop
infect
mean
baselin
sap
score
cri
occur
week
icu
admiss
median
day
mean
day
pathogenassoci
cri
scn
aureu
e
faecali
candida
spp
hospit
mortal
patient
develop
cri
conclus
studi
hospit
mortal
critic
ill
patient
develop
cri
high
seem
primarili
determin
baselin
sever
underli
condit
reflect
sap
score
prolong
delay
icu
admiss
septicaemia
staphylococcu
epidermidi
import
pathogen
system
infect
object
studi
genom
dna
profil
epidermidi
isol
catheterrel
infect
bloodstream
infect
compar
strain
isol
skin
nasal
swab
patient
hospitalis
tertiari
care
univers
hospit
method
catheterrel
infect
defin
accord
cdc
definit
patient
cultur
epidermidi
blood
cathet
tip
cfu
select
swab
skin
nasal
epidermidi
epidermidi
type
use
pfge
antibiot
suscept
test
biofilm
detect
congo
red
method
perform
result
twelv
patient
episod
catheterrel
infect
includ
studi
strain
analys
episod
dna
profil
detect
cvcblood
skinnas
seven
episod
clone
caus
cvcblood
infect
found
skinnas
mean
time
isol
epidermidi
clonal
relat
cvcblood
skin
nasal
colonis
first
day
hospitalis
detect
cvcblood
day
episod
without
epidermidi
clonal
relat
mean
time
day
pfge
identifi
three
hospit
endem
profil
present
strain
episod
includ
strain
cvcblood
infect
skinnas
colonis
strain
skinnas
colonis
endem
profil
present
strain
endem
dna
profil
biofilm
produc
resist
penicillin
g
oxacillin
ciprofloxacin
variabl
suscept
aminoglycosid
suscept
vancomycin
conclus
patient
long
term
hospitalis
previous
colonis
hospit
endem
epidermidi
strain
respons
catheterrel
infect
requir
cvc
includ
retrospect
cohort
follow
data
analys
patient
cvc
characterist
risk
factor
microbiolog
result
diagnosi
cvcri
base
brunbuisson
methodolog
comparison
done
use
chisquar
student
ttest
multipl
logisticregress
model
use
identifi
risk
factor
cvcri
accord
adjust
odd
ratio
aor
ci
complet
surviv
analysi
adjust
durat
hospitalis
cvc
unit
time
cvc
implement
admiss
unit
result
total
patient
includ
requir
cvc
cvc
implant
per
hospitalis
studi
unit
gr
patient
admiss
unit
gr
total
cathet
day
respect
gr
gr
number
cvcri
cvc
incid
rate
per
patient
part
number
cvcri
respect
gr
gr
incid
densiti
cvcri
cathet
day
total
cohort
gr
gr
total
cohort
cvcri
monomicrobi
case
case
preval
bacteria
coagulaseneg
staphylococcu
spp
staphylococcu
aureu
case
plurimicrobi
infect
preval
agent
staphylococcu
aureu
coagulaseneg
staphylococcu
spp
enterococcu
faecali
intestinum
somatoplasti
risk
factor
cvcri
studi
crude
mortal
rate
cvcri
noncvcri
respect
p
conclus
surgic
unit
incid
cvcri
high
relat
frequenc
manipul
line
infus
parenter
nutrit
inject
dress
even
adjust
durat
cvc
time
cvc
implant
intervent
focus
risk
factor
plan
reduc
cvcri
improv
qualiti
care
case
schizophren
man
admit
hospit
fever
week
durat
affect
diabet
type
ii
nh
lymphoma
diagnos
month
earlier
treat
chemotherapi
groshong
cvc
subsequ
chronic
steroid
multipl
blood
cultur
perform
cvc
peripher
vein
posit
e
faecali
e
coli
patient
treat
ceftriaxon
g
ev
qid
lockin
therapi
teicoplanin
mg
ml
ciprofloxacin
mg
ml
h
day
day
obtain
clinic
microbiolog
resolut
without
remov
cvc
case
man
admit
hospit
septic
fever
month
earlier
groshong
cvc
place
treat
chemotherapi
rhinopharyng
carcinoma
multipl
blood
cultur
cvc
peripher
vein
posit
multidrugresist
stenotrophomona
maltophilia
chloramphenicol
trimethoprimsulfamethoxazol
levofloxacin
patient
success
treat
without
remov
cvc
system
trimethoprimsulfamethoxazol
levofloxacin
combin
antibiot
lock
ciprofloxacin
mg
ml
h
day
day
conclus
case
report
aa
confirm
mani
cathet
infect
maintain
place
sterilis
lockin
therapi
avoid
replac
expens
intravascular
line
unnecessari
riski
insert
one
question
resolv
whether
concomit
system
antibiot
therapi
necessari
background
nosocomi
infect
influenc
upon
mortal
qualiti
patient
life
cost
length
hospitalis
sourc
infect
might
staff
member
contamin
water
system
aircondit
pest
disinfect
help
reduc
erad
harm
pathogen
exist
hospit
environ
bacteria
abl
grow
surfac
biofilm
form
resist
extern
harm
condit
antibiot
disinfect
host
defenc
bacteri
adhes
recognis
import
virul
factor
colonis
patient
biofilm
format
studi
suscept
bacteri
strain
isol
hospit
environ
colonis
infect
patient
carri
german
cockroach
antibiot
chemic
disinfect
determin
moreov
efficaci
disinfect
work
solut
activ
ingredi
sodium
dichloroisocyanor
mgl
glucoprotamin
mgl
potassium
persulph
mgl
select
bacteri
strain
adher
cathet
grow
day
treat
min
determin
result
suscept
profil
antibiot
vari
among
gramposit
bacteria
mlsb
mrcn
strain
found
among
gramneg
bacteria
esbl
ampc
phenotyp
describ
determin
mic
valu
disinfect
rang
sodium
dichloroisocyanor
mgl
glucoprotamin
mgl
potassium
persulph
mgl
result
indic
work
solut
disinfect
might
ineffect
strain
wellknown
pathogen
serratia
marcescen
citrobact
freundii
enterobact
cloaca
staphylococcu
epidermidi
examin
disinfect
efficaci
select
strain
show
bacteri
strain
resist
grown
cathet
day
mic
valu
lower
work
solut
chemic
even
time
moreov
found
test
disinfect
ineffect
strain
adher
cathet
ex
marcescen
e
cloaca
strain
isol
bodi
surfac
german
cockroach
conclus
possibl
biofilm
format
could
explain
increas
resist
disinfect
strain
german
cockroach
carri
hospit
consid
nuisanc
insect
also
real
sourc
resist
antibiot
disinfect
bacteria
background
indwel
cathet
commonli
colonis
skin
flora
propionibacterium
spp
among
commonest
bacteria
normal
human
skin
current
recommend
cathetercultur
procedur
would
detect
presenc
furthermor
propionibacterium
nearli
alway
regard
blood
cultur
contamin
autom
blood
cultur
method
may
detect
proport
object
determin
rate
cathet
colonis
propionibacterium
spp
unselect
intravascular
cathet
submit
cultur
method
intravascular
cathet
process
rollplat
techniqu
incub
air
c
least
day
organ
present
signific
count
subcultur
identif
suscept
test
convent
aerob
process
finish
primari
cultur
plate
reincub
anaerob
jar
day
anaerob
incub
plate
read
look
bacteri
coloni
initi
present
control
plate
inocul
suspens
p
acn
assess
influenc
aerob
preincub
final
number
coloni
form
unit
cfu
convent
process
detect
signific
growth
bacteria
cathet
signific
number
coloni
addit
sampl
anaerob
reincub
yield
p
acn
signific
count
cathet
posit
cathet
signific
number
coloni
addit
sampl
three
sampl
yield
signific
growth
aerob
anaerob
bacteria
organ
recov
signific
count
coagulaseneg
staphylococci
repres
p
acn
aureu
corynebacterium
spp
enterococcu
spp
bacteria
yeast
anaerob
bacteria
p
acn
rare
recov
nonsignific
count
aerob
preincub
day
substanti
affect
final
number
cfu
conclus
p
acn
second
frequent
colonis
intravascular
cathet
anaerob
reincub
plate
use
standard
routin
simpl
method
could
use
catheterrel
research
project
potenti
p
acn
caus
catheterrel
bacteraemia
merit
studi
result
nineteen
patient
includ
male
nine
femal
whose
age
rang
year
mean
year
patient
hospitalis
neurosurg
depart
common
underli
condit
intracrani
haemorrhag
case
follow
hydrocephalu
case
cranial
injuri
secondari
trauma
patient
underw
surgic
procedur
prior
infect
includ
craniotomi
four
ventriculostomi
patient
receiv
antibiot
therapi
onset
infect
mean
time
surgic
procedur
diagnosi
mening
day
day
fever
neck
stiff
found
eight
seven
patient
respect
patient
serum
leukocyt
count
higher
mm
mean
leukocyt
count
serum
cerebrospin
fluid
mm
min
mm
max
mm
cu
mm
min
mm
max
mm
respect
mean
csf
protein
concentr
mgdl
mean
csf
glucos
concentr
mgdl
case
microorgan
isol
cerebrospin
fluid
acinetobact
spp
case
k
pneumonia
two
case
e
cloaca
isol
microorgan
acinetobact
isol
suscept
carbapenem
resist
thirdgener
cephalosporin
combin
carbapenem
plu
aminoglycosid
andor
vancomycin
therapi
appli
patient
addit
intrathec
aminoglycosid
dosag
need
seven
patient
respond
poorli
overal
mortal
rate
patient
conclus
increas
post
neurosurgeri
mening
case
addit
emerg
strain
resist
thirdgener
cephalosporin
group
also
note
recent
year
becom
great
therapeut
challeng
earli
diagnosi
initi
appropri
antibiot
therapi
need
potenti
fatal
diseas
object
pulmonari
resect
associ
consider
risk
infect
antimicrobi
prophylaxi
becom
routin
practic
thorac
surgeri
aim
studi
assess
chang
microflora
upper
respiratori
tract
hospitalis
patient
nonsmal
cell
lung
cancer
nsclc
preoper
antimicrobi
prophylaxi
method
patient
nsclc
age
year
subdivid
two
group
control
group
patient
without
antimicrobi
prophylaxi
surgeri
b
prophylaxi
group
patient
undergo
pulmonari
oper
preoper
antimicrobi
prophylaxi
includ
piperacillin
cefuroxim
ceftriaxon
alon
combin
amikacin
throat
nasal
specimen
taken
two
time
examin
day
hospit
admiss
examin
ii
third
fourth
day
hospitalis
group
third
fourth
day
surgeri
group
b
routin
microbiolog
method
use
isol
identif
bacteria
fungi
statist
analys
perform
nonparametr
test
result
colonis
nasal
mucou
membran
pathogen
microflora
differ
significantli
hospitalis
group
b
similar
situat
observ
case
pathogen
microflora
throat
mucou
membran
group
differ
result
obtain
group
b
increas
preval
pathogen
microflora
throat
mucou
membran
observ
examin
examin
ii
differ
statist
signific
p
group
b
colonis
throat
mucou
membran
enterobacteriacea
famili
candida
spp
increas
significantli
hospitalis
respect
conclus
result
indic
antimicrobi
prophylaxi
regard
import
predispos
factor
chang
upper
respiratori
tract
microflora
colonis
mucou
membran
throat
enter
gramneg
rod
yeastlik
fungi
candida
spp
microorgan
potenti
caus
agent
endogen
infect
immunocompromis
patient
lung
cancer
object
purpos
studi
determin
aerob
anaerob
bacteria
colonis
pleural
drain
patient
nonsmal
cell
lung
cancer
nsclc
undergo
thorac
surgeri
defin
antimicrobi
agent
suscept
isol
strain
routin
antimicrobi
prophylaxi
includ
piperacillin
cefuroxim
case
betalactam
use
combin
amikacin
method
materi
research
fluid
pleural
drain
collect
patient
age
year
two
time
day
pulmonari
resect
fourth
day
oper
sampl
routin
cultur
aerob
anaerob
condit
determin
use
api
system
biomerieux
antimicrobi
resist
estim
disc
diffus
method
accord
nccl
recommend
result
aerob
strain
anaerob
strain
bacteria
found
sampl
respect
among
aerob
bacteria
gramneg
rod
strain
belong
nonfer
rod
coagulas
neg
staphylococci
cn
strain
often
cultur
fifteen
strain
nonfer
rod
isol
cn
classifi
multidrug
resist
mdr
organ
two
isol
marcescen
produc
extend
spectrum
betalactamas
esbl
induc
betalactamas
ibl
staphylococci
suscept
vancomycin
teicoplanin
cn
strain
resist
penicillin
oxacillin
sensit
amoxicillinclavulan
frequent
isol
two
methicillinresist
strain
belong
haemolyticu
found
common
anaerob
bacteria
genera
eubacterium
nine
strain
actinomyc
six
strain
highli
suscept
antimicrobi
agent
except
metronidazol
resist
strain
chloramphenicol
resist
isol
conclus
colonis
pleural
drain
mean
infect
howev
knowledg
bacteri
speci
found
drain
fluid
local
popul
antimicrobi
resist
especi
mdr
strain
major
impact
success
prophylaxi
therapi
potenti
postop
infect
artero
jj
camarena
r
zaragoza
sancho
j
tamarit
r
j
nogueira
valencia
e
object
know
clinic
microbiolog
characterist
diabet
patient
sever
bacteraemia
identifi
differenti
featur
sever
bacteraemia
patient
without
diabet
mellitu
dm
materi
method
period
evalu
bacteraemia
sever
sepsi
septic
shock
intens
care
unit
teach
hospit
clinic
microbiolog
featur
record
clinic
chart
spss
packag
use
identifi
signific
differ
dm
nodm
case
determin
presenc
dm
associ
mortal
multivari
analysi
result
preval
dm
patient
sever
bacterem
infect
n
group
dm
mean
age
patient
ae
year
relat
menwomen
origin
bacteraemia
nosocomi
sever
sepsi
present
septic
shock
focu
infect
diabet
patient
unknown
n
cathet
n
respiratori
n
urinari
n
abdomin
n
vascular
n
cutan
n
main
microorgan
caus
bacteraemia
patient
dm
cn
acinetobact
baumannii
staphylococcu
aureu
escherichia
coli
enterococcu
spp
higher
proport
nosocomi
case
dm
differenti
featur
patient
without
dm
p
global
mortal
patient
without
dm
p
respect
relat
mortal
p
respect
dm
relat
neither
global
ic
relat
mortal
ic
multivari
analysi
conclus
dm
preval
critic
ill
patient
sever
bacteraem
sepsi
bacteraem
septic
shock
diabet
patient
higher
proport
nosocomi
origin
bacteraemia
find
dm
relat
mortal
sever
bacteraem
infect
poulou
f
markou
x
efthimi
f
mountaki
object
brucellosi
zoonot
diseas
whose
preval
northern
greec
high
constitut
signific
problem
local
health
author
aim
studi
report
rare
case
transmiss
brucella
melitensi
patient
femal
infant
show
sign
respiratori
distress
deliveri
obstetrician
charg
tri
clear
respiratori
tract
saliva
amniot
fluid
attempt
swallow
secret
blood
cultur
infant
incub
bactec
day
b
melitansi
isol
case
prove
rare
case
congenit
brucellosi
famili
infant
check
mother
found
posit
titr
brucella
agglutin
test
though
blood
cultur
neg
neither
husband
two
children
posit
wright
agglutin
test
parent
involv
anim
husbandri
two
month
deliveri
infect
infant
obstetrician
report
pain
back
neck
low
fever
blood
test
reveal
leucopenia
neutropenia
white
cell
count
wright
agglutin
test
posit
titr
blood
cultur
taken
b
melitensi
isol
transaminas
normal
obstetrician
report
consum
unpasteuris
milk
dairi
product
treat
vibramycin
rifadin
day
two
month
later
wright
agglutin
test
found
neg
white
cell
count
normal
conclus
b
melitansi
usual
transmit
consumpt
unpasteuris
diari
product
case
transplacent
transmiss
transmiss
infecti
secret
via
gastrointestin
tract
therefor
essenti
detail
medic
case
histori
taken
pregnant
women
order
avoid
congenit
infect
medic
personnel
awar
possibl
transmiss
object
coryneform
bacteria
gradual
acquir
greater
import
infecti
patholog
especi
opportunist
nosocomi
pathogen
display
resist
variou
antibiot
aim
report
describ
bacteria
signific
implic
differ
clinic
pictur
method
period
characteris
coryneform
isol
presum
clinic
signific
clinic
signific
isol
evalu
accord
clinic
inform
receiv
fever
intravascular
devic
underli
diseas
prolong
antibiot
therapi
etc
well
microbiolog
criteria
one
isol
habitu
steril
anatom
area
andor
repeat
isol
predomin
flora
site
contamin
comens
flora
result
patient
isol
clinic
signific
frequent
isol
found
blood
cultur
seven
corynebacterium
amycolatum
five
corynebacterium
jeikeium
two
corynebacterium
minutissimum
two
dermabact
homini
one
corynebacterium
group
g
one
brevibacterium
sp
anoth
eight
case
bacteraemia
accompani
isol
speci
intraven
cathet
two
c
amycolatum
one
c
striatum
one
c
jeikeium
one
c
group
g
pacemak
cabl
c
minutissimum
soft
tissu
wound
one
c
urealyticum
one
brevibacterium
sp
addit
four
c
striatum
isol
three
respiratori
secret
one
lower
limb
abcess
two
c
amycolatum
mammari
abscess
one
c
jeikeium
articular
fluid
two
c
urealyticum
urin
isol
sensit
vancomycin
mic
mgl
sensit
betalactam
macrolid
fluorquinolon
variabl
conclus
c
amycolatum
c
jeikeium
frequent
found
corynebacteria
presum
clinic
signific
dermabact
brevibacterium
genera
identifi
among
noncorynebacteria
outbreak
nosocomi
ssss
impetigo
bullosa
infant
welldescrib
associ
well
babi
nurseri
sourc
infect
trace
health
care
worker
deliveri
room
newborn
nurseri
initi
site
sa
colonisationinfect
may
anterior
nare
nasopharynx
conjuctiva
umbilicu
andor
blood
rather
skin
often
personnel
asymptomat
carrier
epidem
strain
sa
object
aim
determin
genet
related
sa
isol
patient
staff
investig
potenti
sourc
infect
materi
method
novemb
strain
sa
isol
variou
materi
newborn
hospitalis
neonatolog
obstetrician
depart
well
staff
biochem
test
api
staph
use
speci
identif
molecular
type
isol
use
puls
field
gel
electrophoresi
pfge
interpret
criteria
gel
follow
manufactur
guidelin
isol
ident
restrict
profil
assign
type
isol
differ
one
genet
event
one
three
band
consid
close
relat
isol
fourto
fiveband
differ
consid
possibl
relat
isol
differ
six
band
differ
strain
result
compar
analysi
band
pattern
isol
divid
sever
categori
genet
type
asix
strain
newborn
impetigo
bullosa
one
staff
babi
nurseri
type
b
two
strain
staff
type
c
seven
strain
staff
type
two
strain
staff
nine
type
one
one
person
staff
conclus
case
impetigo
bullosa
caus
one
genet
type
aureu
allow
characteris
infect
hospit
infect
strain
isol
staff
except
one
person
belong
differ
genet
type
unrel
strain
isol
genet
type
infect
newborn
person
stuff
may
suggest
person
sourc
infect
exclud
accident
colonis
hospit
outbreak
defin
whether
bacteri
transloc
process
involv
seri
event
follow
multipl
trauma
method
crush
fractur
middl
right
femor
perform
new
zealand
rabbit
blood
sampl
perform
h
fractur
determin
tumour
necrosi
factoralpha
tnfalpha
nitric
oxid
tnfalpha
estim
bioassay
fibrosarcoma
cell
line
colorimetr
assay
surviv
record
death
segment
liver
spleen
lower
lobe
right
lung
cut
quantit
cultur
conclus
vivo
model
pp
gat
strongli
effect
fulli
suscept
strain
efflux
deriv
despit
emerg
rm
later
one
gat
ineffect
expect
resist
gyra
strain
surprisingli
parc
mutat
strain
mainli
due
presenc
rm
mutant
select
vivo
msw
precis
defin
pkpd
paramet
use
mpc
low
level
resist
fq
detect
simpl
test
guid
therapeut
option
object
boost
system
neutrophil
count
gcsf
prior
infect
lead
diminish
growth
pneumococci
experiment
meninig
improv
surviv
whether
protect
effect
also
includ
attenu
hear
loss
report
materi
method
rat
infect
intracistern
pneumonia
serotyp
randomli
alloc
receiv
gcsf
lgkg
sc
td
h
prior
infect
n
late
treatment
h
postinfect
n
gcsf
n
anim
also
receiv
ceftriaxon
start
h
postinfect
infect
document
blood
csf
tap
h
post
infect
h
day
infect
assess
hear
made
measur
distort
product
otoacoust
emiss
dpoae
f
khz
assess
hear
threshold
auditori
brain
stem
respons
abr
khz
level
db
spl
result
postinfect
hear
loss
significantli
increas
gcsf
treat
anim
compar
untreat
hear
loss
vs
anim
f
hz
vs
f
hz
respect
mannwhitney
p
day
postinfect
among
surviv
anim
sever
hear
loss
gcsf
pretreat
anim
furthermor
increas
compar
control
group
sever
hear
loss
vs
f
hz
respect
mannwhitney
p
late
gcsf
treatment
affect
hear
loss
significantli
compar
control
group
object
bacteri
mening
characteris
intens
inflammatori
host
respons
contribut
high
mortal
morbid
diseas
doxycyclin
clinic
use
antibiot
antiinflammatori
effect
separ
distinct
antimicrobi
action
includ
reduct
cytokin
releas
inhibit
matrix
metalloproteas
present
studi
assess
effect
doxycyclin
given
adjuv
therapi
experiment
pneumococc
mening
method
elevendayold
rat
infect
intracistern
salin
contain
cfuml
streptococcu
pneumonia
h
infect
anim
receiv
ceftriaxon
mgkg
ip
h
randomis
administr
singl
dose
doxycyclin
mgkg
sc
n
equal
volum
salin
n
h
infect
surviv
anim
sacrif
albumin
concentr
brain
assess
index
bloodbrain
barrier
bbb
leakag
brain
damag
quantifi
histomorphometri
result
singl
dose
doxycyclin
mgkg
vs
salin
improv
surviv
surviv
rate
vs
p
protect
bbb
cortic
albumintot
protein
vs
lgmg
p
reduc
injuri
cerebr
cortex
damag
percent
cortex
median
rang
vs
p
conclus
adjuv
treatment
doxycyclin
may
promis
approach
prevent
death
neuron
injuri
consequ
bacteri
mening
establish
condit
result
null
surviv
antibodi
protect
antibiot
treatment
method
fulli
amoxicillinresist
mic
mgl
serotyp
streptococcu
pneumonia
use
infect
strain
amoxicillin
administ
dose
mgkg
produc
serum
concentr
lower
mic
infect
strain
treatment
period
c
max
mgl
passiv
immunis
perform
hyperimmun
serum
hs
obtain
mice
weekli
inocul
whole
cell
heatinactiv
inoculum
week
dilut
pb
dilut
shown
null
protect
surviv
preliminari
experi
group
balbc
mice
weigh
g
passiv
immunis
onesingl
intraperiton
ip
inject
dilut
hs
h
prior
infect
pneumococcu
amoxicillin
treatment
start
h
inocul
continu
tid
h
group
anim
receiv
placebo
pb
nonimmun
serum
nondilut
hs
dilut
hs
amoxicillin
mgkg
alon
includ
control
group
mortal
record
followup
period
result
surviv
rate
control
group
lower
except
nondilut
hs
antibiot
treatment
passiv
immunis
anim
produc
surviv
rate
signific
differ
vs
control
except
nondilut
hs
conclus
sinc
amoxicillin
concentr
mic
mgl
infect
organ
treatment
period
c
max
mgl
presenc
specif
antibodi
produc
vivo
efficaci
subinhibitori
concentr
vivo
combin
effect
antibodiesamoxicillin
synergist
addit
consid
surviv
rate
obtain
antibodi
surviv
amoxicillin
subinhibitori
concentr
surviv
alon
obtain
act
togeth
surviv
mgkg
cro
mgkg
inject
hour
v
mgkg
inject
hour
cro
v
standard
dose
correspond
high
dose
human
csf
sampl
repeatedli
collect
therapi
order
determin
antibiot
level
kill
rate
serum
level
peak
mgl
decreas
slowli
mgl
h
later
csf
level
rang
mgl
penetr
inflam
mening
result
bactericid
activ
differ
regimen
express
delta
log
cfuml
h
delta
log
cfuml
h
result
present
tabl
conclus
highli
efficaci
penr
penr
qurr
pneumococci
experiment
mening
sterilis
csf
rabbit
within
h
treatment
group
monotherapi
significantli
superior
standard
regimen
base
combin
cro
v
strain
efficaci
also
confirm
timekil
assay
h
object
skintemperatur
effect
measur
sever
pneumococc
pneumonia
mice
use
predict
lung
bacteri
count
immin
death
skintemperatur
vari
consider
group
infect
mice
thu
drug
intervent
particular
skintemperatur
close
resembl
use
human
studi
compar
efficaci
moxifloxacin
mfx
levofloxacin
lvx
treatment
pneumococc
pneumonia
use
novel
skintemperatur
model
method
swiss
webster
mice
inocul
endotrach
cfu
streptococcu
pneumonia
strain
mic
mfx
lgml
lvx
lgml
skin
temperatur
h
use
assess
diseas
sever
prior
drug
treatment
skin
temperatur
c
indic
moder
infect
pulmonari
bacteri
count
cfu
wherea
temperatur
c
c
suggest
sever
infect
count
cfu
mice
temperatur
c
exclud
studi
death
immin
within
h
mgkg
subcutan
dose
mfx
lvx
given
twice
daili
day
skin
temperatur
measur
daili
monitor
clinic
improv
failur
c
least
h
mice
deem
fail
therapi
euthanis
immedi
viabl
count
lung
determin
mice
result
mice
class
moder
mice
treat
mfx
mice
treat
lvx
surviv
complet
erad
obtain
mice
treat
mfx
lvx
respect
group
mice
class
sever
mice
treat
mfx
lvx
respect
surviv
complet
erad
obtain
mice
treat
mfx
lvx
group
conclus
mfx
show
significantli
enhanc
activ
lvx
earli
late
stage
pneumococc
lung
infect
partial
knee
replac
perform
silicon
implant
fit
intramedullari
canal
tibia
cfu
mrsa
inject
knee
rx
start
day
inocul
continu
day
intramuscularli
result
mic
mgl
lzd
van
rif
respect
vivo
lzd
reduc
significantli
mean
log
cfug
bone
ae
n
vs
control
van
ae
n
ae
n
respect
p
rx
suffici
sterilis
anim
respect
combin
rif
lzd
ae
cfu
g
bone
steril
anim
van
ae
cfug
bone
steril
anim
significantli
effect
monotherapi
p
emerg
resist
rif
detect
vivo
conclus
mrsa
joint
prosthesi
infect
lzd
combin
rif
highli
effect
vivo
prevent
select
mutant
resist
rifampin
lzd
interest
treat
mrsa
joint
prothesi
infect
staphylococcu
aureu
nasal
decolonis
model
studi
role
multidrug
efflux
system
acrabtolc
resist
salmonella
typhimurium
deterg
bile
salt
evalu
import
compon
acrb
tolc
efflux
system
colonis
multidrugresist
typhimurium
strain
chick
method
acrb
tolc
mutant
multidrugresist
typhimurium
strain
construct
delet
insert
inactiv
gene
mic
deterg
bile
salt
determin
acrb
tolc
mutant
compar
wild
type
mutidrugresist
strain
effect
sodium
choleat
vitro
growth
three
strain
evalu
strain
measur
one
day
old
chicken
model
inocul
sever
dose
log
cfu
oral
rout
day
postinocul
colonis
level
assess
sublet
dose
day
postinocul
determin
number
cfu
salmonella
faec
caeca
spleen
liver
result
decreas
resist
deterg
bile
salt
much
import
tolc
mutant
acrb
mutant
exampl
mic
sd
decreas
time
mic
sodium
deoxychol
decreas
time
tolc
acrb
mutant
respect
addit
choleat
cultur
medium
effect
growth
wild
type
strain
acrb
mutant
inhibit
growth
tolc
mutant
old
chicken
model
log
cfu
log
cfu
wild
type
strain
acrb
mutant
respect
calcul
tolc
mutant
small
number
dead
chick
furthermor
contrast
acrb
mutant
tolc
mutant
unabl
colonis
caeca
spleen
liver
week
infect
moreov
chick
intestin
excret
detect
tolc
mutant
colonis
level
acrb
mutant
parent
strain
conclus
tolc
acrb
appear
essenti
multidrugresist
typhimurium
colonis
chick
accord
respect
role
resist
deterg
bile
salt
therefor
tolc
could
better
target
acrb
develop
efflux
system
inhibitor
deriv
produc
plasmidmedi
ampctyp
blactamas
vitro
studi
micmbc
microdilut
method
nccl
inoculum
cfuml
vitro
postantibiot
effect
pae
investig
expos
bacteria
imp
cep
concentr
equal
two
six
time
mic
h
pae
quantit
calcul
differ
time
requir
number
drugexpos
untreat
organ
increas
number
present
immedi
remov
antibiot
pkpd
paramet
c
max
time
mic
determin
singl
dose
antimicrobi
vivo
studi
experiment
pneumonia
mice
intratrach
inoculum
cfuml
anim
group
con
treatment
cfp
mgkgday
imp
mgkgday
h
variabl
mortal
rate
bacteri
clearanc
lung
statist
analysi
chisquar
fisher
test
anova
posthoc
test
result
imp
vivo
cfp
imp
decreas
mortal
respect
con
vs
p
vs
p
imp
therapi
decreas
mortal
compar
con
cfp
vs
p
bacteri
clearanc
lung
cfp
imp
clear
lung
respect
con
vs
log
cfuml
p
cfp
better
imp
p
cfp
imp
clear
lung
respect
con
vs
log
cfu
ml
p
conclus
presenc
plasmidmedi
ampctyp
blactamas
k
pneumonia
diminish
vivo
efficaci
cefepim
imipenem
inoculum
effect
cefepim
pae
imipenem
partial
explain
result
abscessu
rapidli
grow
mycobacterium
rgm
emerg
signific
pathogen
human
respiratori
pathogen
patient
without
recognis
comorbid
agent
inocul
infect
histopatholog
featur
human
infect
suggest
abscessu
caus
tuberculosislik
infect
investig
system
challeng
mice
type
strain
abscessu
intraven
intraperiton
rout
high
cfu
low
cfu
dose
initi
bacteri
load
remain
stabl
day
liver
spleen
establish
granulomat
respons
differenti
granuloma
central
epithelioid
cell
peripher
lymphocyt
crown
contemporari
drastic
decreas
bacteri
load
organ
studi
howev
day
follow
challeng
mice
still
harbour
bacteria
capabl
vitro
growth
liver
spleen
despit
overal
effect
control
infect
mice
infect
present
granuloma
variou
differenti
stage
liver
respons
highli
reminisc
ifnc
depend
respons
tuberculosi
mice
delet
gene
encod
ifnc
challeng
intraperiton
abscessu
significantli
fail
reduc
bacteri
load
day
show
first
time
rapidli
grow
abscessu
caus
long
last
tuberculosislik
ifnc
depend
infect
mice
result
show
promis
elucid
abscessu
diseas
sinc
data
tuberculosi
might
relev
reciproc
abscessu
faith
model
key
featur
mycobacteri
infect
campylobact
jejuni
infect
common
anteced
axon
variant
syndrom
gb
antibodi
nerv
gangliosid
found
gb
patient
recognis
cross
reactiv
epitop
lipopolysaccharid
lp
c
jejuni
led
molecular
mimicri
hypothesi
gb
investig
connect
among
c
jejuni
antibodi
anti
gangliosid
gb
design
anim
model
employ
lp
isol
gb
patient
method
immunis
eleven
rabbit
lp
extract
penner
serotyp
c
jejuni
strain
isol
patient
gb
freund
adjuv
cfa
group
second
experi
immunis
seven
rabbit
lp
cfa
keyhol
limpet
hemocyanin
klh
group
ii
result
rabbit
group
ii
develop
strong
humor
respons
lp
elev
igm
igg
antibodi
lp
could
detect
earli
week
first
immunis
igg
rais
immunis
period
group
group
ii
igm
antibodi
detect
low
titr
week
first
immunis
group
rais
group
group
ii
igg
could
alreadi
detect
low
titr
group
week
first
immunis
increas
group
group
ii
titr
igg
show
steep
rise
week
follow
first
immunis
western
immunoblot
c
jejuni
lp
serum
immunis
rabbit
react
strongli
band
comigr
kd
level
ct
pna
serum
patient
antibodi
kinet
igm
igg
similar
antibodi
maxim
titr
lower
igg
rais
group
group
ii
igm
low
titr
group
throughout
experi
wherea
igg
rais
group
group
ii
igm
igg
detect
group
ii
sera
conclus
c
jejuni
lp
potent
bcell
stimul
capabl
induc
strong
antigangliosid
respons
rabbit
howev
induc
neuropathi
crucial
employ
klh
glycoprotein
known
stimul
humor
cellular
respons
first
anim
model
reproduc
pathogenet
process
hypothesis
axon
gb
antigangliosid
antibodi
postc
jejuni
infect
method
three
separ
experi
conduct
order
screen
abil
five
clinic
c
concisu
isol
atcc
type
strain
oral
origin
infect
balbca
mice
mice
pretreat
vancomycin
half
anim
receiv
cyclophosphamid
disturb
immun
function
prior
c
concisu
challeng
direct
intragastr
inocul
ml
cfu
control
receiv
ml
pb
measur
paramet
bacteri
isol
stool
intern
organ
loss
bodi
weight
histolog
examin
tissu
sampl
mice
sacrif
day
studi
isol
c
concisu
perform
select
filter
method
pcr
result
isol
identif
c
concisu
isol
day
cyclophosphamid
treat
group
infect
clinic
isol
studi
liver
ileum
jejunum
cultur
posit
pcr
result
tissu
sampl
posit
one
mous
group
liver
ileum
jejunum
faecal
pellet
consist
neg
two
follow
studi
isol
c
concisu
possibl
histolog
examin
microabscess
found
liver
two
untreat
group
oedema
villi
ileum
occasion
note
infect
group
control
studi
two
mice
untreat
group
infect
atcc
type
strain
present
leukocyt
infiltr
colon
loss
bodi
weight
compar
control
c
concisu
infect
mice
signific
weight
loss
p
studi
loos
stool
day
c
concisu
inocul
group
loos
slimi
stool
compar
control
group
studi
one
mous
inocul
clinic
isol
die
day
studi
discuss
present
model
mimic
relev
intragastr
exposur
c
concisu
infect
imunocompet
balbca
mice
upon
cyclophosphamid
treatment
result
indic
possibl
transient
colonis
liver
ileum
clinic
sign
ill
loss
bodyweight
loos
stool
histolog
examin
inconclus
isol
c
concisu
reproduc
two
subsequ
studi
sever
hamper
present
model
futur
studi
concentr
first
day
infect
organ
rapidli
clear
gi
tract
coadminist
antimicrobi
experiment
model
sepsi
mdr
isol
method
sepsi
induc
rabbit
iv
infus
log
inoculum
p
aeruginosa
isol
resist
ceftazidim
cz
imipenem
ciprofloxacin
amikacin
cathet
insert
right
jugular
vein
anim
assign
five
group
treatment
six
anim
control
b
iv
cz
c
iv
cz
alcohol
iv
cz
alcohol
solut
gla
e
iv
cz
alcohol
solut
aa
therapi
administ
min
bacteri
challeng
cz
given
mgkg
dose
mgkg
n
pufa
mgkg
n
pufa
infus
within
min
agent
administ
cathet
insert
left
jugular
vein
surviv
record
death
segment
variou
organ
cut
quantit
cultur
result
synergi
test
experiment
model
method
thirtyf
wistar
rat
becam
neutropen
intraperiton
inject
mgkg
cyclophosphamid
day
mgkg
day
day
log
inoculum
one
mdr
isol
intramuscularli
inject
right
femor
anim
rat
assign
four
group
treatment
n
control
b
n
rf
treat
c
n
cl
treat
n
treat
agent
therapi
given
four
hour
bacteri
challeng
cl
administ
im
mgkg
left
femor
rf
iv
cathet
insert
right
jugular
vein
mgkg
surviv
record
result
mean
ae
se
surviv
anim
group
b
c
ae
day
ae
day
p
compar
ae
p
compar
ae
p
compar
respect
conclus
coadministr
cl
rf
beneficiari
accompani
prolong
surviv
experiment
model
sepsi
mdr
baumannii
infect
acinetobact
baumannii
ab
highdegre
resist
hdr
carbapenem
recent
increas
colistin
seem
keep
vitro
efficaci
clinic
practic
scarc
knowledg
clinic
data
current
avail
evalu
systemat
use
betalactam
bl
aminoglycosid
ag
combin
treat
seriou
ab
infect
way
similar
infect
gramneg
bacteria
object
analys
efficaci
combin
two
bl
imipenem
method
use
immunocompet
mice
three
strain
ab
suscept
moderatedegre
resist
hdr
carbapenem
e
respect
mic
mgl
strain
e
vivo
activ
examin
quantit
evalu
lung
homogen
cultur
h
induct
pneumonia
result
control
con
anim
n
bacteri
count
lung
h
mean
ae
sd
ae
ae
ae
log
cfug
tissu
strain
e
respect
p
ns
strain
result
antibiot
activ
express
differ
treat
n
therapi
con
group
delta
log
cfug
see
tabl
conclus
mice
pneumonia
model
kept
efficaci
ab
moder
resist
carbapenem
infect
caus
strain
combin
confer
possibl
greater
efficaci
bl
infect
ab
hdr
carbapenem
alon
also
effect
interestingli
combin
bl
ag
also
show
higher
effect
infect
hdr
strain
e
monotherapi
total
ineffect
although
pharmacodynam
model
may
overestim
peak
level
achiev
usual
found
human
recommend
dose
c
max
ae
mgl
result
promis
treat
multiresist
ab
infect
object
investig
effect
oral
administ
cranberri
juic
organ
acid
escherichia
coli
experiment
mous
model
ascend
urinari
tract
infect
method
e
coli
clinic
isol
patient
uti
use
express
type
fimbria
p
fimbria
transurethr
infect
mice
time
allow
free
access
chow
water
control
group
treatment
control
group
treat
group
consist
six
mice
everi
trial
week
mice
sacrif
urin
bladder
kidney
collect
determin
bacteri
count
treatment
repeat
two
time
independ
trial
data
pool
treatment
commerci
avail
cranberri
juic
cocktail
freshli
prepar
cranberri
juic
hydrophil
fraction
cranberri
juic
contain
sugar
organ
acid
organ
acid
quinic
malic
shikim
citric
acid
concentr
correspond
cranberri
juic
result
reduc
number
organ
could
recov
bladder
p
urin
p
mice
oral
treat
unsweeten
cranberri
juic
commerci
avail
cranberri
juic
cocktail
also
reduc
cfu
bladder
p
hydrophil
fraction
cranberri
juic
p
quinic
malic
shikim
citric
acid
administ
combin
one
one
four
organ
acid
decreas
cfu
bladder
administ
togeth
p
combin
malic
plu
citric
acid
p
malic
plu
quinic
acid
p
data
indic
benefici
effect
organ
acid
cranberri
juic
urinari
tract
infect
obtain
acid
administ
togeth
conclus
fist
time
effect
cranberri
juic
domin
organ
acid
test
experiment
mous
model
longterm
ascend
urinari
tract
infect
control
condit
cranberri
juic
inhibit
e
coli
colonis
bladder
organ
acid
activ
compon
involv
activ
treatment
reduc
bacteri
load
bladder
sub
therapeut
concentr
indic
cranberri
juic
final
treatment
remedi
could
help
patient
clear
infect
eventu
becom
final
cystiti
mellado
et
al
mol
microbiol
describ
kinet
microbroth
method
measur
growth
rate
aspergillu
fumigatu
spectrophotometr
use
method
growth
rate
defin
v
max
valu
determin
nine
aspergillu
fumigatu
isol
valu
temporarili
neutropen
mice
infect
intraven
previous
obtain
method
inoculum
spore
sab
medium
gave
us
uniformli
shape
growth
curv
allow
measur
v
max
valu
greater
sensit
soft
max
pro
softwar
use
determin
v
max
valu
growth
curv
perform
linear
regress
mani
five
data
point
line
segment
possibl
calcul
slope
line
segment
report
steepest
slope
v
max
modmin
growth
rate
determin
quadrupl
three
separ
experi
averag
v
max
measur
across
experi
calcul
result
mean
growth
rate
vari
vari
comparison
growth
rate
valu
isol
suggest
correl
exist
two
paramet
omit
one
signific
outlier
amphotericin
b
resist
r
conclus
data
import
describ
simpl
method
measur
growth
rate
common
filament
fungu
fumigatu
prove
direct
link
pathogen
vivo
growth
rate
vitro
object
compar
histolog
chang
viral
persist
localis
viru
pancrea
small
intestin
mice
experiment
infect
oral
intraperiton
rout
method
mice
infect
cvb
nanci
oral
intraperiton
rout
dose
rang
select
organ
mous
embed
paraffin
section
attach
silanis
slide
histolog
observ
section
stain
mayer
haematoxylin
eosin
method
localis
antigen
immunohistochem
stain
protein
serv
indic
presenc
viru
method
standardis
tissu
section
process
stain
avidinbiotin
method
use
monoclon
mous
antienteroviru
antibodi
protein
result
histolog
observ
reveal
tissu
exocrin
pancrea
show
inflammatori
chang
day
postinfect
exocrin
pancrea
intraperiton
infect
mice
oral
infect
destruct
exocrin
pancrea
observ
day
postperor
infect
liposi
seen
detect
mainli
third
seventh
day
infect
small
intestin
found
differ
localis
oral
intraperiton
infect
small
intestin
oral
infect
mice
posit
stain
localis
smooth
intestin
muscl
wherea
intraperiton
infect
detect
within
villi
correl
viru
concentr
tissu
damag
conclus
pathogenesi
infect
influenc
rout
viru
administr
direct
implic
use
mous
model
studi
pathogenesi
coxsackievirus
object
portal
entri
coxsackievirus
may
influenc
pathogenesi
infect
caus
virus
studi
outbr
murin
model
swiss
albino
mice
use
experiment
infect
coxsacki
viru
strain
nanci
followup
viru
shed
stool
presenc
replic
viru
small
intestin
mice
oral
intraperiton
rout
infect
method
infect
mice
differ
concentr
viru
use
stool
small
intestin
specimen
dissect
mice
collect
day
postinfect
pi
day
weekli
interv
day
pi
suspens
made
collect
specimen
studi
presenc
replic
viru
cell
cultur
viru
titr
determin
monolay
microtitr
plate
calcul
reed
muench
method
result
replic
viru
stool
pellet
detect
day
pi
day
pi
oral
intraperiton
infect
mice
viru
titr
reach
level
ml
small
intestin
oral
infect
mice
presenc
replic
viru
detect
day
pi
small
intestin
intraperiton
infect
mice
replic
viru
present
shorter
time
day
pi
irrespect
dose
infect
conclus
differ
length
viru
shed
stool
specimen
mice
infect
oral
intraperiton
rout
howev
longer
presenc
replic
viru
small
intestin
oral
infect
mice
contrast
intraperiton
infect
mice
observ
confirm
immunohistopatholog
studi
observ
support
suggest
pathogenesi
coxsackievir
infect
influenc
rout
viru
administr
object
xenotransplant
porcin
neonat
pancreat
cell
cluster
npcc
risk
crossspeci
porcin
endogen
retroviru
perv
infect
remain
problem
use
sever
combin
immunodefici
scid
mous
lewi
rat
model
identifi
perv
transmiss
time
cours
differ
model
method
npcc
transplant
scid
mice
lewi
rat
left
day
sacrif
dna
rna
extract
liver
spleen
pancrea
lung
kidney
testi
examin
perv
transmiss
nestedpcr
rtpcr
use
upon
polenvgag
region
perv
pig
mitochondri
cytochrom
oxidas
ii
subunit
gene
coii
amplifi
simultan
monitor
microchimer
result
total
sampl
seven
mice
five
rat
test
ten
week
xenotransplant
two
mice
four
rat
identifi
permiss
perv
infect
scid
mice
test
organ
posit
pervpol
gene
posit
coii
gene
dna
examin
lewi
rat
organ
posit
pervpol
gene
coii
gene
dna
examin
examin
organ
mice
show
organ
posit
pervpol
gene
coii
gene
simultan
presum
microchimer
organ
rat
presum
microchimer
result
pervpol
posit
coii
neg
presum
permiss
perv
infect
observ
organ
scid
mice
lewi
rat
organ
presum
permiss
perv
infect
spleen
day
liver
day
lung
day
testi
day
scid
mice
dna
examin
lewi
rat
spleen
testi
day
liver
spleen
kidney
day
testi
kidney
day
liver
spleen
lung
testi
day
identifi
permiss
perv
infect
conclus
crossspeci
perv
infect
identifi
anim
model
express
perv
depend
immun
recipi
xenotranspl
scid
mice
perv
microchimer
less
permiss
infect
lewi
rat
detect
rate
increas
time
cours
accordingli
earli
period
transplant
perv
consid
exist
inact
form
therapi
numer
antimicrobi
class
includ
recent
introduc
quinupristindalfopristin
telithromycin
oxazolidinon
clearli
need
antimicrobi
discoveri
persist
continu
prioriti
pharmaceut
industri
report
address
spectrum
activ
test
collect
recent
clinic
isol
cultur
patient
infect
pathogen
within
spectrum
peptid
deformylas
inhibitor
method
acquir
novarti
compound
dispens
refer
broth
microdilut
tray
appropri
media
rang
mgl
muellerhinton
broth
supplement
lyse
hors
blood
test
fastidi
streptococci
corynebacteria
nccl
qc
strain
use
concurr
mic
result
within
propos
rang
result
gramposit
strain
test
speci
rank
order
aureu
strain
con
object
new
peptid
deformylas
inhibitor
activ
wide
varieti
gramposit
neg
bacteria
current
studi
examin
activ
compar
ciprofloxacin
levofloxacin
gatifloxacin
moxifloxacin
vancomycin
teicoplanin
linezolid
ranbezolid
daptomycin
oritavancin
quinupristindalfopristin
aureu
methicillin
resist
coagulaseneg
staphylococci
methicillin
resist
microdilut
use
frozen
tray
contain
cationadjust
muellerhinton
broth
inocula
cfu
ml
tray
incub
air
result
mic
mic
valu
lgml
seen
follow
tabl
equal
activ
staphylococc
strain
mic
lgml
irrespect
suscept
agent
quinolon
resist
mainli
seen
methicillin
r
strain
vancomycin
linezolid
ranbezolid
daptomycin
oritavancin
quinupristindalfopristin
activ
mic
lgml
teicoplanin
less
activ
coagulaseneg
strain
conclus
new
peptid
deformylas
inhibitor
activ
vitro
staphylococci
antipneumococc
activ
compar
agent
p
appelbaum
l
edni
jacob
hershey
cleveland
usa
background
drug
resist
pneumococci
found
worldwid
object
new
peptid
deformylas
inhibitor
activ
gramposit
neg
bacteria
studi
test
activ
amoxicillin
ae
clavulan
imipenem
meropenem
ceftriaxon
cefuroxim
cefpodoxim
cefdinir
ciprofloxacin
levofloxacin
gatifloxacin
moxifloxacin
azithromycin
clarithromycin
linezolid
quinupristindalfopristin
vancomycin
teicoplanin
pen
pen
pen
r
pneumococci
macrolid
r
quinolon
r
strain
defin
r
genotyp
method
agar
dilut
use
cationadjust
muellerhinton
agar
sheep
blood
inocula
cfuspot
plate
incub
air
result
valu
lgml
shown
tabl
equal
activ
pneumococci
irrespect
activ
drug
betalactam
mic
rose
pen
g
moxi
potent
quinolon
follow
gati
levo
cipro
vanco
teico
linez
quindalf
activ
mic
lgml
conclus
activ
vitro
betalactam
macrolid
quinolon
r
pneumococci
object
nvp
new
peptid
deformylas
inhibitor
activ
gramposit
gramneg
strain
studi
test
activ
nvp
ciprofloxacin
levofloxacin
gatifloxacin
moxifloxacin
vancomycin
teicoplanin
linezolid
ranbezolid
daptomycin
tigecyclin
oritavancin
quinupristin
dalfopristin
six
aureu
methi
r
six
con
methi
r
method
nccl
macrodilut
mic
use
timekil
cfuml
inocula
cationadjust
muellerhinton
broth
incub
aerob
shake
water
bath
mic
viabil
done
h
ca
ad
dapto
result
mic
rang
lgml
nvp
cipro
levo
gati
moxi
vanco
teico
linez
ranbez
dapto
tige
nvp
cipro
levo
gati
moxi
vanco
teico
linezolid
ranbez
depto
tigecyt
oritavan
quindalf
orita
quinudalfo
strain
mic
mic
log
cfuml
log
cfu
ml
log
cfuml
kill
variou
time
period
shown
tabl
nvp
cidal
mic
mic
static
strain
mic
h
cipro
moxi
cidal
four
seven
strain
mic
h
vanco
cidal
mic
nine
strain
h
oxazolidinon
tigec
quinudalfo
mainli
bacteriostat
dapto
orita
rapidli
cidal
conclus
nvp
gave
low
mic
static
activ
strain
irrespect
methicillin
suscept
statu
timekil
studi
antipneumococc
activ
nvp
new
peptid
deformylas
inhibitor
compar
agent
p
appelbaum
g
pankuch
jacob
hershey
cleveland
usa
background
drugresist
pneumococci
increas
worldwid
problem
object
nvp
new
peptid
deformylas
inhibitor
studi
use
timekil
analysi
examin
antipneumococc
activ
nvp
compar
imipenem
meropenem
ceftriaxon
moxifloxacin
levofloxacin
gatifloxacin
azithromycin
clarithromycin
vancomycin
teicoplanin
linezolid
daptomycin
quinupristindalfopristin
twelv
strain
test
three
penicillin
sensit
two
intermedi
seven
resist
pneumococci
strain
test
macrolid
resist
erm
b
mef
two
quinolon
resist
methodolog
nccl
macrodilut
mic
methodolog
use
timekil
analys
cationadjust
muellerhinton
broth
lyse
hors
blood
final
inocula
cfuml
muellerhinton
broth
supplement
final
concentr
mg
ca
l
test
daptomycin
viabil
count
done
h
result
mic
lgml
follow
nvp
imipen
meropen
ceftriax
moxi
levo
gati
azithro
clarithro
vanco
teico
linez
dapto
quindal
number
strain
mic
mic
log
cfuml
valu
kill
kill
kill
variou
time
period
shown
tabl
conclus
nvp
kill
kinet
similar
linezolid
nvp
mic
bactericid
kill
six
strain
h
linezolid
mic
bactericid
seven
strain
period
daptomycin
quinupristindalfopristin
show
rapid
kill
imipenem
meropenem
vancomycin
quinupristindalfopristin
bactericid
strain
mic
h
object
new
peptid
deformylas
inhibitor
antimicrobi
excel
activ
gramposit
cocci
includ
methicillinresist
staphylococcu
aureu
mrsa
penicillinresist
streptococcu
pneumonia
prsp
use
neutropen
murin
thighinfect
model
measur
vivo
postantibiot
effect
pae
determin
pkpd
paramet
best
correl
vivo
efficaci
method
mice
cfuthigh
staphylococcu
aureu
atcc
streptococcu
pneumonia
atcc
treat
h
mgkgday
fraction
dose
mice
sacrif
end
therapi
ten
per
cent
thigh
homogen
prepar
serial
dilut
plate
cfu
determin
serum
level
oral
subcutan
inject
dose
mgkg
measur
microbiolog
assay
nonlinear
regress
analysi
use
determin
pkpd
paramet
aucmic
peakmic
time
mic
best
correl
cfuthigh
h
vivo
pae
measur
serial
h
cfuthigh
valu
dose
mgkg
result
pharmacokinet
studi
exhibit
linear
kinet
dose
mgkg
peakdos
valu
aucdos
valu
halfliv
min
oral
bioavail
protein
bind
mous
serum
low
produc
vivo
pae
h
aureu
h
pneumonia
aucmic
highli
correl
efficaci
r
aucmic
compar
peakmic
time
mic
pneumonia
aureu
respect
rapid
halflif
mice
oncedaili
dose
slightli
less
effect
frequent
dose
regimen
conclus
aucmic
paramet
best
correl
vivo
activ
prolong
vivo
pae
would
support
least
twice
daili
dose
vivo
pharmacodynam
activ
multipl
bacteri
pathogen
w
craig
and
madison
wisconsin
usa
object
aucmic
pkpd
paramet
best
correl
vivo
activ
new
peptid
deformylas
inhibitor
use
murin
thighinfect
model
nvp
imipen
meropen
ceftriax
moxi
levo
gati
azithro
clarithro
vanco
teico
linez
depto
quindal
normal
neutropen
mice
determin
magnitud
aucmic
need
efficaci
variou
pathogen
includ
mrsa
penicillin
macrolideand
tetracyclineresist
strain
pneumonia
impact
neutrophil
drug
vivo
activ
method
mice
cfuthigh
five
isol
staphylococcu
aureu
two
mrsa
six
isol
streptococcu
pneumonia
five
penicillinresist
four
macrolideresist
three
tetracyclineresist
strain
treat
h
mgkg
subcutant
everi
h
streptococcu
pneumonia
staphylococcu
aureu
atcc
studi
simultan
normal
neutropen
mice
mice
sacrif
start
end
therapi
ten
per
cent
thigh
homogen
prepar
serial
dilut
plate
cfu
determin
serum
level
determin
microbiolog
assay
subcutan
dose
mgkg
sigmoid
doserespons
model
use
estim
dose
h
requir
achiev
net
bacteriostat
effect
h
result
pk
studi
exhibit
linear
kinet
aucdos
valu
halfliv
min
protein
bind
mic
rang
mgl
static
dose
variou
organ
rang
mgkgday
mean
auc
free
mic
valu
aesd
ae
aureu
ae
pneumonia
differ
signific
methicillin
penicillin
resist
alter
magnitud
aucmic
requir
efficaci
presenc
neutrophil
reduc
free
mic
requir
efficaci
fourfold
conclus
aucmic
requir
vivo
efficaci
rel
similar
among
variou
pathogen
alter
drug
resist
reduc
fourfold
presenc
neutrophil
determin
qualiti
control
guidelin
mic
dilut
disk
diffus
method
test
novel
peptid
deformylas
inhibitor
fritsch
anderegg
r
jone
north
liberti
usa
background
qualiti
control
qc
guidelin
remain
necessari
accur
determin
antimicrobi
suscept
test
establish
earli
develop
new
antimicrobi
class
pdf
inhibitor
rapidli
progress
phase
ii
iii
human
clinic
trial
thu
qc
guidelin
appear
necessari
nccl
method
method
multilaboratori
seven
eight
site
trial
initi
use
nccl
guidelin
qc
determin
key
technic
detail
mic
phase
four
muellerhinton
mh
broth
lot
eight
particip
site
replic
four
appropri
qc
strain
disk
diffus
phase
three
mh
agar
lot
seven
site
replic
three
qc
strain
result
analys
statist
method
found
control
drug
includ
vancomycin
clarithromycin
linezolid
levofloxacin
control
result
within
publish
nccl
rang
result
mic
zone
test
respect
inoculum
concentr
control
averag
mic
trial
result
seven
eight
particip
provid
qualifi
result
two
separ
qc
studi
calcul
propos
rang
rang
result
rang
e
faecali
atcc
mg
l
aureu
atcc
mgl
pneumonia
atcc
mgl
mm
h
influenza
atcc
mgl
mm
aureu
atcc
mm
qc
rang
maximis
contain
report
result
zone
sise
variat
elev
due
bacteriostat
charact
pdf
inhibitor
creat
nondiscreet
zone
edg
conclus
qc
rang
nccl
method
test
establish
result
nccl
trial
utilis
control
accuraci
suscept
test
pdf
inhibitor
project
among
first
reach
human
clinic
studi
determin
dryform
commerci
reagent
reproduc
mic
valid
novel
peptid
deformylas
inhibitor
g
moet
r
jone
p
rhomberg
fritsch
north
liberti
usa
background
new
pdf
inhibitor
rapidli
advanc
human
clinic
trial
commerci
reagent
broth
microdilut
mic
panel
requir
investig
laboratori
use
especi
product
extend
shelfliv
dryform
studi
report
result
reagent
qualifi
test
method
experi
perform
nccl
guidelin
assess
dryform
mic
reproduc
organ
testsday
day
test
compar
mic
accuraci
refer
mic
ref
use
strain
repres
follow
organ
group
staphylococci
enterococci
pneumonia
streptococci
h
influenza
select
speci
refractori
pdf
inhibitor
action
tray
manufactur
sensititr
trek
diagnost
cleveland
oh
result
reproduc
result
show
mic
ident
mic
within
one
log
dilut
step
valid
test
result
compar
dryform
ref
mic
identicaltwofoldfourfold
staphylococci
enterococci
pneumonia
streptococci
h
influenza
consist
variat
detect
spn
dryform
panel
result
one
dilut
higher
ref
hi
result
one
dilut
lower
ref
mic
offscal
mic
valu
mgl
enterobacteriacea
nonfer
gramneg
bacilli
strain
overal
sensititr
mic
result
within
one
log
dilut
ref
mic
valu
conclus
dryform
diagnost
mic
panel
valid
accuraci
reproduc
use
recent
clinic
isol
five
major
pathogen
group
spectrum
activ
pdf
inhibitor
compound
appear
focus
toward
gramposit
cocci
specif
fastidi
respiratori
tract
pathogen
object
emerg
antibiot
resist
among
gramposit
pathogen
impact
clinic
manag
infect
paratek
pharmaceut
initi
programm
appli
medicin
chemistri
core
structur
tetracyclin
tet
goal
creat
novel
class
proprietari
antibiot
would
unaffect
known
tet
resist
mechan
b
retain
safeti
toler
profil
tet
famili
sinc
crossresist
tet
antibiot
new
agent
would
expect
activ
isol
resist
current
avail
class
aim
programm
synthesis
new
agent
activ
gramposit
common
gramneg
atyp
anaerob
bacteria
method
seri
deriv
sancyclin
synthesis
test
activ
vitro
mrsa
vre
enterococcu
faecali
streptococcu
pneumonia
microdilut
presenc
tetresist
determin
assess
pcr
confirm
resist
current
avail
tet
result
number
amc
heteroaryl
sancyclin
potent
activ
vitro
mic
rang
less
equal
mgl
identifi
novel
seri
potent
one
resist
strain
current
avail
antibiot
test
mic
rang
mgl
amc
deriv
activ
bacteria
resist
tet
efflux
ribosomeprotect
mechan
conclus
studi
identifi
amc
novel
class
antibiot
evolv
tet
exhibit
potent
activ
vitro
tetresist
bacteria
includ
gramposit
bacteria
resist
current
avail
antibiot
one
agent
class
bay
discov
paratek
pharmaceut
inc
boston
design
ptk
chosen
develop
bay
novel
antibiot
compound
develop
treatment
sever
bacteri
infect
first
compound
select
novel
class
aminomethylcyclin
design
meet
increasingli
signific
need
addit
therapi
treatment
infect
includ
resist
current
avail
antibiot
efficaci
bay
differ
mous
model
skin
soft
tissu
infect
ssti
compar
vancomycin
van
linezolid
lin
method
two
mous
model
employ
determin
efficaci
bay
infect
abscess
model
induc
implant
subsequ
infect
gelfoam
tm
infect
thigh
muscl
model
neutropen
mice
staphylococcu
aureu
strain
mssa
use
infect
respect
structur
skin
soft
tissu
infect
abscess
bear
mice
treat
iv
bid
day
thigh
muscl
infect
model
mice
treat
sc
min
postinfect
cfu
reduct
infect
tissu
bacteri
load
differ
organ
spread
infect
site
use
readout
therapeut
efficaci
result
measur
reduct
bacteri
load
therapi
infect
abscess
bay
cfu
reduct
log
unit
mgkg
superior
van
lin
reduct
bacteri
load
furthermor
bay
reduc
overal
bacteri
load
spleen
liver
lung
heart
reduct
organ
load
bay
efficaci
van
conclus
dal
activ
survey
indic
new
glycopeptid
signific
gramposit
activ
inhibit
mgl
superior
avail
agent
class
potenc
similar
european
isol
compar
prior
experi
geograph
area
background
tigecyclin
tig
novel
glycylcyclin
broad
spectrum
activ
increas
report
resist
r
among
commonli
occur
gramposit
cocci
gpc
produc
respiratori
tract
skin
soft
tissu
infect
creat
need
develop
new
antimicrobi
agent
studi
activ
potenc
tig
tetracyclin
tc
compar
agent
evalu
use
contemporari
isol
commonli
occur
speci
gpc
includ
presenc
r
organ
subset
tabl
organ
method
activ
tig
nine
compar
challeng
collect
gpc
includ
oxacillin
oxa
suscept
strain
r
strain
aureu
sa
oxa
strain
r
strain
coagulaseneg
staphylococci
con
penicillin
pen
strain
nonsuscept
ns
strain
pneumonia
spn
penicillin
strain
ns
strain
viridansgroup
streptococci
vg
betahaemolyt
streptococci
bh
strain
vancomycin
strain
r
strain
enterococci
ent
broth
microdilut
suscept
test
perform
analys
use
nccl
refer
method
interpret
criteria
result
wherea
oxar
subset
sa
con
display
crossresist
tc
macrolid
clindamycin
quinolon
differ
seen
tig
mgl
respect
among
streptococci
spn
vg
regardless
pen
bh
demonstr
tig
mgl
one
except
penintermedi
vg
mgl
tig
also
uniformli
activ
enterococc
isol
vancomycin
r
subset
mgl
mgl
respect
use
nccl
tc
breakpoint
mgl
staphylococci
streptococci
enterococci
test
would
classifi
tig
conclus
tig
display
remark
spectrum
activ
potenc
r
subset
gpc
highest
mgl
addit
use
treat
communityacquir
respiratori
tract
infect
tig
may
also
candid
treatment
complic
skin
soft
tissu
infect
possibl
urinari
tract
infect
caus
gpc
endem
highli
resist
acinetobact
intens
care
unit
tigecyclin
answer
object
find
satisfactori
antibiot
treatment
organ
acinetobact
baumanii
becam
endem
intens
care
unit
busi
district
gener
hospit
organ
resist
mani
antibiot
one
case
ultim
resist
current
market
antibiot
method
surveil
patient
intens
care
unit
presenc
acinetobact
baumanii
clinic
assess
patient
organ
establish
need
antibiot
therapi
patient
requir
treatment
given
antibiot
combin
use
colistin
usual
combin
oral
minocyclin
tigecyclin
monotherapi
firstinclass
glycylcyclin
agent
treatment
outcom
monitor
studi
observ
alloc
treatment
categori
randomis
blind
tigecyclin
use
compassion
basi
result
intens
care
unit
free
acinetobact
begin
end
new
isol
acinetobact
baumanii
isol
per
quarter
initi
pathogen
sensit
imipenem
meropenem
tobramycin
amikacin
colistin
minocyclin
sensit
began
wane
end
one
patient
die
acinetobact
baumanii
bloodstream
resist
everyth
avail
death
test
isol
acinetobact
tigecyclin
new
broad
spectrum
agent
current
phase
develop
found
activ
endem
strain
two
patient
ventilatorassoci
pneumonia
caus
organ
treat
tigecyclin
made
full
recoveri
advers
effect
relat
tigecyclin
treatment
convers
five
patient
ventilatorassoci
pneumonia
caus
organ
treat
colistin
fail
respond
acinetobact
find
respiratori
system
favour
environ
combin
fact
vast
major
patient
ventil
result
ventilatorassoci
pneumonia
commonest
infect
conclus
tigecyclin
like
use
agent
clinic
practic
intens
care
unit
deal
difficult
organ
evalu
warrant
may
well
antibiot
choic
antimicrobi
activ
tigecyclin
test
enterobacteriacea
select
nonfer
gramneg
bacilli
worldwid
sampl
r
jone
fritsch
h
sader
beach
north
liberti
usa
background
resist
r
among
gramneg
bacilli
gnb
expand
antimicrobi
agent
develop
address
clinic
problem
tigecyclin
tig
novel
glycylcyclin
expand
spectrum
activ
potenc
tigecyclin
cover
mani
routin
gramneg
resist
strain
addit
possess
activ
versu
uncommonli
isol
nonfer
gnb
studi
compar
tig
contemporari
broadspectrum
agent
use
recent
clinic
isol
europ
contin
method
strain
central
process
refer
broth
microdilut
method
antimicrobi
concurr
qc
result
within
nccl
publish
rang
identif
perform
tradit
method
andor
vitek
system
isol
test
enterobacteriacea
ent
nonfer
gnb
categori
suscept
tig
defin
mgl
breakpoint
use
tetracyclin
nccl
result
ent
divid
three
group
analysi
esblproduc
isol
strain
protea
group
strain
includ
p
mirabili
indoleposit
speci
enter
bacilli
tig
activ
esblproduc
isol
mgl
highest
among
tcr
subset
ent
mgl
protea
mgl
one
tigr
intermedi
strain
mic
mgl
morganii
p
mirabili
p
aeruginosa
margin
inhibit
tig
mgl
contrast
acinetobact
spp
mgl
maltophilia
mgl
readili
inhibit
tig
among
ent
studi
tcr
one
strain
p
mirabili
tigr
mic
mgl
conclus
remark
potenc
breadth
spectrum
observ
tig
ent
mgl
vs
tc
maltophilia
acinetobact
spp
limit
activ
note
versu
p
aeruginosa
mgl
protea
mgl
tig
valu
treatment
infect
caus
sever
commonli
r
gnb
group
background
tigecyclin
tig
formerli
novel
glycylcyclin
current
phase
clinic
trial
vitro
activ
tig
evalu
comparison
tetracyclin
tet
antimicrobi
agent
recent
clinic
isol
collect
worldwid
patient
respiratori
infect
mening
method
total
isol
test
tig
compar
agent
broth
microdilut
accord
nccl
refer
method
interpret
criteria
collect
includ
h
influenza
hi
strain
betalactamaseproduc
catarrhali
mcat
strain
betalactamaseproduc
n
meningitidi
nm
strain
result
tig
demonstr
excel
activ
organ
isol
inhibit
mgl
tet
suscept
breakpoint
tig
highli
activ
hi
mgl
mcat
mgl
potenc
pathogen
affect
betalactamas
product
tig
fourfold
potent
tet
hi
tetresist
isol
show
low
mgl
tig
mic
nm
isol
highli
suscept
tig
mgl
vast
major
antimicrobi
agent
evalu
conclus
result
indic
tigecyclin
potent
vitro
activ
clinic
import
gramneg
bacteria
caus
communityacquir
respiratori
infect
mening
includ
tetr
isol
evalu
tig
activ
well
clinic
studi
necessari
assess
role
compound
treatment
communityand
hospitalacquir
infect
background
object
betalactamas
product
major
mechan
bacteri
resist
betalactam
antibiot
gramneg
pathogen
surveil
betalactamas
determin
import
issu
microbi
drug
resist
given
great
divers
betalactamas
overlap
substrat
specif
molecular
analysi
necessari
identifi
natur
betalactamas
gene
clinic
isol
work
investig
potenti
dna
microarray
technolog
rapid
comprehens
detect
betalactamas
gene
drugresist
bacteria
method
total
oligonucleotid
probe
design
specif
recognit
betalactamas
gene
differ
lineag
molecular
class
class
b
class
c
class
dna
chip
design
includ
triplic
set
probe
well
posit
hybridis
control
microarray
print
epoxymodifi
glass
slide
use
affymetrix
gm
robot
spotter
genom
dna
label
random
prime
hybridis
signal
detect
use
affymetrix
laser
scanner
imag
analys
genepix
pro
version
softwar
result
dna
chip
test
gramneg
strain
includ
refer
strain
clinic
isol
repertoir
betalactamas
gene
partial
known
unknown
predict
betalactamas
gene
among
member
blatem
blashv
blactxm
blaper
blavim
blaimp
blacmylat
group
acquir
gene
correctli
detect
microarray
hybridis
clinic
isol
unknown
betalactamas
content
microarray
detect
gene
whose
presenc
subsequ
confirm
convent
pcr
assay
falseposit
observ
subset
probe
redesign
overcom
problem
conclus
success
detect
sever
differ
betalactamas
gene
clinic
import
achiev
use
dna
microchip
dna
microarray
technolog
appear
sensit
specif
tool
rapid
detect
characteris
betalactamas
gene
clinic
isol
object
member
genu
citrobact
potenti
pathogen
debilit
hospit
patient
becom
resist
betalactamas
includ
third
gener
cephalosporin
due
overexpress
chromosom
betalactamas
eleven
speci
current
known
speciat
often
difficult
use
biochem
test
isol
previous
type
citrobact
diversu
known
citrobact
koseri
measur
sequenc
variat
betalactamas
structur
gene
amongst
group
clinic
isol
origin
identifi
c
diversu
api
profil
method
nine
c
diversu
isol
collect
faecal
sampl
children
treat
oncolog
depart
bristol
children
hospit
earli
betalactamas
rrna
gene
amplifi
pcr
sequenc
standard
method
betalactamas
induct
attempt
liquidgrown
cultur
use
cefoxitin
mgl
h
nitrocefin
hydrolysi
assay
perform
use
spectrophotomet
result
analysi
rrna
gene
sequenc
confirm
nine
clinic
isol
five
induc
betalactamas
gene
whose
sequenc
close
relat
c
diversu
actual
citrobact
amalonaticu
given
c
diversu
isol
renam
c
koseri
error
nomenclatur
must
address
reason
error
c
diversu
known
variabl
abil
utilis
malon
differenti
c
koseri
c
diversu
four
test
isol
type
c
koseri
use
rrna
sequenc
true
c
koseri
isol
produc
novel
acid
class
betalactamas
name
ckoa
constitut
sequenc
beta
lactamas
gene
determin
ident
c
diversu
c
amalonaticu
cdia
conclus
present
new
betalactamas
sequenc
c
koseri
show
c
koseri
retyp
c
amalonaticu
betalactamasespecif
pcr
may
provid
valuabl
tool
type
citrobact
spp
isol
suitabl
separ
c
amalonaticu
c
koseri
close
relat
biochem
knowledg
clinic
c
koseri
isol
produc
betalactamas
constitut
low
level
may
use
clinic
singletub
pcr
mgb
eclips
probe
detect
shvtype
extendedspectrum
betalactamas
esbl
ekimov
edelstein
e
belousov
smolensk
ru
bothel
usa
object
esbl
shvtype
one
common
clinic
signific
betalactamas
number
shv
variant
continu
grow
howev
esbl
activ
shv
enzym
associ
mutat
rel
amino
acid
posit
aa
compar
tem
enzym
propos
simpl
rapid
method
allow
detect
known
shv
esbl
singl
realtim
pcr
reaction
method
propos
method
base
amplif
blashv
gene
presenc
short
nt
fluorogen
probe
capabl
hybridisationtrigg
fluoresc
probe
commerci
known
mgb
eclips
probe
contain
dark
quencher
conjug
minor
groov
binder
fluoresc
dye
structur
allow
detect
differenti
nucleotid
polymorph
target
site
postpcr
melt
curv
analysi
four
probe
design
perfectli
match
wildtyp
wt
sequenc
mutat
site
correspond
aa
thu
mutat
confer
esbl
activ
expect
specif
lower
melt
temperatur
tm
probetempl
duplex
probe
label
uniqu
dye
permit
analysi
mutat
multipl
site
singl
reaction
result
method
valid
use
laboratori
strain
produc
wt
nonesbl
control
strain
carri
clone
blashv
fragment
natur
occur
mutat
introduc
sitedirect
mutagenesi
follow
care
design
probe
optimis
pcr
condit
mutat
success
detect
discrimin
wt
sequenc
accord
specif
tm
detect
precis
highli
reproduc
repeat
experi
furthermor
appli
analysi
clinic
isol
klebsiella
pneumonia
express
esbl
phenotyp
method
abl
detect
multipl
shv
allel
wt
isol
observ
particularli
import
consid
high
frequenc
coproduct
esbl
klebsiella
conclus
pcr
mgb
eclips
probe
great
potenti
studi
epidemiolog
shv
esbl
possibl
analysi
antimicrobi
resist
mechan
associ
mutat
defin
loci
method
total
nonrepeat
enterococc
blood
isol
e
faecali
e
faecium
collect
hospit
locat
south
east
sweden
bacteri
isol
identifi
standard
microbiolog
method
suscept
test
perform
gentamicin
disk
pdmagar
ab
biodisk
detect
hlgr
isol
isol
test
presenc
aac
ieaph
ia
gene
use
polymeras
chain
reaction
pcr
techniqu
result
complet
correl
gentamicin
disk
diffus
test
pcr
result
hlgr
isol
defin
disk
diffus
posit
control
e
faecali
atcc
carri
aac
ieaph
ia
gene
judg
pcr
result
resist
gene
found
neg
control
atcc
nonhlgr
enterococci
conclus
studi
show
set
sensit
specif
disk
diffus
method
detect
hlgr
enterococci
high
total
agreement
result
obtain
use
pcr
techniqu
detect
aac
ieaph
ia
aminoglycosid
modifi
gene
object
main
object
develop
pyrosequenc
method
identif
enterococcu
spp
speci
pyrosequenc
method
also
develop
antibiot
resist
special
refer
macrolid
resist
studi
suscept
test
sampl
isol
serial
subject
expos
clindamycin
method
biochem
identif
enterococc
strain
faecal
sampl
done
growth
c
catalas
hydrolys
pyr
speci
identif
done
pyrosequenc
method
psq
pyrosequenc
techniqu
enabl
identif
differ
enterococcu
speci
base
rrna
signaturesequ
antibiot
suscept
test
done
agar
dilut
method
llerhinton
ii
medium
accord
nccl
mic
valu
test
erythromycin
clindamycin
ciprofloxacin
ampicillin
gentamicin
vancomycin
tetracyclin
macrolid
resist
gene
erm
b
erm
tr
mef
studi
multiplexpcr
result
pyrosequenc
method
identifi
enterococcu
faecium
e
faecali
e
avium
e
casseliflavu
speci
nonenterococci
speci
antibiot
suscept
test
show
enterococcu
strain
resist
erythromycin
ciprofloxacin
tetracyclin
enterococca
erm
b
gene
conclus
pyrosequenc
rapid
easi
method
identif
bacteri
strain
even
speci
level
antibiot
resist
vari
lot
differ
bacteri
strain
e
faecium
e
casseliflavu
speci
resist
one
pyrosequenc
result
correl
well
speci
phenotyp
antibiot
resist
object
determin
speci
distribut
vancomycin
resist
enterococci
vre
isol
hospitalis
patient
detect
gene
encod
resist
vancomycin
teicoplanin
sandwich
hybridis
method
cpha
gene
pcr
actual
enzym
product
may
attribut
socal
silent
gene
suscept
strain
known
abl
convert
highlevel
betalactamcarbapenem
resist
increas
express
nearli
silent
metallobetalactamas
gene
metallobetalactamas
found
carri
small
plasmid
kb
appear
selftransmiss
pose
potenti
threat
rapid
spread
resist
therefor
earli
recognit
metallobetalactamas
produc
strain
imper
describ
distribut
speci
nocardia
isol
evalu
use
easi
rapid
method
base
short
batteri
suscept
test
identifi
clinic
nocardia
isol
compar
pcr
restrict
analysi
routin
use
laboratori
method
nocardia
sp
isol
select
studi
molecular
identif
perform
pcrrflp
identif
suscept
test
disk
diffus
gentamicin
cn
tobramycin
tob
amikacin
ak
erythromycin
e
broth
microdilut
etest
ampicillin
amp
ciprofloxacin
c
cefotaxim
ctx
amoxicillinclavulan
aug
result
isol
nocardia
sp
studi
distribut
speci
accord
result
pcrrflp
n
asteroid
n
asteroid
vi
n
farcinica
n
nova
n
otitidiscaviarum
n
asteroid
isol
two
differ
suscept
pattern
two
isol
cn
tob
ak
er
two
cnr
tob
ak
er
n
asteroid
isol
amp
lgml
c
lgml
ctx
lgml
eightyseven
per
cent
n
asteroid
vi
cn
tob
ak
er
amp
lgml
ctx
lgml
wherea
c
variabl
hundr
per
cent
isol
n
farcinica
cnr
tobr
ak
er
amp
lgml
c
lgml
ctx
lgml
n
nova
isol
cn
tob
ak
es
amp
lgml
ctx
lgml
c
lgml
n
otitidiscaviarum
isol
cn
tob
ak
er
amp
lgml
ctx
lgml
c
lgml
medium
time
obtain
result
method
h
conclus
isol
belong
former
n
asteroid
complex
n
farcinica
n
nova
easili
distinguish
nocardia
speci
suscept
pattern
main
group
n
asteroid
vi
difficult
distinguish
n
asteroid
n
otitidiscaviarum
short
batteri
suscept
test
permit
rapid
differenti
frequent
nocardia
isol
although
genotyp
test
discriminatori
ixod
ricinu
tick
common
ectoparasit
anim
human
main
vector
lyme
diseas
czech
republ
detect
borrelia
microscop
isol
bskh
medium
pcr
identif
aim
work
method
tick
crush
drop
steril
phosphat
buffer
salin
admir
microscop
darkfield
sampl
spirochet
detect
incub
liquid
bskh
medium
sigma
c
admir
weekli
week
strai
passag
twice
frozen
aliquot
c
direct
fluoresc
assay
dfa
fluorescein
label
polyclon
antibodi
borrelia
burgdorferi
use
screen
deoxyribonucl
acid
borreli
strain
isol
invisorb
genom
dna
kit
iii
invitec
three
set
primer
b
burgdorferi
sensu
lato
b
garinii
b
afzelii
deriv
gene
rosa
schwan
use
elementari
identif
strain
detail
analysi
strain
made
light
cycler
realtim
pcr
rtpcr
primer
probe
deriv
reca
gene
use
method
result
collect
tick
urban
suburban
local
czech
republ
year
incid
spirochet
tick
popul
differ
differ
local
spirochet
cultur
least
one
six
tick
test
posit
darkfield
microscopi
strain
react
posit
dfa
gave
posit
respons
primer
specif
b
burgdorferi
sensu
lato
complex
nineteen
strain
belong
b
garinii
four
b
afzelii
two
b
burgdorferi
sensu
stricto
genospeci
one
strain
react
primer
b
garinii
melt
temperatur
reca
gene
product
ident
b
garinii
type
strain
identifi
genotyp
two
strain
determin
b
burgdorferi
sensu
lato
neither
pcr
rtpcr
uor
blood
tissu
subject
sequenc
dideoxi
chain
termin
techniqu
use
ceq
sequenc
cultiv
immunocytochemistri
western
blot
use
confirm
result
cultur
four
blood
six
skin
six
csf
isol
numer
tick
two
anim
isol
realtim
pcr
target
reca
ospa
gene
show
involv
nervou
system
joint
skin
czech
patient
predominantli
caus
b
garinii
serotyp
b
burgdorferi
ss
b
afzelii
remain
compris
coinfect
anaplasma
phagocytophila
mix
borreli
infect
similar
result
found
anim
among
game
anim
test
posit
b
garinii
b
burgdorferi
wild
boar
murid
host
borrelia
sp
preval
b
afzelii
signific
differ
notic
infect
adult
nymphal
tick
reach
june
septemb
respect
difer
also
region
east
bohemia
b
garinii
prevail
moravia
preval
b
afzelii
human
case
erythema
migran
acrodermat
atrophican
infect
preval
data
patient
agreement
data
tick
anim
object
aim
studi
identifi
strain
borrelia
isol
tick
lyme
diseas
patient
russian
far
east
analys
taxonom
posit
base
ospa
gene
phylogeni
method
analys
strain
borrelia
burgdorferi
sensu
lato
isol
ixod
persulcatu
tick
skin
biopsi
erythema
migran
lyme
diseas
patient
isol
standard
method
last
year
russian
far
east
amplif
newli
design
primer
obtain
fulllength
ospa
gene
sequenc
strain
result
identifi
four
strain
b
afzelii
complet
ident
strain
isol
japan
isol
tick
strain
found
genet
variabl
closest
homolog
found
b
garinii
phylogenet
analysi
ospa
gene
found
strain
form
three
distinct
welldefin
clade
phylogenet
tree
genogroup
repres
speci
isol
far
easter
region
russian
feder
japan
wherea
genogroup
repres
mostli
european
isol
includ
seroand
genogroup
defin
work
b
wilssk
et
al
g
et
al
four
isol
russian
far
east
european
serogroup
form
clade
localis
genogroup
human
strain
found
within
genogroup
conclus
b
garinii
found
domin
among
b
burgdorferi
sensu
lato
strain
isol
tick
lyme
diseas
patient
form
russian
far
east
phylogenet
analysi
show
speci
identifi
b
garinii
signific
variabl
ospa
gene
form
three
major
group
two
group
consist
strain
isol
far
east
significantli
remot
b
burgdorferi
sensu
lato
speci
bootstrap
valu
distanc
among
group
suggest
solid
especi
genogroup
probabl
indic
distinct
origin
defin
genogroup
b
garinii
may
suggest
anoth
taxonom
statu
object
diagnosi
lyme
borreliosi
lb
twostep
approach
recommend
cdc
dghm
screen
elisa
follow
immunoblot
ib
case
reactiv
elisa
though
borrelia
ib
wide
use
still
poorli
defin
regard
sensit
specif
standardis
recent
describ
recombin
western
immunoblot
wib
complement
borrelia
antigen
produc
vivo
cultur
ie
vlse
could
improv
previou
test
recombin
borrelia
line
ib
lib
develop
recombin
antigen
separ
detect
even
antigen
ident
molecular
weight
method
follow
recombin
igg
igm
ib
compar
wib
describ
strain
pko
b
afzelii
strain
pbi
b
garinii
ospatyp
bmpa
strain
b
burgdorferi
sensu
stricto
pko
pbi
vlse
strain
ospc
strain
pko
pbi
b
garinii
strain
dbpa
strain
pko
pbr
b
garinii
ospatyp
b
lib
antigen
wib
addit
vlse
strain
pko
pbi
ospc
strain
ple
b
afzelii
dbpa
strain
pbi
verifi
sensit
specif
sera
patient
earli
lb
earli
neuroborreliosi
erythema
migran
control
sera
blood
donor
rheumatoid
factor
posit
syphili
patient
patient
fever
unknown
origin
studi
result
ib
interpret
criteria
defin
serum
posit
least
two
reactiv
band
case
igm
least
one
strong
ospc
band
use
sensit
significantli
increas
wib
lib
igg
wib
lib
igm
specif
remain
unchang
igg
test
igm
test
increas
sensit
mainli
due
line
blot
techniqu
allow
detect
identif
antibodi
differ
reactiv
homologu
protein
conclus
lib
sensit
wib
igg
igm
antibodi
detect
acut
lb
specif
remain
unchang
lib
better
standardis
result
easier
interpret
background
tick
ixod
ricinu
group
well
known
major
vector
caus
agent
lyme
borreliosi
granulocyt
anaplasmosi
ehrlichiosi
babesiosi
european
countri
human
infect
agent
experi
wide
rang
clinic
manifest
ricinu
wide
distribut
tick
lithuania
may
transmit
pathogen
mammalian
host
includ
human
be
singl
tick
may
contain
sever
differ
pathogen
doubleinfect
borreliosi
ehrlichiosi
may
seen
object
aim
studi
determin
whether
ricinu
tick
collect
differ
region
lithuania
infect
caus
agent
lyme
borreliosi
anaplasmosi
ehrlichiosi
babesiosi
agent
estim
preval
mix
infect
pcr
investig
carri
assess
preval
borrelia
anaplasma
ehrlichia
babesia
infect
ricinu
lithuania
use
pcr
method
method
altogeth
ricinu
tick
collect
differ
region
lithuania
includ
studi
tick
analys
individu
presenc
ehrlichiaanaplasma
group
pathogen
determin
use
pcr
ehrlichiaanaplasmaspecif
primer
multiplex
pcr
use
speciesspecif
borrelia
primer
girgil
borrelia
burgdorferi
ss
giirgiil
b
garinii
giiirgiiil
b
afzelii
realtim
pcr
method
abi
prism
system
use
detect
babesia
divergen
ehrlichiaanaplasma
speci
determin
use
revers
line
blot
hybridis
result
individu
process
tick
posit
ehrlichiaanaplasma
hge
hge
variant
e
schotii
identifi
borrelia
b
burgdorferi
ss
one
b
garinii
b
afzelii
posit
babesia
divergen
one
tick
contain
ehrlichiaanaplasma
babesia
two
contain
babesia
b
afzelii
one
ehrlichiaanaplasma
b
garinii
conclus
result
repres
first
studi
lithuania
borrelia
ehrlichia
anaplasma
babesia
parasit
directli
identifi
ricinu
tick
pcr
multiplex
pcr
revers
line
blot
hybridis
realtim
pcr
detect
b
afzelii
domin
genospeci
lithuanian
tick
ehrlichiaanaplasma
babesia
found
tick
might
caus
human
diseas
molecular
bacteriolog
characteris
agent
improv
autom
ribotyp
use
hindiii
discrimin
previous
uniform
listeria
monocytogen
serotyp
strain
heller
k
grif
dierich
r
rzner
innsbruck
object
develop
improv
autom
subtyp
approach
listeria
monocytogen
characteris
discriminatori
power
differ
restrict
enzym
ribotyp
pvuii
hindiii
evalu
abil
differenti
among
isol
repres
one
two
major
serotyp
epidem
clone
ribotyp
refer
pattern
differ
clone
ecori
pattern
utmost
import
presenc
two
major
pattern
within
serotyp
allow
suffici
epidemiolog
listeria
infect
method
result
eight
select
l
monocytogen
isol
serotyp
ribotyp
refer
pattern
respons
human
listeriosi
outbreak
franc
canada
switzerland
turkey
sporad
foodborn
case
austria
england
usa
ribotyp
perform
use
riboprint
microbi
characteris
system
accord
manufactur
instruct
use
ecori
pvuii
hindiii
restrict
enzym
found
eight
isol
belong
ie
indistinguish
ecori
also
indistinguish
pvuii
yield
two
clearli
differ
pattern
use
hindiii
conclus
conclud
autom
ribotyp
use
hindiii
allow
discrimin
previous
uniform
l
monocytogen
isol
discrimin
may
facilit
trace
outbreak
may
also
improv
epidemiolog
survey
detect
bft
isoform
enterotoxin
gene
cfia
gene
bacteroid
fragili
isol
differ
origin
g
terh
j
soki
k
ago
e
urban
e
nagi
szege
hun
object
bacteroid
fragili
oblig
anaerob
gramneg
rod
constitut
normal
intestin
flora
human
gramneg
anaerob
rod
frequent
isol
human
clinic
sampl
b
fragili
isol
produc
zincdepend
metalloproteas
enterotoxin
code
bft
gene
protein
enterotox
activ
caus
fluid
accumul
lamb
ligat
ileal
loop
model
date
three
differ
isoform
design
identifi
literatur
regard
enterotoxinproduc
properti
b
fragili
virul
factor
sinc
strain
isol
often
sever
infect
sepsi
abdomin
deep
softtissu
abscess
also
thought
involv
diarrhoea
children
aim
method
aim
present
studi
examin
preval
enterotoxin
product
among
b
fragili
strain
isol
specimen
origin
clinic
ward
univers
hospit
cytotox
test
pcr
detect
bft
gene
result
obtain
two
method
compar
frequenc
three
allel
bft
gene
enterotoxigen
strain
differ
sourc
determin
use
pcrrestrict
fragment
length
polymorph
analysi
b
fragili
strain
divid
two
major
group
molecular
type
method
importantli
accord
carriag
cfia
gene
therefor
also
examin
occurr
cfia
gene
pcr
coincid
bft
cfia
among
collect
strain
result
averag
occurr
toxigen
b
fragili
strain
differ
group
clinic
sampl
deeptissu
infect
pcr
method
cytotox
assay
bft
gene
found
cfianeg
group
preval
cfia
gene
correspond
earlier
find
data
literatur
observ
coincid
bft
cfia
gene
studi
introduct
addit
two
larg
clostridi
cytotoxin
lct
toxin
b
strain
clostridium
difficil
also
produc
actinspecif
adpribosyltransferas
binari
toxin
cdt
cdt
may
serv
addit
virul
factor
method
use
pcr
southern
blot
method
detect
gene
encod
enzymat
cdta
bind
cdtb
compon
binari
toxin
strain
isol
patient
suspect
c
difficileassoci
diarrhoea
coliti
binari
toxin
product
assess
western
blot
use
antisera
iota
toxin
c
perfringen
antiia
ib
toxin
activ
detect
adpribosyltransferas
assay
pcr
amplif
perform
detect
gene
encod
toxin
b
binari
posit
strain
subject
toxinotyp
characteris
phenotyp
serogroup
genotyp
marker
pcrribotyp
arbitrarili
prime
pcr
appcr
pulsedfield
gel
electrophoresi
pfge
result
twentytwo
strain
preval
harbour
gene
cdta
cdtb
strain
react
antisera
iota
toxin
c
perfringen
binari
toxin
activ
posit
strain
strain
also
produc
toxin
b
howev
signific
chang
tcda
tcdb
gene
belong
variant
toxinotyp
iii
iv
v
vii
ix
xiii
type
method
use
could
differenti
profil
indic
binari
toxin
posit
strain
unrel
conclus
binari
toxinproduc
isol
c
difficil
widespread
preval
vari
one
countri
anoth
studi
need
defin
role
binari
toxin
pathogenesi
clostridium
difficil
singapor
wy
leong
r
da
ramada
th
koh
kp
song
singapor
sgp
object
occurr
nosocomi
clostridium
difficileassoci
diarrhoea
pseudomembran
coliti
relat
product
toxin
b
encod
tcda
tcdb
respect
pathogen
tcda
tcdb
togeth
accessori
gene
tcdce
arrang
within
welldefin
chromosom
region
term
pathogen
locu
paloc
anoth
virul
factor
adpribosyltransferas
binari
toxin
encod
cdt
gene
report
found
approxim
pathogen
strain
c
difficil
despit
avail
number
detect
method
identif
method
commonli
use
design
detect
virul
factor
known
present
altern
characteris
toxigen
relat
gene
c
difficil
base
genotyp
correl
paloc
cdt
gene
also
examin
method
clinic
isol
singapor
gener
hospit
sgh
screen
pcr
multiplex
pcr
presenc
tcdae
cdtab
paloc
region
cdt
operon
respect
product
activ
toxin
b
analys
commerci
kit
cytotox
test
result
isol
could
classifi
group
base
genotyp
analysi
paloc
cdt
gene
approxim
share
common
profil
refer
strain
vpi
complet
devoid
gene
test
variat
demonstr
tcdce
complic
specif
profil
could
attribut
particular
genotyp
atyp
toxigen
variant
discov
contain
tcdb
contrast
data
report
elsewher
none
pathogen
strain
found
contain
complet
cdt
gene
test
tcda
tcdb
product
six
strain
identifi
toxin
aneg
bposit
conclus
great
genet
polymorph
display
c
difficil
isol
confirm
strain
highli
heterogen
could
origin
endogen
sourc
signific
correl
presenc
structur
gene
tcdab
accessori
gene
tcdce
cdt
gene
pathogen
strain
necessarili
contain
gene
paloc
conclus
result
use
toxinogenotyp
method
studi
genet
distribut
toxinogen
gene
correl
well
phenotyp
bacteria
ie
toxin
express
characteris
clostridium
difficil
strain
isol
differ
time
period
belong
differ
ribotyp
p
spigaglia
v
carucci
p
mastrantonio
rome
object
seventyfour
clostridium
difficil
clinic
isol
collect
differ
time
period
type
pcrribotyp
strain
belong
two
main
pcrribotyp
characteris
virul
determin
antibiot
resist
method
paloc
gene
analysi
detect
binari
toxin
gene
antibiot
resist
determin
ermb
tetm
catd
perform
pcr
assay
erm
b
sequenc
type
identifi
rflppcr
mic
erythromycin
clindamycin
tetracyclin
chloramphenicol
determin
etest
result
two
main
pcrribotyp
name
r
respect
identifi
pcrribotyp
collect
strain
wherea
strain
belong
pcrribotyp
r
old
strain
belong
pcrribotyp
wherea
recent
strain
belong
pcrribotyp
r
strain
pcrribotyp
classic
paloc
gene
binari
toxin
gene
nineti
percent
strain
multiresist
sequenc
type
ermb
gene
similar
c
difficil
strain
belong
pcrribotyp
r
binari
toxin
gene
four
show
major
variat
toxin
gene
mutat
toxin
neg
regul
none
strain
multiresist
although
one
show
three
antibiot
resist
determin
fifti
three
percent
tetm
gene
tetm
ermb
gene
ermb
gene
sequenc
similar
c
perfringen
interestingli
far
resist
concern
correspond
phenotyp
genotyp
strain
particular
strain
tetm
catd
gene
suscept
tetracyclin
chloramphenicol
vitro
wherea
five
strain
resist
erythromycin
clindamycin
ermb
gene
strain
show
induct
erythromycin
clindamycin
resist
coloni
conclus
result
seem
indic
recent
spread
c
difficil
clone
add
togeth
potenti
increas
virul
acquisit
binari
toxin
variat
gene
belong
paloc
acquisit
differ
mechan
antibiot
resist
enterococci
natur
inhabit
gastrointestin
flora
human
anim
wide
distribut
environ
member
genu
recognis
import
opportunist
pathogen
respons
seriou
infect
molecular
mechan
enterococc
virul
yet
complet
understood
studi
enterococci
differ
sourc
includ
clinic
isol
human
veterinarian
origin
nonclin
isol
refer
strain
enterococc
speci
typifi
virul
potenti
characteris
relationship
among
enterococci
first
analys
use
smai
pulsedfield
gel
electrophoresi
pcrfingerprint
order
evalu
genom
heterogen
isol
enterococci
also
screen
sever
virul
trait
cytolysin
cyl
gene
adhesin
agg
esp
efaaf
efaafm
gene
gelatinas
gele
reveal
distinct
virul
potenti
enterococcu
faecali
recent
describ
virul
determin
cluster
larg
pathogen
island
pheromonerespons
plasmid
dotblot
dnadna
hybridis
use
locat
virul
determin
bacteri
genom
enterococci
studi
conclus
result
obtain
esp
gele
wherea
efaaf
efaafm
found
chromosom
expect
although
cyl
gene
agg
plasmid
isol
detect
chromosom
five
strain
suggest
enterococci
may
harbour
pathogen
island
beyond
widespread
natur
virul
trait
chromosom
integr
virul
gene
seem
occur
differ
enterococc
speci
isol
nonclin
sourc
identif
salmonella
serotyp
sheep
pcr
zahraeisalehi
tehran
ir
introduct
salmonella
abortusovi
dublin
montevideo
typhimurium
common
serotyp
sheep
one
way
transfer
contamin
viscer
organ
special
gallbladd
intestin
liver
transfer
meat
human
research
essenti
consid
object
isol
salmonella
serotyp
viscer
organ
sheep
goat
detect
inva
gene
isol
serotyp
pcr
materi
method
goal
sampl
liver
gallbladd
mesenter
lymph
node
faec
total
sampl
taken
cultur
enrich
select
media
doubt
coloni
select
transfer
tsi
agar
urea
agar
sim
mrvp
broth
nitrat
broth
pcr
reaction
carri
master
cycl
eppendorf
dna
extract
isol
salmonella
serotyp
cultur
lb
broth
h
c
lb
broth
boil
min
centrifug
min
total
supernat
use
amplif
pcr
salmonellaspecif
primer
result
three
salmonella
serotyp
isol
mesenter
lymph
node
two
case
gallbladd
one
case
serotyp
test
show
two
belong
group
b
one
group
salmonella
subject
salmonellaspecif
primer
inva
isol
includ
posit
control
gener
singl
amplifi
dna
fragment
agaros
gel
conclus
salmonellaspecif
pcr
primer
set
inva
rapid
sensit
reliabl
detect
salmonella
mani
clinic
sampl
present
research
support
abil
specif
primer
set
confirm
isol
salmonella
isol
includ
posit
control
typhimurium
dublin
screen
pcr
result
amplifi
product
amplifi
product
obtain
neg
control
water
escherichia
coli
serotyp
object
variabl
salmonella
typhimurium
strain
studi
pcrbase
method
method
strain
typhimurium
isol
food
anim
sourc
cours
surveil
programm
strain
phagotyp
antibiot
resist
determin
disk
diffus
method
fluoresc
aflp
done
use
ecori
msei
enzym
aflp
product
separ
capillari
electrophoresi
result
presenc
integron
analys
strain
typhimurium
three
differ
integron
profil
ip
detect
amplif
variabl
region
integron
profil
characteris
two
pcr
product
kb
present
six
strain
strain
multiresist
resist
acssut
acssutna
profil
contain
singl
kb
pcr
product
present
six
strain
resist
asutmp
assutmp
gene
confirm
integr
part
integron
total
kb
pcr
product
amplifi
two
strain
sensit
antimicrobi
lysogen
bacteriopahg
could
frequent
transfer
dna
bacteri
cell
thu
chang
chromosom
composit
phagerel
sequenc
probe
typhimurium
strain
pcr
primer
complementari
four
gene
phage
eae
eac
three
differ
type
pcr
product
detect
multiplex
reaction
presenc
sequenc
simultan
occurr
eac
presenc
nine
strain
contain
test
phagerel
gene
related
strain
monitor
aflp
observ
high
straintostrain
similar
dice
coeffici
fell
rang
accord
presenc
sever
dna
fragment
strain
separ
eight
aflp
cluster
conclus
comparison
method
obtain
correspond
result
strain
cluster
method
use
subtyp
typhimurium
strain
produc
klebsiella
strain
isol
nosocomi
infect
k
matusiewicz
b
maczynska
olejniczak
przondomordarska
r
franiczek
wroclaw
pl
object
klebsiella
bacilli
present
mani
pathogen
properti
determin
abil
surviv
rapid
spread
hospit
environ
adhes
properti
klebsiella
bacilli
associ
presenc
fimbrial
nonfimbri
adhesin
play
import
role
pathogen
bacteria
rapid
spread
patogen
factor
often
connect
presenc
plasmidmedi
gene
aim
studi
detect
plasmid
chromosom
born
fimh
mrkd
gene
encod
main
adhesin
ms
mr
respect
method
total
klebsiella
clinic
isol
obtain
patient
hospitalis
differ
hospit
ward
studi
phenotyp
activ
fimbria
characteris
haemagglutin
method
genom
plasmid
dna
isol
use
manual
method
well
qiagen
dna
kit
presenc
gene
encod
main
adhesin
detect
use
pcrmethod
primer
detect
fimh
mrkd
gene
result
strain
display
phenotyp
activ
type
type
fimbria
show
activ
type
fimbria
type
fimbria
strain
show
lack
hemagglutin
activ
percentag
detect
gene
use
pcr
higher
show
result
phenotyp
activ
presenc
mrkd
gene
detect
investig
strain
chromosom
dna
show
mrkd
fimh
gene
total
strain
demonstr
fimh
gene
chromosom
dna
strain
show
gene
plasmid
dna
presenc
main
adhesin
gene
confirm
klebsiella
strain
mrkd
gene
strain
fimh
mrkd
fimh
strain
conclus
presenc
fimh
mrkd
gene
genom
plasmid
dna
alway
lead
phenotyp
express
fimbrial
adhesin
activ
type
fimbria
connect
chromosom
variant
mrkd
gene
case
fimh
gene
plasmid
variant
enough
haemagglutin
activ
type
fimbria
percentag
detect
fimh
mrkd
plasmid
gene
depend
hospit
unit
strain
isol
suggest
spread
plasmidencod
adhesin
among
klebsiella
strain
object
bacteria
genu
klebsiella
opportunist
pathogen
respons
increas
number
multiresist
infect
hospit
two
clinic
epidemiolog
import
speci
klebsiella
pneumonia
k
oxytoca
recent
shown
subdivid
three
two
respect
phylogenet
group
aim
studi
indepth
evalu
amplifi
fragment
length
polymorph
aflp
genet
characteris
method
method
first
investig
variabl
aflp
pattern
klebsiella
strain
within
differ
outbreak
second
use
care
characteris
phylogenet
repres
strain
examin
whether
differ
klebsiella
speci
phylogenet
group
discrimin
use
aflp
twentyfour
strain
origin
seven
presum
outbreak
nonassoci
strain
investig
result
aflp
fingerprint
epidemiolog
associ
strain
show
three
fewer
fragment
differ
wherea
unrel
strain
differ
least
four
fragment
cluster
analysi
aflp
data
reveal
high
concord
phylogenet
assign
strain
base
gyra
sequenc
ribotyp
data
speci
k
pneumonia
k
oxytoca
k
terrigena
possibl
synonym
pair
k
planticolak
ornithinolytica
form
separ
cluster
similarli
strain
phylogenet
group
k
pneumonia
k
oxytoca
fell
correspond
cluster
two
except
conclus
studi
provid
preliminari
cutoff
valu
distinguish
epidemiolog
nonrel
klebsiella
isol
base
aflp
data
confirm
sharp
delin
recent
identifi
phylogenet
group
demonstr
aflp
suitabl
identif
klebsiella
speci
phylogenet
group
object
kserotyp
ie
determin
capsular
antigen
prefer
type
method
klebsiella
isol
highli
discriminatori
known
ktype
known
differ
pathogen
potenti
unfortun
kserotyp
requir
larg
collect
sera
restrict
refer
centr
moreov
kserotyp
suffer
crossreact
applic
noncapsul
strain
object
work
develop
molecular
method
would
enabl
determin
kserotyp
without
use
antiserum
method
amplifi
pcr
capsular
antigen
gene
cluster
cp
pcr
product
kb
long
digest
hincii
follow
agaros
gel
electrophoresi
cp
pcrrflp
result
profil
call
cpattern
obtain
strain
repres
known
kserotyp
show
four
band
size
rang
kb
total
distinct
cpattern
obtain
follow
import
observ
made
cpattern
obtain
strain
kserotyp
distinct
cpattern
kserotyp
except
serotyp
known
crossreact
ii
ktype
cpattern
variat
found
among
strain
kserotyp
case
strain
variant
cpattern
belong
klebsiella
speci
refer
strain
thu
cp
pcrrflp
higher
discriminatori
power
classic
kserotyp
iii
within
k
pneumonia
observ
cpattern
ident
among
strain
given
ktype
exampl
collect
mani
year
apart
distinct
sourc
stabil
cpattern
indic
cp
pcrrflp
suitabl
longterm
epidemiolog
capsular
type
iv
compar
classic
kserotyp
strain
analys
cp
pcrrflp
nontyp
pcr
amplif
fail
v
valu
cp
pcrrflp
kserotyp
determin
test
recent
k
pneumonia
clinic
isol
kserotyp
could
deduc
comparison
cpattern
databas
vi
four
five
noncapsul
strain
analys
show
recognis
cpattern
conclus
cp
pcrrflp
allow
determin
kserotyp
easier
perform
discriminatori
classic
serotyp
allow
characteris
noncapsul
strain
composit
vagin
microbi
commun
eight
vagin
swab
three
grade
two
grade
ii
three
grade
iii
studi
cultur
clone
rrna
gene
obtain
direct
amplif
speciesspecif
pcr
atopobium
vagina
gardnerella
vaginali
carri
vagin
swab
sampl
fortysix
cultur
isol
identifi
tdnapcr
clone
rrna
gene
fragment
sequenc
yield
total
speci
result
clone
reveal
vagina
abund
four
five
nongrad
specimen
lactobacillu
iner
lactobacillu
speci
present
nongrad
specimen
absent
grade
sampl
respect
grade
grade
ii
grade
iii
vagin
swab
sampl
posit
vagina
g
vaginali
speciesspecif
pcr
p
chi
squar
discuss
cultur
independ
molecular
analysi
reveal
higher
microbi
divers
nongrad
specimen
cultur
togeth
cultur
rrna
gene
clone
speciesspecif
pcr
point
presenc
nine
presumpt
novel
bacteri
speci
strong
associ
vagina
g
vaginali
bacteri
vaginosi
ambigu
role
l
iner
appear
vagina
may
constitu
low
number
human
vagina
possibl
attain
replic
domin
associ
decreas
lactobacillari
grade
presenc
vagina
bacteri
vaginosi
like
microflora
may
shed
new
light
aetiolog
condit
use
multilocu
pcr
test
variou
primer
genom
strain
isol
territori
russia
turkmenistan
abl
detect
three
housekeep
gene
hapa
toxr
rtxa
nine
virul
gene
locat
prophag
pathogen
persist
island
ctxphi
ctxa
zot
ace
rstc
vpi
tcpa
alda
toxt
nanh
epi
mshq
besid
use
method
ribotyp
pcr
type
involv
random
primer
elucid
genet
relationship
strain
vari
epidem
signific
genom
clinic
isol
obtain
patient
sever
epidem
outbreak
shown
stabl
contain
gene
test
c
vibrio
isol
interepidem
period
natur
ecosystem
form
heterogen
popul
repres
singl
virul
clone
retain
complet
set
gene
studi
nontoxinogen
strain
lost
individu
gene
pathogen
block
gene
ie
either
ctxphi
ctxphi
vpi
carri
defici
prophag
ctxphi
zot
ace
vpi
alda
toxt
well
clone
contain
housekeep
chromosom
gene
sometim
gene
persist
island
soon
virul
clone
get
water
environ
lose
virul
block
follow
order
ctxphi
vpi
gene
last
one
lost
conform
result
three
genotyp
method
epidem
hazard
strain
repres
homogen
group
suggest
singl
clonal
origin
close
genet
relationship
strain
nontoxinogen
vibrio
partli
retain
virul
gene
also
establish
time
shown
ribotyp
pcr
type
studi
avirul
water
vibrio
form
independ
group
genotyp
manifest
quit
distinct
featur
contrast
first
two
vibrio
group
thu
observ
genotyp
heterogen
el
tor
cholera
vibrio
live
water
ecosystem
like
result
loss
dna
fragment
vari
length
function
genotyp
procedur
use
work
made
possibl
discov
evolut
relationship
among
bacteri
strain
studi
bacteroid
fragili
gramneg
anaerob
rod
strain
isol
poland
franc
intestin
extraintestin
sourc
compar
studi
identif
bacteri
strain
done
basi
gram
stain
growth
select
bbe
bacteroid
bile
esculin
medium
biochem
characterist
determin
api
test
franc
assess
presenc
enterotoxin
fragilysin
gene
analys
strain
pcr
method
use
dna
pcr
isol
use
genom
dna
prep
plu
biotechnolog
poland
amplif
perform
techn
thermocycl
primer
ccg
aag
acg
gtg
tat
gtg
att
tca
gcg
ccc
agt
ata
tga
cct
pcr
program
consist
follow
step
min
cycl
c
min
c
min
c
min
among
polish
strain
contain
fragilysin
gene
french
strain
contain
fragilysin
gene
strain
puls
field
gel
electrophoresi
pfge
perform
bacteria
suspend
se
buffer
mm
nacl
edta
ph
embed
agaros
plug
lyse
overnight
c
plug
wash
five
time
se
room
temperatur
afterward
dna
plug
digest
use
boehring
mannheim
germani
electrophoresi
perform
chef
mapper
biorad
venenda
netherland
voltag
vcm
h
linear
ramp
angl
conclus
strain
isol
franc
isol
poland
contain
fragilysin
gene
pfge
analysi
reveal
strain
isol
poland
franc
show
genet
differenti
strain
genet
homogen
object
differ
molecular
mechan
resist
azol
antifung
agent
exist
simultan
describ
candida
albican
strain
one
mechan
includ
alter
gene
encod
target
enzym
present
studi
use
pyrosequenc
method
conduct
epidemiolog
survey
ketoconazolesuscept
resist
strain
clinic
c
albican
strain
isol
region
determin
differ
gene
encod
lanosteroldemethylas
method
strain
c
albican
obtain
swab
oral
mucosa
subject
oropharyng
candidiasi
suscept
ketoconazol
test
use
broth
microdilut
method
recommend
nccl
document
concentr
ketoconazol
test
rang
mgml
mic
endpoint
defin
lowest
concentr
growth
inhibit
compar
drugfre
control
yeast
grown
sabouraud
agar
dna
extract
use
qiaamp
dna
mini
kit
quiagen
pcr
primer
match
gene
region
bp
one
primer
pcr
fragment
biotinyl
singl
strand
pcr
product
obtain
streptavidinco
bead
method
sampl
analys
use
psq
system
sqa
softwar
sqa
reagent
result
total
strain
exhibit
dd
resist
ketoconazol
mic
lgml
sequenc
analysi
design
cover
region
gene
includ
codon
previou
studi
show
region
mutat
associ
azol
resist
c
albican
studi
sensit
strain
shown
mutat
among
dd
resist
strain
mutat
found
two
strain
mutat
demonstr
remain
isol
conclus
studi
first
use
pyrosequenc
system
characteris
chang
nucleotid
sequenc
gene
fragment
involv
azol
resist
c
albican
strain
observ
one
point
mutat
two
resist
strain
test
suggest
limit
role
region
gene
analys
azol
resist
among
c
albican
strain
present
region
howev
pyrosequenc
system
shown
fast
specif
techniqu
detect
point
mutat
region
gene
c
albican
strain
escherichia
coli
verocytotoxin
variant
correl
clinic
manifest
persson
f
scheutz
kep
olsen
copenhagen
dk
background
verocytotoxin
verocytotoxin
produc
escherichia
coli
vtec
potent
toxin
capabl
produc
seriou
complic
excret
bacteria
colonis
intestin
tract
matur
toxin
compos
one
asubunit
five
ident
bsubunit
encod
approxim
bp
operon
base
variabl
nucleic
acid
sequenc
subunit
sever
toxin
variant
identifi
object
subtyp
design
import
sequenc
motif
clinic
signific
variant
consist
throughout
literatur
shed
light
featur
novel
type
method
develop
investig
subtypespecif
correl
clinic
outcom
method
subtyp
method
reli
pcr
sequenc
use
univers
primer
fragment
cover
variabl
region
subunit
b
amplifi
pcr
subsequ
sequenc
result
conclus
present
method
use
analysi
strain
strain
collect
count
strain
isol
patient
known
clinic
manifest
hu
hc
bloodi
diarrhoea
diarrhoea
fever
etc
compar
tradit
subtyp
preliminari
result
indic
strain
strain
collect
harbour
subtyp
addit
strain
contain
activat
carboxyterminu
subunit
refer
correl
subtyp
clinic
complic
present
addit
novel
sequenc
strain
collect
investig
sequenc
motif
connect
clinic
outcom
sequenc
becom
access
less
expens
believ
method
offer
good
reliabl
altern
diagnost
subtyp
vtec
strain
infect
shiga
toxinproduc
escherichia
coli
slovenia
p
zabukovnik
andlov
zore
ljubljana
si
object
institut
microbiolog
immunolog
depart
bacteri
diagnost
diarrhoeal
infect
medic
faculti
ljubljana
want
introduc
multiplex
pcr
test
detect
shiga
toxinproduc
escherichia
coli
stec
recent
use
enzym
immunoassay
eia
detect
product
shiga
toxin
stx
specimen
institut
microbiolog
immunolog
extens
collect
e
coli
isol
human
faec
mostli
hospit
ljubljana
decid
test
isol
collect
serogroup
use
multiplex
pcr
assay
amplifi
sequenc
four
virul
gene
shiga
toxin
shiga
toxin
intimin
eaea
enterohemolysin
ehxa
method
isol
serotyp
rabbit
antisera
use
multiplex
pcr
detect
presenc
shiga
toxin
shiga
toxin
sub
variant
discrimin
intimin
enterohemolysin
gene
also
test
strain
product
stx
eia
result
test
e
coli
isol
serogroup
found
stec
ehxa
gene
present
almost
stec
isol
common
pcr
profil
five
isol
eaea
ehxa
gene
one
isol
gene
produc
shiga
toxin
possibl
eia
detect
produc
shiga
toxin
stec
isol
summer
month
juli
august
two
stec
isol
year
shortli
one
anoth
ident
multiplex
pcr
profil
happen
year
conclus
notic
increas
number
stec
isol
per
year
year
may
use
better
diagnost
method
last
year
stec
pcr
profil
eaea
ehxa
domin
year
domin
pcr
profil
eaea
ehxa
gene
background
chronic
prostat
recognis
caus
infecti
noninfecti
prostat
inflamm
well
noninflammatori
diseas
separ
variou
prostat
syndrom
difficult
perform
bacteri
prostat
common
diagnosi
frequent
indic
antimicrobi
therapi
howev
confirm
aetiolog
inflamm
exceedingli
uncommon
object
aim
studi
determin
preval
aetiolog
chronic
bacteri
prostat
among
patient
clinic
confirm
diagnosi
method
octob
octob
patient
suspect
prostat
examin
clinic
diagnosi
confirm
patient
within
month
greater
durat
follow
sign
symptom
perin
discomfort
pain
follow
ejacul
urinari
frequenc
urgenc
dysuria
low
back
pain
suprapub
pain
palpat
tender
prostat
physic
examin
bacteriolog
diagnosi
determin
patient
take
antibiot
previou
month
mear
stamey
techniqu
prostat
categoris
accord
nih
classif
result
total
patient
examin
chronic
bacteri
prostat
nih
categori
ii
found
nine
patient
inflammatori
chronic
pelvic
pain
syndrom
nih
categori
iiia
noninflammatori
chronic
pelvic
pain
syndrom
nih
categori
iiib
follow
pathogen
isol
nih
categori
ii
staphylococcu
spp
three
anaerob
bacteria
prevotella
spp
prevotella
spp
peptostreptococcu
spp
three
escherichia
coli
two
patient
acinetobact
lwoffii
one
conclus
chronic
bacteri
prostat
import
rare
clinic
entiti
care
examin
use
quantit
segment
bacteriolog
cultur
lead
proper
categoris
recognis
form
prostat
syndrom
common
pathogen
chronic
bacteri
prostat
staphylococcu
spp
anaerob
bacteria
prevotella
spp
peptostreptococcu
spp
e
coli
object
prospect
multicent
urolog
outpati
survey
undertaken
examin
prostat
itali
use
compar
preval
characteris
diagnosi
treatment
prostat
patient
north
american
na
prostat
patient
method
materi
seventi
urologist
repres
crosssect
urolog
centr
itali
count
record
overal
total
male
patient
report
clinic
overal
total
patient
diagnos
prostat
period
result
compar
publish
practic
preval
cohort
data
particular
nih
chronic
prostat
cohort
studi
cpc
seattl
prostat
cohort
examin
similar
data
na
result
total
patient
identifi
prostat
mean
age
prostat
patient
rang
common
urinari
diseas
benign
prostat
hyperplasia
recurr
urinari
tract
infect
urinari
calculogenesi
common
concurr
diseas
diabet
depress
frequent
report
sever
symptom
time
evalu
irrit
void
symptom
perin
suprapub
pain
discomfort
three
quarter
patient
dissatisfi
qualiti
life
bacteria
cultur
ep
semen
specimen
respect
comparison
na
data
suggest
european
prostat
patient
european
urologist
approach
diagnosi
treatment
prostat
dissimilar
preval
manag
prostat
na
conclus
prostat
common
worldwid
outpati
diagnosi
compris
signific
percentag
male
outpati
visit
urologist
europ
na
similar
preval
characteris
manag
typic
prostat
suggest
intern
collabor
research
effort
indic
import
urolog
condit
observ
unit
h
discharg
admit
two
factor
significantli
correl
hospit
admiss
sever
uti
complic
ac
aup
complic
ap
acut
prostat
patient
age
ae
year
admit
complic
ac
vs
ae
year
nonadmit
demograph
factor
underli
condit
symptom
sign
laboratori
radiolog
microbiolog
data
antimicrobi
therapi
outcom
final
diagnosi
evalu
result
express
percentag
median
appropri
result
median
age
year
femal
nurs
home
resid
seventyfour
per
cent
depend
activ
daili
live
perman
urinari
cathet
cognit
impair
frequent
symptom
fever
declin
function
dyspnoea
refer
dysuria
stupor
crackl
ronchi
commonest
sign
leucocytosi
elev
urea
mgdl
respiratori
failur
high
creactiv
protein
mgl
main
laboratori
abnorm
pyuria
observ
chest
xray
show
pulmonari
infiltr
case
fulfil
criteria
sever
sepsi
blood
urin
cultur
posit
patient
respect
gramneg
bacilli
gnb
found
posit
cultur
escherichia
coli
common
agent
pneumococci
isol
either
blood
sputum
amoxicillinclavulan
antimicrobi
therapi
frequent
administ
median
hospit
stay
mortal
day
respect
urinari
tract
infect
commonest
final
diagnosi
conclus
respiratori
manifest
predomin
disabl
old
patient
gnb
sever
urinari
sepsi
initi
diagnos
suari
respiratori
distress
may
underli
present
studi
requir
support
content
enterococcu
patient
hospitalis
emerg
depart
raveh
rosenzweig
b
rudenski
yinnon
jerusalem
il
object
determin
incid
risk
factor
isol
pseudomona
aeruginosa
enterococcu
urin
cultur
obtain
patient
emerg
depart
ed
method
one
year
prospect
nonintervent
studi
urin
specimen
collect
ed
one
organ
isol
concentr
cfuml
studi
includ
patient
p
aeruginosa
enterococcu
bacteriuria
studi
patient
control
patient
escherichia
coli
bacteriuria
subsequ
hospitalis
ratio
two
control
studi
case
patient
interview
structur
questionnair
chart
review
demograph
clinic
laboratori
indic
enterococcu
pseudomona
bacteriuria
compar
e
coli
bacteriuria
result
studi
period
posit
urin
sampl
obtain
ed
patient
enterobacteriacea
includ
isol
e
coli
organ
p
aeruginosa
enterococcu
comparison
randomli
chosen
control
cohort
patient
e
coli
bacteriuria
reveal
sever
indic
pseudomona
bacteriuria
includ
male
gender
odd
ratio
ci
p
presenc
perman
urinari
cathet
ci
p
past
prostatectomi
ci
p
hospitalis
previou
month
ci
p
pregnanc
ci
p
addit
enterococcu
pseudomona
compar
e
coli
significantli
often
indic
asymptomat
bacteriuria
patient
diagnos
oppos
clinic
manifest
bacteriuria
isol
e
coli
ci
p
conclus
pseudomona
enterococcu
isol
signific
minor
urin
sampl
obtain
ed
patient
clinic
suspect
bacteri
infect
isol
organ
compar
e
coli
often
indic
asymptomat
bacteriuria
patient
infecti
diseas
diagnos
addit
sever
independ
clinic
indic
pseudomona
bacteriuria
identifi
data
may
assist
select
optim
antibiot
treatment
patient
admit
suspect
urinari
tract
infect
object
certain
virul
factor
vf
particularli
pap
fimbria
abl
trigger
product
cytokin
especi
activ
tolllik
receptor
therefor
produc
inflamm
aim
studi
assess
influenc
certain
vf
degre
inflamm
febril
urinari
tract
infect
futi
method
adult
patient
febril
commun
acquir
futi
femal
acut
pyelonephr
mean
age
sd
acut
prostat
mean
age
sd
caus
escherichia
coli
prospect
includ
level
c
reactiv
protein
crp
white
blood
cell
count
wbcc
day
apirexia
begin
antibiot
treatment
record
patient
consid
indirect
marker
inflamm
gene
encod
haemolysin
type
fimbria
pap
g
fimbria
cytotox
necrotis
factor
aerobactin
autotransport
toxin
detect
pcr
addit
express
type
fimbria
haemolysin
detect
agglutin
growth
blood
agar
result
strain
carri
pap
g
fimbria
involv
futi
higher
crp
level
pap
g
fimbria
neg
strain
vs
p
relat
rest
vf
crp
level
reach
statist
signific
differ
found
regard
wbcc
durat
fever
conclus
data
indirectli
suggest
degre
inflamm
futi
caus
e
coli
associ
presenc
pap
g
fimbria
coher
fact
pap
g
fimbria
coreceptor
mycolog
candida
aspergillosi
initi
activ
surveil
programm
yeastrel
bloodstream
infect
franc
aspyrif
activ
surveil
program
implement
franc
prospect
analys
yeastrel
blood
stream
infect
pilot
studi
conduct
octob
septemb
medic
centr
pari
suburb
patient
one
isol
identifi
speci
sent
nrcm
togeth
clinic
data
fill
standard
form
identif
confirm
use
phenotyp
test
pcr
assay
perform
candida
albican
isol
identifi
c
dubliniensi
antifung
suscept
test
amphotericin
b
flucytosin
fluconazol
itraconazol
voriconazol
caspofungin
perform
accord
eucast
recommend
median
age
patient
year
year
male
predomin
underli
factor
yeastrel
blood
stream
infect
often
multipl
given
patient
domin
recent
surgeri
central
venou
cathet
hospitalis
intens
care
unit
malign
immunosuppress
therapi
hiv
infect
solid
organ
bone
marrow
transplant
prosthet
devic
overal
mortal
rate
high
death
within
day
first
posit
blood
cultur
candida
spp
frequent
genu
c
albican
c
glabrata
c
parapsilosi
c
tropicali
frequent
speci
isol
candida
recov
c
krusei
c
kefyr
c
lusitania
noncandida
spp
trichosporon
asahii
mucoid
geotrichum
capitatum
cryptococcu
neoforman
data
show
percentag
nonalbican
speci
equal
c
albican
among
yeast
recov
fungaemia
proport
four
major
speci
differ
significantli
accord
presenc
central
venou
cathet
p
analysi
antifung
suscept
test
result
reveal
isol
usual
antifung
suscept
profil
conclus
aspyrif
power
tool
allow
us
accur
describ
epidemiolog
yeastrel
blood
stream
infect
franc
without
restrict
underli
diseas
speci
background
nosocomi
candidaemia
associ
signific
morbid
mortal
critic
ill
emerg
fluconazol
resist
rais
problem
newer
antifung
drug
voriconazol
caspofungin
ambisom
abelcet
offer
altern
therapeut
option
also
rais
issu
treatmentassoci
cost
novemb
clinic
audit
conduct
across
two
tertiari
care
hospit
western
infirmari
gartnavel
gener
hospit
glasgow
distribut
candida
speci
fluconazoleitraconazol
resist
emphasi
highrisk
area
studi
also
address
newer
antifung
option
cost
implic
patient
riskstratif
approach
object
evalu
outcom
complic
patient
candidaemia
treat
antifung
identifi
common
candida
speci
isol
vamc
patient
candida
evalu
risk
factor
epidemiolog
data
patient
method
patient
admit
vamc
august
august
blood
cultur
posit
candida
includ
studi
epidemiolog
data
medic
histori
risk
factor
comorbid
diseas
laboratori
result
evalu
record
review
candida
speci
identifi
determin
preval
candida
speci
vamc
patient
assign
three
differ
group
accord
therapeut
regim
provid
patient
primari
physician
outcom
complic
includ
nephrotox
electrolyt
disturb
hepatotox
evalu
therapeut
group
statist
analysi
perform
use
spss
statist
packag
social
scienc
regress
model
use
analysi
risk
factor
associ
mortal
patient
candidaemia
result
one
hundr
seven
patient
randomis
studi
c
tropicali
commonli
isol
candida
speci
follow
c
albican
mortal
rate
high
especi
patient
infect
c
tropicali
c
glabrata
p
mortal
rate
increas
treatment
given
p
wors
c
tropicali
isol
treat
patient
treat
similar
mortal
rate
irrespect
administ
agent
amphotericin
abelcet
diflucan
wors
patient
admit
icu
amphotericin
abelcet
diflucan
p
respons
rate
patient
infect
c
albican
vs
patient
c
tropicali
nephrotox
develop
patient
differ
found
patient
treat
amphotericin
b
vs
abelcet
conclus
candidaemia
increas
frequenc
c
tropicali
commonli
isol
candida
speci
institut
candidaemia
high
mortal
rate
wors
c
tropicali
isol
patient
admit
icu
treatment
given
differ
respons
rate
within
differ
therapeut
option
nephrotox
higher
patient
treat
amphotericin
irrespect
formul
administ
background
invas
candidaemia
lifethreaten
complic
occur
especi
hospitalis
cancer
patient
due
surgic
oper
applic
aggrav
chemotherapi
candida
colonis
dysfunct
humor
cellular
immun
system
prolong
period
hospitalis
consid
risk
factor
invas
candidaemia
develop
earli
diagnosi
evalu
risk
factor
still
major
challeng
object
aim
studi
evalu
relationship
rate
candida
colonis
disord
immun
respons
associ
advers
chang
concentr
tnfalpha
myeloperoxidas
develop
invas
candidaemia
hospitalis
cancer
patient
method
studi
group
includ
patient
lung
cancer
admit
surgic
oper
women
carcinoma
ovariorum
third
cours
treatment
taxol
cisplatin
patient
examin
fungal
colonis
mucos
membran
cultur
method
presenc
candida
antigen
dna
pathogen
bloodstream
determin
elisa
pcr
assay
respect
cytokin
myeloperoxidas
concentr
serum
patient
specifi
elisa
commerci
kit
result
studi
reveal
lung
cancer
patient
colonis
candida
nosepharynx
oper
pneumonia
wound
infect
observ
patient
group
candida
albican
isol
pathogen
three
patient
colonis
previous
candida
case
patient
group
ovariorum
carcinoma
colonis
candida
two
three
site
demonstr
five
women
candida
antigen
present
blood
four
posit
pcr
result
found
blood
sampl
collect
one
signific
relationship
candida
colonis
infect
myeloperoxidas
concentr
found
vs
ngml
healthi
person
conclus
high
rate
candida
colonis
drastic
decreas
myeloperoxidas
serum
concentr
patient
lung
ovariorum
cancer
predispos
risk
factor
invas
candida
infect
detect
candida
antigen
dna
pathogen
may
improv
earli
diagnosi
candidosi
evalu
bactalert
system
diagnos
bloodstream
infect
due
yeast
effect
voriconazol
ergosterol
content
costadeoliveira
c
pinavaz
e
pinto
oliveira
c
tavar
rodrigu
porto
p
voriconazol
vor
new
azol
antifung
agent
similar
structur
fluconazol
flu
azol
primari
mechan
action
disrupt
normal
sterol
biosynthet
pathway
lead
reduct
ergosterol
content
nevertheless
vor
potent
candida
spp
show
wide
spectrum
activ
thu
candida
krusei
intrins
resist
fluconazol
unknown
mechan
show
low
mic
valu
vor
lack
crossresist
fact
fungicid
fungi
suggest
distinct
mechan
action
object
studi
effect
vor
amount
ergosterol
c
krusei
strain
comparison
flu
method
mic
vor
determin
accord
nccl
protocol
strain
c
krusei
resist
flu
mic
lgml
ergosterol
isol
c
krusei
cell
saponif
nonsaponifi
lipid
extract
heptan
ergosterol
identifi
spectrophotometr
absorb
profil
nm
quantif
ergosterol
determin
incub
without
azol
mic
subinhibitori
concentr
result
strain
mic
vor
rang
ugml
c
krusei
signific
amount
ergosterol
signific
differ
among
strain
incub
mic
concentr
vor
reduct
ergosterol
content
observ
similar
effect
obtain
fluconazol
highest
concentr
ug
ml
conclus
vor
induc
consider
impair
biosynthesi
ergosterol
c
krusei
strain
much
potent
inhibitor
ergosterol
biosynthesi
flu
background
mycot
infect
hospitalis
patient
emerg
signific
public
health
issu
numer
studi
shown
candidaemia
associ
signific
attribut
mortal
prolong
hospit
stay
report
analys
incid
candida
spp
wound
object
analys
speci
distribut
antifung
suscept
candida
infect
wound
hospit
period
method
vitro
activ
amphotericin
b
ab
fluconazol
fz
itraconazol
iz
ketoconazol
kz
flucytosin
determin
broth
microdilut
method
follow
nccl
criteria
mic
visual
determin
h
incub
c
result
process
wound
sampl
laboratori
posit
show
bacteri
growth
without
candida
candida
rate
isol
candida
woundsyear
follow
global
candida
albican
frequent
isol
speci
per
patient
follow
c
parapsilosi
c
glabrata
c
tropicali
trend
speci
distribut
similar
adult
paediatr
popul
evolut
success
year
wound
one
speci
candida
follow
overal
percentag
resist
candida
spp
isol
ab
fz
iz
kz
fc
conclus
studi
show
increas
presenc
candida
spp
among
wound
isol
microbiolog
laboratori
high
proport
due
speci
c
albican
probabl
attribut
increas
antibiot
burden
hospit
infant
perform
estim
diseas
burden
shortterm
outcom
microbiolog
characterist
caus
organ
method
prospect
enhanc
surveil
invas
fungal
infect
vlbw
g
infant
began
februari
case
defin
meet
one
follow
diagnost
criteria
cultur
steril
site
csf
blood
peripher
sampl
urin
suprapub
aspir
inout
cathet
sampl
bonejoint
periton
pleural
space
pathognomon
find
ophthalmolog
examin
pathognomon
find
renal
ultrasound
examin
autopsi
diagnosi
invas
fungal
infect
case
identifi
three
separ
surveil
scheme
monthli
notif
paediatrician
british
paediatr
surveil
unit
continu
report
microbiolog
laboratori
communic
diseas
surveil
centr
england
scottish
centr
infect
environment
health
scotland
report
three
system
reconcil
analys
rate
calcul
use
offic
nation
statist
total
live
birth
estim
result
februari
juli
confirm
case
invas
fungal
infect
vlbw
infant
report
birth
vlbw
median
age
diagnosi
day
rang
birth
weight
g
thirtyfour
infant
extrem
low
birth
weight
g
candida
albican
common
pathogen
found
case
c
parapsilosi
organ
commonli
isol
blood
follow
urin
csf
central
line
tip
third
case
receiv
prophylact
antifung
therapi
one
case
drug
resist
identifi
period
fluconazol
resist
nonalbican
candida
spp
infant
outcom
data
avail
aliv
week
postconcept
age
conclus
preliminari
find
enhanc
surveil
suggest
incid
invas
mycos
vlbw
infant
one
per
adult
case
c
albican
common
fungal
pathogen
involv
although
c
parapsilosi
rel
common
adult
major
case
occur
extrem
low
birth
weight
infant
mortal
found
high
method
surveil
swab
throat
rectum
taken
admiss
twice
weekli
afterward
diagnost
sampl
obtain
clinic
indic
sampl
process
use
standard
mycolog
techniqu
overgrowth
defin
yeast
cellsml
saliva
andor
gram
faec
carriag
index
ratio
sum
semiquantit
growth
densiti
posit
surveil
swab
divid
total
number
swab
particular
sampl
day
oral
polyen
start
follow
identif
carrier
state
result
total
children
requir
minim
day
ventil
enrol
observ
prospect
studi
median
paediatr
index
mortal
iqr
actual
mortal
enter
polyen
part
select
digest
decontamin
sdd
administ
half
studi
popul
median
length
stay
day
object
candida
dubliniensi
newli
describ
pathogen
speci
first
isol
hivinfect
patient
oropharyng
candidiasi
share
mani
phenotyp
featur
c
albican
includ
abil
form
germ
tube
chlamydospor
similar
caus
signific
problem
differenti
c
albican
routin
clinic
microbiolog
laboratori
studi
report
isol
identif
c
dubliniensi
first
time
kuwait
present
data
antifung
suscept
profil
method
period
month
germtub
posit
yeast
identifi
c
albican
recov
differ
clinic
specimen
screen
abil
grow
c
sabouraud
dextros
agar
isol
fail
grow
c
presumpt
identifi
c
dubliniensi
ident
c
dubliniensi
isol
confirm
format
rough
coloni
chlamydospor
sunflow
seed
agar
vitek
system
seminest
pcr
use
speciesspecif
primer
correspond
uniqu
sequenc
within
intern
transcrib
spacer
c
dubliniensi
direct
sequenc
antifung
suscept
test
perform
rpmi
medium
recommend
nccl
document
result
germ
tube
posit
yeast
isol
identifi
c
dubliniensi
isol
sputum
n
vagin
swab
n
endotrach
secret
n
throat
swab
n
urin
n
one
bronchoalveolar
lavag
cathet
tip
periton
fluid
none
isol
origin
hivposit
patient
c
dubliniensi
isol
suscept
amphotericin
b
fluconazol
itraconazol
voriconazol
howev
isol
resist
lgml
without
known
previou
exposur
conclus
identif
c
dubliniensi
yeast
isol
studi
suggest
speci
uncommon
kuwait
need
carri
systemat
studi
highrisk
patient
group
know
epidemiolog
signific
acknowledg
work
support
kuwait
univers
research
grant
background
fungaemia
remain
sever
nosocomi
complic
emerg
nonalbican
speci
pose
new
challeng
clinician
microbiologist
object
assess
incid
clinic
present
c
glabrata
fungaemia
suscept
clinic
outcom
method
episod
fungaemia
case
correspond
c
glabrata
thirti
case
six
cirrhosi
patient
miscellan
follow
eortcmsg
criteria
patient
classifi
proven
ia
n
probabl
ia
n
possibl
ia
n
colonis
n
mean
sap
ii
score
predict
mortal
overal
mortal
n
mortal
proven
probabl
group
respect
among
patient
surviv
colonis
aspergillu
postmortem
examin
nonhaematooncolog
group
done
patient
die
autopsi
show
hyphael
invas
aspergillu
mainli
lung
target
organ
five
proven
case
patient
without
compromis
host
factor
accord
eortcmsg
definit
three
liver
cirrhosi
one
pneumonia
man
one
klebsiella
sepsi
mof
conclus
ia
emerg
infecti
diseas
nonhaematooncolog
icu
patient
seem
broad
group
patient
risk
ia
ia
diagnos
patient
without
characterist
describ
eortcmsg
definit
seem
worthwhil
investig
valid
avail
diagnost
tool
nonhaematooncolog
patient
risk
ia
prospect
manner
epidemiolog
invas
aspergillosi
teach
hospit
franc
survey
cornillet
c
camu
nimubona
v
gandem
p
tattevin
c
bellegu
chevrier
c
meunier
c
lebert
b
lelong
c
guiguen
jp
gangneux
aspergillosi
studi
group
object
method
aim
survey
characteris
file
patient
develop
invas
aspergillosi
ia
institut
risk
factor
manag
analys
retrospect
case
ia
occur
prospect
new
case
end
overal
survey
cover
period
case
classifi
suspect
probabl
proven
ia
use
criteria
deriv
eortcmsg
classif
result
discuss
case
ia
analys
nine
histolog
proven
probabl
ia
suspect
ia
sex
ratio
male
one
femal
mean
age
year
rang
year
fifti
percent
case
diagnos
intens
care
unit
haematolog
unit
adult
paediatr
neutropenia
major
risk
factor
patient
haematolog
malign
solid
cancer
howev
also
note
increas
number
ia
patient
corticosteroid
therapi
cobp
asthma
rheumatoid
arthriti
horton
microvascular
diseas
comparison
avail
data
literatur
case
occur
solid
organ
transplant
recipi
one
patient
infect
hiv
prognosi
factor
discuss
regard
biolog
diagnosi
good
sensit
mycolog
examin
microscopi
cultur
galactomannan
antigen
detect
enzym
immunoassay
platelia
aspergillu
biorad
note
respect
sensit
reach
test
combin
pulmonari
imageri
less
effici
probabl
due
fact
institut
ct
scan
perform
later
propos
literatur
survey
observ
great
modif
therapeut
approach
first
line
treatment
progress
switch
deoxychol
amphotericin
b
amb
voriconazol
second
line
treatment
includ
lipid
formul
amb
caspofungin
acet
amb
deoxychol
voriconazol
two
drug
use
empir
therapi
overal
mortal
conclus
ia
remain
major
lifethreaten
infect
among
immunosuppress
patient
although
protect
measur
air
filtrat
significantli
reduc
incid
neutropen
patient
howev
point
increas
number
case
nonneutropen
patient
hospitalis
ward
without
air
filtrat
emerg
popul
patient
must
taken
account
impos
reinforc
surveil
highrisk
group
rethink
prevent
measur
priat
chest
ct
appear
sole
basi
diagnosi
pt
remain
seven
pt
posit
elisa
accompani
either
histopatholog
microbiolog
evid
ia
five
pt
later
upgrad
definit
ia
nineteen
pt
assess
efficaci
end
ca
rx
favour
respons
rate
pt
whose
evid
ia
ca
onset
elisa
characterist
chest
ct
find
success
rate
followup
elisa
data
avail
pt
four
five
pt
favour
respons
ca
neg
elisa
end
rx
one
pt
favour
respons
quantit
elisa
improv
tempor
associ
clinic
radiograph
respons
pt
unfavour
respons
followup
elisa
data
elisa
improv
two
normalis
elisa
ca
conclus
studi
use
elisa
result
exagger
favour
respons
rate
gener
elisa
associ
clinicalradiograph
respons
paradox
elisa
increas
pt
clinicallyradiograph
respond
ca
note
best
rapd
pattern
respect
number
spread
intens
band
highest
level
discrimin
achiev
combin
data
gener
therefor
emphasis
conveni
use
least
two
primer
rapd
type
object
gain
insight
molecular
epidemiolog
staphylococcu
aureu
tertiari
hospit
method
aureu
isol
recov
blood
sampl
period
analys
demograph
clinic
microbiolog
data
patient
collect
antimicrobi
suscept
test
perform
wider
system
disk
diffus
method
methicillinresist
aureu
mrsa
isol
underw
confirmatori
pcr
analysi
meca
gene
molecular
characteris
perform
pulsedfield
gel
electrophoresi
pfge
follow
dna
extract
smai
digest
pattern
differ
less
seven
dna
fragment
dice
coeffici
correl
consid
common
bacteri
type
subtyp
includ
isol
indistinguish
pfge
pattern
univari
multivari
analys
perform
epiinfo
spss
softwar
result
one
hundr
sixtytwo
episod
aureu
bacteraemia
whether
methicillinresist
methicillinsuscept
mssa
nosocomi
origin
case
associ
healthcar
system
total
case
bacteraemia
one
mrsa
mssa
strictli
consid
communityacquir
thirtyf
uniqu
aureu
pfge
type
identifi
among
dna
macrorestrict
pattern
within
isol
mrsa
four
major
genotyp
identifi
isol
repres
singl
pfge
type
contrast
isol
mssa
compris
differ
pfge
type
repres
one
isol
three
pfge
type
found
repres
mssa
isol
common
strain
found
equal
frequenc
among
adult
paediatr
patient
evenli
distribut
nosocomi
communityacquir
case
conclus
result
provid
indirect
evid
ongo
transmiss
mrsa
mssa
hospit
case
mrsa
spread
predominantli
due
singl
clone
transmiss
favour
increas
length
stay
hospit
administr
betalactam
antibiot
contrast
spread
mssa
bacteraemia
popul
associ
multipl
genet
distinct
strain
use
realtim
pcr
detect
presenc
meca
gene
aureu
clinic
isol
method
seventythre
strain
obtain
clinic
specimen
identifi
microscan
dade
behr
coagulas
test
aureu
epidermidi
coagulas
neg
staphylococci
vitro
suscept
determin
microscan
disc
diffus
total
aureu
strain
classifi
accord
methicillin
suscept
resist
suscept
methicillin
dna
obtain
incub
c
lysi
buffer
realtim
pcr
perform
lightcycl
instrument
roch
diagnost
spain
use
two
commerci
avail
kit
lightcycl
staphylococcu
kit
mgrade
pcr
posit
staphylococci
differenti
accord
melt
temperatur
ae
c
aureu
c
cn
lightcycl
mrsa
detect
kit
pcr
posit
meca
posit
aureu
intern
control
exclud
presenc
inhibit
dna
extract
whole
process
take
h
result
twentyseven
aureu
strain
clearli
identifi
realtim
pcr
due
melt
temperatur
rang
c
one
aureu
show
melt
temperatur
c
epidermidi
strain
show
melt
temperatur
c
lugdunensi
show
melt
temperatur
c
cn
show
melt
temperatur
c
twentyf
strain
test
meca
posit
use
lightcycl
mrsa
kit
realtim
pcr
among
meca
posit
fenotip
methicillin
resist
whilst
four
methicillin
suscept
meca
neg
strain
suscept
methicillin
phenotyp
method
conclus
realtim
pcr
lightcycl
seem
accur
method
identifi
aureu
differenti
differ
cn
detect
resist
methicillin
aureu
reaction
could
done
simultan
whole
process
take
less
h
dna
extract
plu
realtim
pcr
object
surveil
methicillin
resist
staphylococcu
aureu
mrsa
canada
began
surveil
six
epidem
strain
mrsa
identifi
name
order
better
understand
related
strain
well
genet
content
use
microarray
compar
genom
fulli
characteris
genom
mrsa
strain
col
method
genom
dna
repres
six
epidem
strain
well
col
fragment
label
use
random
primer
label
dctp
col
epidem
strain
label
differ
dye
hybridis
array
contain
pcr
product
bp
oligom
repres
open
read
frame
orf
col
genom
data
process
arraypro
softwar
packag
posit
neg
cutoff
valu
determin
use
genomotyp
analysi
charl
kim
analys
use
genemath
program
macrorestrict
digest
patter
gener
use
smai
result
result
indic
canadian
epidem
strain
six
common
region
delet
portion
type
sccmec
region
bacteriophag
four
smaller
area
compos
two
four
orf
gene
known
function
smaller
area
staphylococc
enterotoxin
b
apart
major
delet
mani
sporad
singl
delet
seen
throughout
strain
larger
region
delet
present
strain
also
occur
obviou
orf
duplic
found
multipl
copi
typeiii
sccmec
region
strain
macrorestrict
digest
data
use
approxim
size
cmrsa
genom
show
smallest
genom
kb
least
genet
content
common
col
though
appear
larger
genom
kb
respect
show
fewer
orf
common
col
strain
respect
suggest
substanti
portion
genom
may
novel
conclus
first
studi
epidem
mrsa
use
compar
genom
hybridis
approach
cmrsa
strain
show
high
degre
related
col
consider
differ
genet
content
studi
also
indic
may
genet
content
unaccount
col
genom
studi
devis
identifi
characteris
novel
genet
content
object
finland
annual
number
mrsa
isol
notifi
nation
infecti
diseas
regist
nidr
constantli
increas
especi
outsid
helsinki
metropolitan
area
molecular
type
reveal
numer
outbreak
strain
mrsa
associ
commun
acquisit
analys
strain
type
identifi
pulsedfield
gel
electrophoresi
pfge
mrsa
isol
sent
nation
refer
laboratori
nrl
method
isol
mrsa
notifi
finnish
clinic
microbiolog
laboratori
sent
nrl
verif
characteris
includ
pfge
analysi
pfge
profil
differ
fewer
six
band
interpret
ident
close
relat
one
isol
per
person
includ
analysi
strain
type
categoris
sporad
strain
type
found
one
person
domest
outbreak
intern
epidem
strain
type
found
one
person
well
communityacquir
strain
type
associ
commun
acquisit
previou
studi
proport
mrsa
isol
includ
categori
assess
result
total
mrsa
isol
studi
number
mrsa
isol
increas
pfge
identifi
differ
strain
type
mrsa
isol
sporad
domest
outbreak
intern
epidem
one
strain
type
disappear
compar
year
new
strain
type
appear
proport
sporad
strain
vari
studi
period
intern
epidem
strain
bel
increas
mainli
outsid
helsinki
metropolitan
area
uk
decreas
helsinki
repres
mlst
strain
respect
uk
vari
three
main
strain
communityacquisit
fluctuat
studi
period
rang
conclus
intens
nation
surveil
molecular
type
reveal
predomin
mrsa
strain
chang
time
intern
spread
epidem
strain
mrsa
also
found
finland
howev
show
decreas
trend
disappear
result
encourag
us
continu
aggress
intervent
new
mrsa
case
introduct
accord
recent
studi
communityacquir
ca
methicillinresist
staphylococcu
aureu
mrsa
strain
often
contain
type
iv
sccmec
cassett
pantonvalentin
leukocidin
pvl
locu
also
shown
certain
multilocu
sequenc
type
st
seem
connect
camrsa
strain
differ
contin
materi
method
studi
finnish
camrsa
strain
genotyp
pulsedfield
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
methicillin
resist
gene
sccmec
pcr
presenc
pvl
gene
locu
pcr
mrsa
defin
commun
acquir
mrsa
specimen
obtain
outsid
hospit
set
within
day
hospit
admiss
person
hospitalis
within
year
date
mrsa
isol
confirm
function
pvlpcr
reaction
qualiti
dna
nuc
gene
amplifi
time
result
major
camrsa
strain
studi
possess
sccmec
cassett
type
iv
pvl
posit
two
pvl
posit
strain
contain
sccmec
type
iv
one
strain
sccmec
cassett
iii
subtyp
one
strain
type
determin
pvl
posit
strain
mostli
multilocu
four
remain
pvlposit
strain
two
strain
sequenc
type
correl
well
pfge
result
strain
analys
pfge
profil
hkiviii
strain
pfge
profil
nurm
sccmec
cassett
iii
subtyp
sccmec
determin
strain
consid
sporad
pvl
neg
camrsa
strain
belong
differ
share
four
sporad
pfge
profil
type
mlst
analysi
pvl
neg
strain
current
underway
conclus
finnish
camrsa
strain
sccmec
cassett
type
iv
minor
contain
pvl
gene
locu
contrast
previou
report
major
pvl
gene
posit
strain
possess
spite
strict
definit
communityacquisit
use
major
finnish
camrsa
pvl
neg
show
heterogen
pfge
profil
object
methicillinresist
staphylococcu
aureu
mrsa
among
major
pathogen
common
method
current
use
identifi
methicillin
oxacillin
resist
mani
clinic
laboratori
suscept
test
perform
test
errat
express
resist
variabl
commonli
heterogen
within
strain
method
retrospect
laboratorybas
studi
carri
clinic
isol
aureu
tertiari
care
provid
univers
hospit
thrace
greec
methicillin
oxacillin
suscept
aureu
isol
recov
variou
clinic
specimen
blood
cultur
tracheal
aspir
wound
swab
central
venou
cathet
studi
four
differ
method
agar
screen
test
mhoxacillin
lgml
agar
supplement
nacl
suscept
determin
vitek
biomerieux
mic
determin
etest
ab
biodisk
meca
gene
detect
pcr
use
specif
primer
strain
evalu
use
presenc
meca
gene
detect
pcr
definit
criteria
mrsa
nonmrsa
suscept
test
carri
recommend
nccl
result
among
isol
identifi
mecaposit
remain
mecaneg
percentag
correct
result
sensit
specif
oxacillin
agar
screen
etest
ten
isol
neg
meca
gene
pcr
recognis
least
one
phenotyp
method
oxacillin
resist
one
strain
mecaposit
incorrectli
identifi
oxacillinneg
oxacillin
agar
screen
conclus
shown
studi
phenotyp
method
complet
reliabl
detect
oxacillin
resist
aureu
specif
gener
high
especi
agar
screen
etest
method
sensit
vari
differ
method
particular
oxacillin
screen
test
accur
test
approach
accuraci
pcr
although
presenc
meca
gene
detect
pcr
still
remain
gold
standard
agarscreen
test
consid
associ
suscept
method
maximis
abil
correctli
detect
oxacillinsuscept
aureu
amplif
dna
fragment
surround
rare
restrict
site
adsrrsfingerprint
type
staphylococcu
aureu
isol
patient
recurr
furunculosi
w
baranskarybak
r
nowicki
e
scieburako
j
kur
e
arlukowicz
samet
gdansk
pl
introduct
present
studi
report
data
phenotyp
genotyp
characterist
staphylococcu
aureu
strain
aim
research
identifi
sa
genotyp
patient
suffer
recurr
furunculosi
materi
obtain
isol
patient
recurr
furunculosi
purul
discharg
furuncl
nasal
throat
swab
taken
cultur
method
ident
strain
sa
confirm
novel
dnatyp
techniqu
amplif
dna
fragment
surround
rare
restrict
site
adsrrsfingerprint
effect
rapid
method
molecular
type
isol
bacteria
method
base
suppress
pcr
polymeras
chain
reaction
reaction
sa
dna
digest
two
restrict
enzym
bamhi
uml
sigma
xbai
uml
sigma
cohes
end
dna
ligat
adapt
xbai
short
adapt
bamhi
long
adapt
amplifi
pcr
product
electrophores
polyacrylamid
gel
stain
ethidium
bromid
photograph
uv
result
adsrrsfingerprint
sa
isol
reveal
uniqu
pattern
case
strain
isol
patient
nose
throat
furuncl
gave
ident
pattern
revers
situat
found
five
patient
conclus
case
confirm
ident
nasalthroat
furuncl
sa
isol
found
specif
genotyp
respons
recurr
furunculosi
adsrrsfingerprint
seem
use
method
epidemiolog
studi
sa
object
rapid
effici
epidemiolog
type
system
may
use
investig
dissemin
lineag
staphylococcu
aureu
compar
use
wellestablish
method
newli
develop
rapid
type
method
epidemiolog
tool
method
total
aureu
isol
analys
pulsedfield
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
repetitiveel
pcr
techniqu
reppcr
base
presenc
dna
sequenc
homolog
repeat
mycoplasma
pneumonia
multiplelocu
variablenumb
tandem
repeat
analysi
mlva
multiplex
pcrbase
method
primer
mix
spa
gene
coa
gene
hypervari
region
adjac
meca
gene
result
fiftynin
aureu
isol
cluster
pfge
differ
genotyp
mlva
highest
compat
pfge
test
method
studi
cluster
differ
genotyp
multiplex
pcrbase
method
cluster
reppcr
cluster
differ
genotyp
reppcr
differenti
aureu
isol
way
similar
mlst
cluster
isol
group
conclus
although
pfge
still
gold
standard
owe
high
discriminatori
power
amongst
molecular
type
method
genotyp
method
base
pcr
may
use
respect
speed
eas
perform
mlva
multiplex
pcrbase
methodolog
reppcr
rapid
reproduc
easi
perform
howev
mlva
multiplex
pcrbase
method
gener
unambigu
result
reppcr
object
determin
whether
variabl
visual
outcom
endophthalm
secondari
coagulaseneg
staphylococci
spp
due
differ
strain
caus
intraocular
infect
possibl
differ
virul
strain
resist
antibiot
given
method
twentyeight
intraocular
sampl
infect
coagulaseneg
staphylococci
spp
analys
use
biotyp
pulsedfield
gel
electrophoresi
strain
identif
result
correl
visual
outcom
month
posttreat
result
four
differ
strain
coagulaseneg
staphylococci
spp
found
caus
endophthalm
epidermidi
haemolyticu
equorum
warneri
twentyon
isol
identifi
epidermidi
other
group
non
epidermidi
correl
clinic
data
compar
epidermidi
non
epidermidi
infect
case
found
mean
visual
gain
significantli
better
non
epidermidi
infect
case
mean
visual
gain
vs
logmar
letter
respect
p
visual
outcom
significantli
wors
patient
infect
epidermidi
antibiot
resist
common
among
isol
although
sensit
least
one
threefour
antibiot
given
compar
non
epidermidi
infect
case
epidermidi
infect
case
sensit
four
antibiot
use
visual
outcom
still
significantli
better
non
epidermidi
group
mean
visual
gain
vs
logmar
letter
respect
p
